<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t78unlijt295 st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" tabindex="0" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="General Pharmacology Part 3.pdf">General Pharmacology Part 3.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">1.7MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> General Pharmacology Part 3.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects-of-benzodiazepines">Side Effects of Benzodiazepines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects-of-benzodiazepines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Daytime drowsiness, ataxia, rebound insomnia on withdrawal</li>
<li>The elderly develop blurred vision, tremors , constipation, and anterograde amnesia.</li>
<li>Respiratory depression which may worsen in COPD</li>
<li>Decrease BP and heart rate.</li>
<li>Paradoxical effects in the first 2 weeks of therapy such as hostility, aggression, excitement, antisocial behavior</li>
<li>cross tolerance with other sedative/hypnotics agents e.g. alcohol/ barbiturates.</li>
<li>withdrawal symptoms may develop any time after stopping E.G. anxiety, insomnia, GIT disturbance, tinnitus, perceptual disturbance, lack of appetite and perspiration. treat with flumazenil</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In pregnancy, shock, acute alcohol intoxication and neonatal withdrawal symptoms, in the elderly and during lactation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Alcohol plus benzodiazepines cause severe CNS depression.</li>
<li>Cimetidine, disulfiram and oral contraceptives cause increase benzodiazepines effects.</li>
<li>Ranitidine and theophylline decrease benzodiazepine effects.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="barbiturates">Barbiturates<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#barbiturates" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Include;-
Mephobarbital (mebaral)
Pentobarbital (Nembutal)
Phenobarbital (luminal, solfoton)
Amobarbital
Thiopental sodium.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-effects">Pharmacological Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cns">CNS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cns" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Depression of CNS
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Sedative hypnotic
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Anticonvulsant
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> General anesthetic (sodium thiopental)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Enhance analgesic effect of morphine</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-application">Therapeutic Application<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-application" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Sedatives
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Hypnotic
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Anticonvulsant
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> pre anesthetic medicament
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Potentiate analgesic activity
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> anti epileptic; phenobarbitone, metharbital
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> general anesthesia ;thiopental sodium</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reaction">Adverse Reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Acute drug dependence
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Drug tolerance
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Withdrawal symptoms
Contraindication</p>
<ul>
<li>Renal damage</li>
<li>Hepatic ailments</li>
<li>Pulmonary insufficient</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anticonvulsant-seizure-anti-epileptic-medication">Anticonvulsant/seizure /anti epileptic medication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anticonvulsant-seizure-anti-epileptic-medication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Barbiturates: Phenobarbital (Luminal), Primidone (Mysoline) amobarbital, metharbital.
Hydantoins: phenytoin (Dilantin)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Benzodiazepines: Diazepam (Valium), Lorazepam (Ativan)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Carboxamide: Carbamazepine (Tegretol, carbatrol), oxcarbazepine (Trileptal)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Phenyltriazine: Lamotrigine (lamictal)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Pyrrolidines: levetiracetam (Keppra)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Succinimides: ethosuximide (zorontin)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Miscellaneous: acetazolamide (Diamox), primidone(mysoline), valproic acid(depakene, Depakote), zonisamide (zonegran)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Unfortunately the mechanism of seizure activity is not well understood.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> AEDs control seizure disorders by various mechanisms, which include:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Slowing the entrance of sodium and calcium back into the neuron and, thus extending the time it takes for the nerve to return to its active state.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Suppressing neuronal firing, which decreases seizure activity and prevents propagation of seizure activity into other areas of the brain.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Decreasing seizure activity by enhancing the inhibitory effects of gamma butyric acid (GABA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phenobarbital">Phenobarbital<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phenobarbital" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Phenobarbital is used for partial seizures and generalized tonic clonic seizures.</li>
<li>This medication is not effective against absence seizures.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phenytoin">Phenytoin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phenytoin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>phenytoin effective against all major forms of epilepsy except absence seizures.</li>
<li>Use IV route for status epilepticus.</li>
</ul>
<p>Phenytoin is an ant dysrhythmic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="carbamazepine">Carbamazepine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#carbamazepine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Carbamazepine is used for the treatment of partial (simple and complex) seizures, tonic-clonic seizures, bipolar disorder, and trigeminal and glossopharyngeal neuralgias.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-use-cont">Therapeutic use Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-use-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ethosuximide is only indicated for absence seizures.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="valproic-acid">Valproic Acid<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#valproic-acid" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Valproic acid is used for partial, generalized, and absence seizures; bipolar disorder; and migraine headaches.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="gabapentin">Gabapentin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gabapentin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Gabapentin is used as a single agent for control of partial seizures.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> This medication is also used for neuropathic pain and the prevention of migraine headaches.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="diazepam">Diazepam<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diazepam" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Diazepam is used in status epilepticus.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-drug-reaction-of-anti-epileptics-anticonvulsant-medication">Adverse drug reaction of anti epileptics/ anticonvulsant medication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-drug-reaction-of-anti-epileptics-anticonvulsant-medication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Almost all cause undesired effects
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> All cross the placenta barrier;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Cleft lip, cardiac malformation; phenobarbitone, phenytoin.
Spina bifida; folate deficiency induced by sodium valproate, phenytoin, phenobarbital</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="phenytoin">Phenytoin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phenytoin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> This is the oldest non sedative anti seizure drug introduced in 1938.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It blocks sodium channels and inhibit the generation of rapidly repetitive action potentials.</p>
<p>Pharmacokinetics
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> oral ,IM, IV.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="metabolism">Metabolism;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Is in the liver.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects-of-phenytoin">Side /Adverse Effects of Phenytoin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects-of-phenytoin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CNS effects (nystagmus, sedation, ataxia, double vision, cognitive impairment)
Monitor for symptoms and notify the provider if symptoms occur.
Gingival hyperplasia (softening and overgrowth of gum tissue, tenderness, and bleeding gums)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Advise clients to maintain good oral hygiene (dental flossing, massaging gums).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Skin rash <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> Stop medication if rash develops.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Teratogenic (cleft palate, heart defects)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Avoid use in pregnancy..</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects-of-phenytoin">Side /adverse Effects of Phenytoin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects-of-phenytoin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cardiovascular effects (dysrhythmias, hypotension)
Administer at slow IV rate and in dilute solution to prevent adverse CV effects.
Endocrine and other effects (coarsening of facial features, hirsutism, and interference with vitamin D metabolism)
Instruct clients to report changes.
Encourage clients to consume adequate amounts of calcium and vitamin D.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="psychothepeutic-agents">PSYCHOTHEPEUTIC AGENTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#psychothepeutic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These are Antipsychotics, Antidepressants and Mood Stabilizers ANTIDEPRESSANTS
Depression is a mood (affective) disorder and is a widespread problem, ranking high among causes of disability.
Clients starting antidepressant medication therapy for depression need to be advised that symptom relief can take 1 to 3 weeks and possibly 2 to 3 months for full benefits to be achieved. Encourage continued adherence.
Clients with major depression may require hospitalization with close observation and suicide precautions until the antidepressant medications reach their peak effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antidepressants-cont">Antidepressants Cont.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antidepressants-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Antidepressant mediations are classified into four main groups:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Tricyclic antidepressants
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Selective serotonin reuptake inhibitors (SSRIs)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Monoamine oxidase inhibitors (MAOIs)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Atypical antidepressant
a)Tricyclic antidepressant;</p>
<p>Amitriptyline (Elavil), Imipramine (Tofranil), Doxepin (Sinequan), Nortriptyline (Aventyl), Amoxapine (Asendin),
Trimipramine (Surmontil)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action-of-antidepressants">Mechanism of Action of Antidepressants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-antidepressants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Tricyclic antidepressant medications block reuptake of norepinephrine and serotonin in the synaptic space, thereby intensifying the effects of these neurotransmitters.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Depression
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Chronic pain
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Childhood Enuresis
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Obsessive compulsive disorders (clomipramine)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects-of-antidepressants">Side Effects of Antidepressants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects-of-antidepressants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Sedation
Anticholinergic Effects
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Dry mouth
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Blurred vision
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Photophobia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Urinary hesitancy or retention
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Constipation
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Seizures and impotence</p>
<ul>
<li>older patients; dizziness, postural hypotension, constipation, delayed micturition, edema, muscle tremors.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="tricyclic-overdose">Tricyclic Overdose<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tricyclic-overdose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Lethal 70 to 80 percent die before reaching the hospital
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> CNS and cardiovascular systems are affected.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> death results from seizures and dysrhythmias
No specific antidote
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Decrease drug absorption with activated charcoal
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Speed elimination by alkalinizing urine
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Manage seizures and dysrhythmias
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Basic life support</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Antipsychotics and steroids may inhibit TCAs
Aspirin may displace TCAs from binding site
TCAs and alcohol potentiate the effects of each other hence death due to severe respiratory distress.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="monoamine-oxidase-inhibitors-maoi-s">Monoamine Oxidase Inhibitors (MAOI s)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#monoamine-oxidase-inhibitors-maoi-s" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Phenelzine (Nardil)
Isocarboxazid (Marplan)
Tranylcypromine (Parnate)
Selegiline (Emsam) - transdermal MAOI
Mechanism of action
MAOIs inhibit the MAO enzyme system in the CNS.
Amines ( Norepinephrine, Dopamine And Serotonin) resulting in higher levels in the brain to transmit impulses.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-use">Therapeutic use<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Highly effective considered second line treatment for depression not responsive to cyclics.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Atypical depression
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Bulimia nervosa
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Obsessive compulsive disorders (OCD)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-effects">Side effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Few side effects most common; orthostatic hypotension.
Tachycardia, dizziness, insomnia, anorexia, blurred vision, palpitation, drowsiness, headache, nausea, impotence</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="maois-overdose">MAOIs overdose<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#maois-overdose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Symptoms appear 12 hours after ingestion.
these are; tachycardia, circulatory collapse, seizure, coma.
Treatment;
gastric lavage
Urine acidification
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> hemodialysis</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="maois-hypertensive-crisis-and-tyramine">Maois Hypertensive Crisis And Tyramine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#maois-hypertensive-crisis-and-tyramine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ingestion of food/drinks with amino acid tyramine leads to hypertensive crisis, which may lead to cerebral hemorrhage, stroke, coma, or death
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Avoid foods that contain tyramine;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Aged mature cheese
Smoked/pickled or aged meat, fish, poultry(herring ,sausages, corned beef, salami, pepperoni).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Red wine(chianti, sherry, vermouth)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Italian broad beans (fava).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> MAOIs are Pregnancy Risk Category C.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> These medications are contraindicated in clients taking SSRIs and in those with pheochromocytoma, heart failure, cardiovascular and cerebral vascular disease, and severe renal insufficiency.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Use cautiously in clients with diabetes and seizure disorders or those taking TCAs.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Transdermal selegiline is contraindicated for clients taking carbamazepine (Tegretol) or oxcarbazepine (Trileptal), which may increase blood levels of the MAOI.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="selective-serotonin-reuptake-inhibitors-ssris">Selective Serotonin Reuptake Inhibitors (SSRIs)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#selective-serotonin-reuptake-inhibitors-ssris" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Fluoxetine (Prozac)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Citalopram (Celexa)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Escitalopram oxalate (Lexapro)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Paroxetine (Paxil)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Sertraline (Zoloft)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacodynamics">Pharmacodynamics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> SSRI inhibit the reuptake of only serotonin at the part of the amine pump that is specifically for reuptake of serotonin.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> This explains why these drugs have lesser unwanted effects compared to TCAs.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> the drug of choice for Depression.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Major depression
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Obsessive compulsive disorders (OCD)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Bulimia nervosa
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Premenstrual dysphoric disorders
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Panic disorders
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Posttraumatic disorder (PTSD)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>SSRIs are well absorbed orally</li>
<li>Wide distribution and half life of fifteen to 24 hour but fluoxetine has a half life of 24 to ninety six hours.</li>
<li>They achieve effects within 2 to 4 weeks.</li>
<li>Paroxetine and fluoxetine are not used with TCAs since they inhibit TCA hepatic metabolism</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="unwanted-effects">- Unwanted effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#unwanted-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This include nausea and vomiting, diarrhea, agitation, anorgasmia priapism.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>MAOIs, TCAs, and St. John's wort increase the risk of serotonin syndrome.</li>
<li>Fluoxetine can displace warfarin (Coumadin) from bound protein and result in increased warfarin levels.</li>
<li>Fluoxetine can increase the levels of tricyclic antidepressants and lithium.</li>
<li>Fluoxetine suppresses platelet aggregation and thus increases the risk of bleeding when used concurrently with NSAIDs and anticoagulants.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="second-generation-antidepressants">Second Generation Antidepressants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#second-generation-antidepressants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="newer">Newer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#newer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Fewer side effects than tricyclic but not superior in overall efficacy or onset of action.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="examples-are">Examples are<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#examples-are" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Trazodone,
Bupropion
Duloxetine</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>selective inhibition of serotonin uptake
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Advantage over tricyclic and MAOIs little or no effect on cardiovascular system.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Depression, bipolar affective disorders, obesity, eating disorders, obsessive compulsive disorders, panic attacks, myoclonus, treatment for various substance abuse problems (bupropion is used for smoking cessation treatment)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CNS; headache, dizziness, nervousness, insomnia, fatigue and tremors.
GI; nausea, diarrheal, constipation, dry mouth, sweating, sexual dysfunction .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antipsychotic-tranquilizers-neuroleptics">ANTIPSYCHOTIC/ TRANQUILIZERS/NEUROLEPTICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antipsychotic-tranquilizers-neuroleptics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Classification of neuroleptic is based on chemical structure or severity of resulting unwanted effects.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Based on unwanted effect;
Conventional (typical, first generation)
Examples;
Chlorpromazine, haloperidol, and fluphenazine
Newer (atypical, second generation)
Example; clozapine, loxapine, asenapine, olanzapine, quetiapine, paliperidone, risperidone, sertindole.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a4b572ad">Classification cont. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7519em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span><span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a4b572ad" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>The distinction between typical and atypical neuroleptic is not clear but rest on ; receptor profile, incidence of extrapyramidal effects which are less in the atypical group, efficacy in treatment and efficacy in negative symptoms.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-according-to-chemical-structures">Classification according to chemical structures;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-according-to-chemical-structures" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Phenothiazines; chlorpromazine 100 to 1500 mg , trifluoperazine, fluphenazine 1 to 10 mg</p>
<p>Butyrophenones; haloperidol 2 to 20mg
Dibenzodiazepine; clozapine 25 to 900mg
Thienobenzodiazepines; olanzapine
Thioxanthene's; flupentixol 6 to 18mg
Benzisoxazole; risperidone 1to 12mg</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacodynamics">Pharmacodynamics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> They act by blocking the dopamine receptor.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indication">Indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Treatment of acute and chronic psychosis
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Schizophrenia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Bipolar disorders (primarily the manic phase)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Tourette's syndrome
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Delusional and schizoaffective disorders
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Dementia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Prevention of nausea/vomiting through blocking of dopamine in the chemoreceptor trigger zone of the medulla
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> hiccups</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects-typical-antipsychotic">Side Effects Typical Antipsychotic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects-typical-antipsychotic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Extrapyramidal effects (dystonia, parkinsonism, tardative dyskinesia)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Anticholinergic effects; (dry mouth, blurred vision, urinary retention, constipation and impotence)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Cardiovascular effects; tachycardia, arrhythmias, postural hypotention
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Galactorrhea,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> gynecomastia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effect-atypical-antipsychotics">Side Effect Atypical Antipsychotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effect-atypical-antipsychotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Clozopine; weight gain, agranulocytosis
Risperidone; insomnia anxiety, agitation
Olanzapine; weight gain, dizziness, sedation, anticholinergic effect</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mood-stabilizers">Mood Stabilizers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mood-stabilizers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lithium-carbonate">lithium carbonate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lithium-carbonate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Lithium produces neurochemical changes in the brain, including serotonin receptor blockade.
There is evidence that the use of lithium can show a decrease in neuronal atrophy and/or an increase in neuronal growth.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Lithium is used in the treatment of bipolar disorders. Lithium controls episodes of acute mania, helps prevent the return of mania or depression, and decreases the incidence of suicide.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Other uses:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Alcoholism
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Bulimia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Schizophrenia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Absorption :rate and extent vary with dose form. absorption is complete within hours of oral use.
Distribution :wide distribution in the body, concentration in thyroid gland, bone and brain tissue exceed serum levels.
Metabolism :not metabolized
Excretion : excreted unchanged in urine. Half lif18 hours (adolescence)to 3 hour (elderly).
Dosage adults : 300 mg to six hundred mg up to q.i.d increasing to achieve optimal dosage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reaction">Adverse reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Gastrointestinal distress (nausea, diarrhea, abdominal pain).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Fine hand tremors that can interfere with purposeful motor skills and can be exacerbated by factors such as stress and caffeine.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Polyuria, mild thirst.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Weight gain
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Renal toxicity
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Goiter and hypothyroidism with long-term treatment Brady dysrhythmia, hypotension, and electrolyte imbalances .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Lithium is Pregnancy Risk Category D. This medication is teratogenic, especially during the first trimester.
Discourage clients from breastfeeding if lithium therapy is necessary.
Use cautiously in clients with renal dysfunction, heart disease, sodium depletion, and dehydration</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Sodium is excreted with the use of diuretics. Reduced serum sodium decreases lithium excretion, which can lead to toxicity.
Concurrent use of NSAIDs (ibuprofen [Motrin] and celecoxib [Celebrex]) will increase renal reabsorption of lithium, leading to toxicity.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Avoid use of NSAIDs.
Use aspirin as a mild analgesic.
Anticholinergics (antihistamines, tricyclic antidepressants) can induce urinary retention and polyuria, leading to abdominal discomfort
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Advise clients to avoid medications with anticholinergic effects. rt.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precaution-during-administration">Precaution during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precaution-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Monitor plasma lithium levels while undergoing treatment. At initiation of treatment, monitor levels every 2 to 3 days and then every 1 to 3 months. Lithium blood levels should be obtained in the morning, usually 12 hr . after the last dose.
During initial treatment of a manic episode, levels should be between 0.8 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">1.4 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.4</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>.
Maintenance level range is between 0.4 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">1.0 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>.
Plasma levels <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">&gt;1.5 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> can result in toxicity.
Care for clients who have a toxic plasma lithium level in an inpatient setting and provide supportive measures. Hemodialysis may be indicated.
Advise clients that effects begin within 7 to 14 days.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precaution-during-administration-cont">Precaution during Administration cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precaution-during-administration-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Advise clients to take lithium as prescribed. Lithium must be administered in 2 to 3 doses daily due to a short half life. Taking lithium with food will help decrease GI distress.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Encourage clients to adhere to laboratory appointments needed to monitor lithium effectiveness and adverse effects. Emphasize the high risk of toxicity due to the narrow therapeutic range.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Provide nutritional counseling. Stress the importance of adequate fluid and sodium intake.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Instruct clients to monitor for signs of toxicity and when to contact the provider. Clients should stop taking medication and seek medical attention if experiencing diarrhea, vomiting, or excessive sweating.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-mood-stabilizing-drugs">Other mood stabilizing drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-mood-stabilizing-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Carbamazepine (Tegretol)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Valproic acid (Depakote)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Lamotrigine (Lamictal) Purpose</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>AEDs help treat and manage bipolar disorders by various mechanisms, which include:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Slowing the entrance of sodium and calcium back into the neuron and, thus extending the time it takes for the nerve to return to its active state.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Potentiating the inhibitory effects of gamma butyric acid (GABA)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Inhibiting glutamic acid (glutamate) which in turn suppresses CNS excitation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Treatment of manic and depressive episodes, prevention of relapse of mania and depressive episodes.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Especially useful for clients with mixed mania and rapid cycling bipolar disorders.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cns-stimulants">CNS STIMULANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cns-stimulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>MEDICATION</th><th>SHORT ACTING</th><th>INTERMEDIATE ACTING</th><th>LONG ACTING</th></tr></thead><tbody><tr><td>Methylphenidate</td><td>Ritalin, Methylin</td><td>Ritalin SR, Methylin ER</td><td>ethylin ER Ritalin LA, Concerta,</td></tr><tr><td>Daytrana (transdermal)</td><td></td><td></td><td></td></tr><tr><td>Dexmethylphenidate</td><td>Focalin</td><td></td><td></td></tr><tr><td>Dextroamphetamine</td><td>Dexedrine</td><td></td><td>Dexedrine Spansule</td></tr><tr><td>Amphetamine mixture</td><td>Adderall</td><td></td><td>Adderall-XR</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cns-stimulants-cont">CNS Stimulants Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cns-stimulants-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action :<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These medications raise the levels of norepinephrine, serotonin, and dopamine into the CNS.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>ADHD ( Attention Deficit Hyperactivity Disorder)</li>
<li>Conduct disorder</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> CNS stimulation (insomnia, restlessness)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Weight loss
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Cardiovascular effects (dysrhythmias, chest pain, high blood pressure) - These medications may increase the risk of sudden death in clients with heart abnormalities.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Development of psychotic symptoms such as hallucinations, paranoia Withdrawal reaction.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hypersensitivity skin reaction to transdermal methylphenidate (hives, papules)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These medications are contraindicated in clients who have a history of drug abuse, cardiovascular disorders, severe anxiety, and psychosis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Concurrent use of MAOI s may cause hypertensive crisis.
Concurrent use of caffeine may increase CNS stimulant effects.
Methylphenidate inhibits metabolism of phenytoin (Dilantin), warfarin (Coumadin), and phenobarbital, leading to increased serum levels.
OTC cold and decongestant medications with sympathomimetic action can increase CNS stimulant effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="muscle-relaxant-neuromuscular-blocking-agents">MUSCLE RELAXANT/ NEUROMUSCULAR BLOCKING AGENTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#muscle-relaxant-neuromuscular-blocking-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Neuromuscular blocking agents have various uses including assisting with:</li>
<li>sedation during general anesthesia,</li>
<li>control of seizures during electroconvulsive therapy,</li>
<li>suppression of gag reflex during endotracheal intubation.</li>
<li>Medications include succinylcholine (Anectine) and vecuronium (Norcuron)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-parkinson-s-drugs">Anti -Parkinson's drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-parkinson-s-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="neuromuscular-agents-cont">Neuromuscular Agents Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#neuromuscular-agents-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Muscle relaxants and antispasmodic agents can affect both the central and peripheral nervous systems.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> These agents are used with spasticity related to muscle injury, cerebral palsy, spinal cord injury, and multiple sclerosis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Agents include diazepam (Valium), baclofen (Lioresal), and dantrolene (Dantrium).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Bethanechol (Urecholine), a muscarinic agonist, is used for urinary retention.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Oxybutynin (Ditropan), a muscarinic antagonist, is used for neurogenic bladder</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="muscle-relaxant-neuromuscular-blocking-agents-cont">Muscle relaxant/ Neuromuscular Blocking Agents cont.'<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#muscle-relaxant-neuromuscular-blocking-agents-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Depolarizing neuromuscular blocker: succinylcholine (Anectine)
Nondepolarizing neuromuscular blockers: pancuronium (Pavulon)
Other Medications:
Nondepolarizing neuromuscular blockers: atracurium (Tracrium), Vecuronium (Norcuron)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Neuromuscular blocking agents block acetylcholine (ACh) at the neuromuscular junction, resulting in muscle relaxation and hypotension. They do not cross the blood-brain barrier, so complete paralysis can be achieved without loss of consciousness or decreased pain sensation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="neuromuscular-agents-cont">Neuromuscular Agents Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#neuromuscular-agents-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Neuromuscular blocking agents are used as adjuncts to general anesthesia to promote muscle relaxation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> These agents are used to control spontaneous respiratory movements in clients receiving mechanical ventilation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> These agents are used as seizure control during electroconvulsive therapy.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Neuromuscular blocking agents are used during endotracheal intubation and endoscopy</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Respiratory arrest from paralyzed respiratory muscles
Hypotension
Low pseudo cholinesterase activity can lead to prolonged apnea
Signs of malignant hyperthermia include muscle rigidity accompanied by increased temperature, reaching levels as high as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>43</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">43^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">4</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">C</mi><mrow><mo fence="true">(</mo><msup><mn>109.4</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">F</mi><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{C}\left(109.4^{\circ} \mathrm{F}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">C</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord">109.</span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">F</span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>.
After 12 to 24 hr . postoperative, clients may experience muscle pain in the upper body and back.
Hyperkalemia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>General anesthetics are often used concurrently in surgery.</p>
<ul>
<li>Dosage of tubocurarine should be reduced to prevent extreme neuromuscular blockade.
Aminoglycosides and tetracyclines can increase the effects of neuromuscular blockade.</li>
<li>Take complete medication history of clients who are to receive neuromuscular blockade.
Neostigmine and other cholinesterase inhibitors increase the effects of depolarizing neuromuscular blockers, such as succinylcholine.</li>
<li>Monitor clients during neuromuscular blockade reversal after surgery</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="local-anaesthetics">LOCAL ANAESTHETICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#local-anaesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>local anesthetic bind reversibly to a specific receptor site within the pore of the sodium channels in nerves and block ion movement when applied locally to nerve tissues in appropriate concentration.
Local anesthetic can act on any part of the nervous system, on every type of nerve fibers, reversibly blocking the action potentials responsible for nerve conduction.
Thus a local anesthetic in contact with a nerve trunk can cause both sensory and motor paralysis in the area innervated.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Local anesthetic block conduction by decreasing or preventing the large transient increase in the permeability of excitable membranes.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> This action is due to direct interaction with voltage gated sodium channels.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> As the anesthetic action progressively develops in the nerve ,the threshold for electrical excitability increase. The rate of rise of the action potential also declines, impulse conduction slows, and nerve conduction eventually fails.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="local-anesthetics">Local anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#local-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>Drug</th><th>Duration of action</th></tr></thead><tbody><tr><td>lidocaine</td><td>medium</td></tr><tr><td>Bupivacaine (Marcaine),levobupivacaine (chirocaine)</td><td>long</td></tr><tr><td>Ropivacaine (naropin)</td><td>long</td></tr><tr><td>Mepivacaine (carbocaine, isocaine)</td><td>medium</td></tr><tr><td>articaine</td><td>medium</td></tr><tr><td>Cocaine</td><td>medium</td></tr><tr><td>benzocaine</td><td>surface use only</td></tr><tr><td>Tetracaine (pontocaine)</td><td>long</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="neuromuscular-agents">Neuromuscular agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#neuromuscular-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The action of non depolarizing muscle relaxant is antagonized, once muscle paralysis is no longer desired with an acetylcholinesterase inhibitor such as neostigmine or edrophonium.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="skeletal-muscle-relaxants">Skeletal Muscle Relaxants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#skeletal-muscle-relaxants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="succinylcholine">Succinylcholine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#succinylcholine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Succinylcholine mimics ACh by binding with cholinergic receptors at the neuromuscular junction. This agent fills the cholinergic receptors, preventing ACh from binding with them, and causes sustained depolarization of the muscle, resulting in muscle paralysis.
Reversal agent: Pseudo cholinesterase enzyme</li>
<li>Pancuronium, atracurium, vecuronium</li>
<li>These agents block ACh from binding with cholinergic receptors at the motor end plate. Muscle paralysis occurs because of inhibited nerve depolarization and skeletal muscle contraction.</li>
<li>Reversal agent: Neostigmine (Prostigmin)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="general-anesthetics">General Anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>General anesthetics depress the CNS sufficiently to permit surgery and other noxious or unpleasant procedures.
Gas have a low therapeutic indices and are require great care in administration.
The consideration of patients age, associated medical condition and medication use is important.
The physiological state induced by general anesthesia include; analgesia, amnesia, loss of consciousness, inhibition of sensory and autonomic reflexes, and skeletal muscle relaxation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-parenteral-anesthetics">a)Parenteral anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-parenteral-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetic-principle">Pharmacokinetic principle<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetic-principle" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>After a single intravenous bolus these drugs preferentially partition into the highly perfused and lipophilic tissues of the brain and the spinal cord where they produce anesthesia within a single circulation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Blood levels falls rapidly, resulting in drug redistribution out of the cns back into the blood.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> The anesthetics then perfuse into less perfused tissues such as muscle and viscera, and at a slower rate into the poorly perfused but very hydrophobic adipose tissue.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="parenteral-anesthetics">Parenteral Anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#parenteral-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*Thiopental and Propofol are the two most commonly used parenteral agents.
*thiopental has a long established track record of safety.
*Propofol is advantageous for procedures where rapid return to a preoperative mental status is desirable.
*Etomidate usually is reserved for patients at risk for hypotension and /myocardial ischemia
*Ketamine is best suited for patients with asthma, children undergoing short ,painful procedures</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-characteristics-of-parenteral-anesthetics-iv">Pharmacological characteristics of parenteral anesthetics (IV)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-characteristics-of-parenteral-anesthetics-iv" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>DRUG</th><th>INDUCTION AND RECOVERY</th><th>COMMENTS</th></tr></thead><tbody><tr><td>etomidate</td><td>Rapid onset and moderate fast recovery</td><td>Provides cardiovascular stability, causes decreased steroidal genesis and involuntary muscle movement</td></tr><tr><td>ketamine</td><td>Moderate onset and recovery</td><td>Causes cardiovascular stimulation, increase cerebral blood flow and emergence reaction that impair recovery</td></tr><tr><td>midazolam</td><td>Slow onset and recovery; flumazenil reversal available</td><td>Provides cardiovascular stability and marked amnesia, used in balanced anesthesia and conscious sedation.</td></tr><tr><td>Propofol</td><td>Rapid onset and recovery</td><td>Used in induction and maintenance can cause hypotension ,has useful antiemetic action.</td></tr><tr><td>thiopental</td><td>Rapid onset and recovery (bolus dose) slow recovery following infusion.</td><td>Standard induction agent, causes cardiovascular depression, avoid in porphyria's</td></tr><tr><td>fentanyl</td><td>Slow onset and recovery.</td><td></td></tr><tr><td>Naloxone reversal available</td><td>opioid used in balanced anesthesia and conscious sedation produces marked analgesia</td><td></td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="inhalation-anesthetics">Inhalation Anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inhalation-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They have a low safety margin.
The selection of inhalation anesthetic is often marching a patient pathophysiology with drug side effects.
The inhalation anesthetics also vary widely in their physical properties, which govern the pharmacokinetics of the inhalation agents
They produce a rapid induction of anesthesia and a rapid recovery following discontinuation.
Examples are: nitrous oxide, halothane, desflurane, sevoflurane, enflurane, and methoxyflurane.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effect-of-anesthetics">Side effect of Anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effect-of-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hemodynamic effect e.g. decrease in systemic arteria BP.
respiratory effects; elimination of both ventilatory drive and reflex that maintain airway patency, gag reflex is lost, no cough stimulus, lower esophageal sphincter tone is reduced.
Hypothermia, nausea and vomiting.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-emergence-postoperative-effects">Other Emergence Postoperative effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-emergence-postoperative-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypotension and tachycardia,myocardial ischemia,post anesthesia shivering, (give small dose of meperidine 12 mg lowers the shivering triggers temperature.
Airway obstruction
Respiratory suppression
Hypoxemia may occur
Negative pressure pulmonary edema may occur due to strong inspiratory efforts against a closed glottispain control can be complicated
These emergence phenomena can be greatly reduced when opioids are employed as part of the intraoperative regimen</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cvs-diuretics">CVS: DIURETICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cvs-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diuretics are drugs that increase the rate of urine flow; clinically useful diuretics also increase the rate of excretion of sodium and accompanying anion chloride.
Most clinical application of diuretics aim to reduce extracellular fluid volume by decreasing total sodium chloride volume.
diuretics alter excretion of sodium and also may modify handling of other cations(potassium, hydrogen and magnesium) anions (chloride, bicarbonate, hydrogen phosphate ), and uric acid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-pharmacology-of-diuretics">Clinical Pharmacology of Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-pharmacology-of-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*Edematous state :in heart failure, kidney disease and in renal failure.
*Non edematous state : in hypertension, nephrolithiasis hypercalcemia.</p>
<p>Classification of diuretics
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Loop Diuretics : furosemide</p>
<blockquote>
<p>Thiazide Diuretics: hydrochlorothiazide
Potassium Sparing diuretics: spironolactone
Osmotic Diuretic: mannitol
Carbonic Anhydrase Inhibitors: acetazolamide (DIAMOX)</p>
</blockquote>
<p>Hormones Acting on the Nephron / Diuretics and Their Site of Action</p>
<p><img src="data:image/jpeg;base64,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" alt="img-0.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-high-ceiling-loop-diuretics">a)High Ceiling Loop Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-high-ceiling-loop-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="furosemide-lasix">Furosemide (Lasix)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#furosemide-lasix" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Other Medications:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Ethacrynic acid (Edecrin)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Bumetanide (Bumex)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Torsemide (Demadex)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> High ceiling loop diuretics work in the ascending limb of loop of Henle to:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Block reabsorption of sodium and chloride and to prevent reabsorption of water, Cause extensive diuresis even with severe renal impairment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses-of-furosemide-lasix">Therapeutic Uses of Furosemide (Lasix)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses-of-furosemide-lasix" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>High ceiling loop diuretics are used when there is an emergent need for rapid mobilization of fluid such as:
*Pulmonary edema caused by heart failure</li>
<li>Conditions not responsive to other diuretics such as edema caused by liver, cardiac, or kidney disease; hypertension</li>
<li>These medications may also be used to treat hypercalcemia related to kidney stone formation.</li>
<li>Route of administration: Oral, IV, IM.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Dehydration, hyponatremia, hypochloremia.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hypotension
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Ototoxicity (transient with furosemide and irreversible with ethacrynic acid)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hypokalemia ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">K</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{K}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">K</span><span class="mord">+</span></span></span></span></span> less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">3.5 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.5</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Other adverse effects (hyperglycemia, hyperuricemia, and decrease in calcium and magnesium levels)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Contraindications/Precautions ;Pregnancy Risk Category C , Avoid using these medications during pregnancy unless absolutely required. Use cautiously in clients who have diabetes and/or gout</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug Interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Digoxin (Lanoxin) toxicity can occur in the presence of hypokalemia.</li>
<li>Concurrent use of antihypertensive can have additive hypotensive effect.</li>
<li>Hyponatremia can lead to decrease in lithium carbonate excretion, which may lead to toxicity.</li>
<li>NSAIDs reduce diuretic effect.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Obtain the client's baseline data to include orthostatic blood pressure, weight, electrolytes, and location and extent of edema.</li>
<li>Weigh clients at the same time each day; usually upon awakening.</li>
<li>Monitor the client's blood pressure and I&amp;O.</li>
<li>Avoid administering the medication late in the day to prevent nocturia. Usual dosing time is 0800 and 1400.</li>
<li>Administer furosemide orally, IV bolus dose, or continuous IV infusion. Infuse IV doses at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> or slower to avoid abrupt hypotension and hypovolemia.
*If potassium level drops below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">3.5 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.5</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>, clients should be placed on a potassium supplement.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-cont">Precautions During Administration Cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>If the medication is used for hypertension, teach clients to self-monitor blood pressure and weight by keeping a log.</li>
<li>Advise clients to get up slowly to minimize postural hypotension. If faintness or dizziness occurs, instruct clients to sit or lie down.</li>
<li>Teach clients to report significant weight loss, lightheadedness, dizziness, GI distress, and/ or general weakness to the provider.</li>
<li>Encourage clients to consume foods high in potassium, such as avocados and strawberries.</li>
<li>Instruct clients with diabetes to monitor for elevated blood glucose levels.</li>
<li>Instruct clients to observe for signs of low magnesium levels such as muscle twitching and tremors.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b-thiazide-diuretics">b)Thiazide Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-thiazide-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Hydrochlorothiazide (Hydrodiuril)
Other Medications:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Chlorothiazide (Diuril)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Methyclothiazide (Enduron)
Thiazide-type diuretics:
indapamide (Lozide, Lozol)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> chlorthalidone (Hygroton)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> metolazone (Zaroxolyn)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Thiazide diuretics work in the early distal convoluted tubule to:</li>
<li>Block the reabsorption of sodium and chloride, and prevent the reabsorption of water at this site</li>
<li>Promote diuresis when renal function is not impaired</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Thiazide diuretics are often the medication of first choice for essential hypertension.
These medications may be used for edema of mild-to-moderate heart failure and liver and kidney disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Dehydration
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hypokalemia (K+ less than 3.5 mEq/L)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hyperglycemia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Digoxin (Lanoxin) toxicity can occur in the presence of hypokalemia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Antihypertensive have additive hypotensive effects. Monitor the client's blood pressure.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hyponatremia can lead to decrease in lithium (Eskalith) excretion, which may lead to toxicity.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> NSAIDs reduce diuretic effect</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Chlorothiazide may be administered orally and IV, all others can only be given orally.</li>
<li>Obtain the client's baseline data to include orthostatic blood pressure, weight, electrolytes, and location and extent of edema.</li>
<li>Monitor the client's potassium levels</li>
<li>Instruct clients to take the medication first thing in the morning; if twice-a-day dosing is prescribed, be sure the second dose is taken by 1400 to prevent nocturia.</li>
<li>Encourage clients to consume foods high in potassium and maintain adequate fluid intake ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>500</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">1,500 \mathrm{~mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">500</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mL</span></span></span></span></span></span> per day, unless contraindicated).</li>
<li>If GI upset occurs, clients should take the medication with or after meals.</li>
<li>Alternate-day dosing can decrease electrolyte imbalance</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="c-potassium-sparing-diuretics">c)Potassium-Sparing Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-potassium-sparing-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Spironolactone (Aldactone)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-medications">Other Medications:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-medications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>t\Triamterene (Dyrenium), amiloride (Midamor)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Potassium-sparing diuretics block the action of aldosterone (sodium and water retention), which results in potassium retention and the secretion of sodium and water.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Potassium-sparing diuretics are combined with other diuretics for potassium-sparing effects.
*Potassium-sparing diuretics are used for heart failure.
*In primary hyperaldosteronism, potassium-sparing diuretics block actions of aldosterone.</li>
</ul>
<p>Route of administration: Oral</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-adverse-effects">Side/Adverse Effects;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hyperkalemia (K+ greater than 5.0 mEq/L)
*Endocrine effects (impotence in male clients; irregularities of menstrual cycle in female clients).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precaution">Contraindications/Precaution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precaution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Do not administer to clients who have hyperkalemia.</li>
<li>Potassium-sparing diuretics are contraindicated in clients who have severe renal failure and anuria.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interaction">Medication/Food Interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Concurrent use of ACE inhibitors increases the risk of hyperkalemia
Concurrent use of potassium supplements increases the risk of hyperkalemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Obtain the client's baseline data.</li>
<li>Monitor the client's potassium levels regularly.</li>
<li>Can only be given orally.</li>
<li>Teach clients to avoid salt substitutes that contain potassium.</li>
<li>Teach clients to self-monitor blood pressure.</li>
<li>Instruct clients to keep a log of blood pressure and weight.</li>
<li>Warn clients that triamterene may turn urine a bluish color.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="d-osmotic-diuretics">d)Osmotic Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-osmotic-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Mannitol (Osmitrol)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Osmotic diuretics reduce intracranial pressure and intraocular pressure by raising serum osmolality and drawing fluid back into the vascular and extravascular space.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Osmotic diuretics prevent renal failure in specific situations, such as hypovolemic shock and severe hypotension.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> These medications decrease intracranial pressure (ICP) caused by cerebral edema.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> These medications decrease intraocular pressure (IOP).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Osmotic diuretics promote sodium retention and water excretion in clients with hyponatremia and fluid volume excess</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Renal failure
Heart failure, pulmonary edema
Fluid and electrolyte imbalances
Contraindications/Precautions
Use extreme caution in clients with heart failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Furosemide contributes to therapeutic effect by promoting renal excretion of fluid drawn into vasculature by osmotic diuretics.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Administer mannitol by continuous IV infusion.
To prevent administering microscopic crystals, use a filter needle when drawing from the vial and a filter in the IV tubing.
Monitor daily weight, I &amp; 0, and serum electrolytes.
Monitor for signs of dehydration, acute renal failure, and edema.
Use of furosemide may help prevent rebound fluid retention; this contributes to therapeutic effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="carbonic-anhydrase-inhibitors">Carbonic Anhydrase Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#carbonic-anhydrase-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Blockade of carbonic anhydrase activity induces a sodium bicarbonate diuresis, which reduces body bicarbonate levels.
These drugs include;
Acetazolamide (DIAMOX)
Dichlorphenamide (DARANIDE)
Methazolamide (GLAUCTABS)
Acetazolamide administration causes a reduction in aqueous humour and CSF fluid production</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acetazolamide-cont">Acetazolamide cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acetazolamide-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>The proximal tubule is the major site of action of carbonic anhydrase inhibitors.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> the collecting duct is the secondary site of action .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-application">Clinical application<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-application" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Glaucoma; because acetazolamide decreases the rate of aqueous humor production, a decline in IOP occurs.
The major indication of carbonate anhydrase inhibitor is open angle glaucoma.
It may also be given in secondary glaucoma
Preoperatively in acute angle glaucoma.
Treatment of epilepsy.
Altitude sickness familial periodic paralysis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="toxicity">Toxicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#toxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hyper chloremic acidosis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Renal potassium loss.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Hepatic cirrhosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antihypertensives">Antihypertensives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antihypertensives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cardiovascular-pharmacology">Cardiovascular pharmacology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-pharmacology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Antihypertensive drugs potential drug targets;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> CNS: decrease sympathetic tone
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Heart: decrease cardiac out put
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Veins: dilate; decrease preload
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> arterioles: dilate; decrease preload
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Kidneys: increase diuresis; inhibit renin angiotensin aldosterone</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-anti-hypertensives-diuretics">Classification of Anti Hypertensives Diuretics:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-anti-hypertensives-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Thiazide and related agents (hydrochlorothiazide, chlorthalidone)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Loop diuretics (furosemide, bumetanide,, torsemide, ethacrynic)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Potassium sparing diuretics (amiloride, triamterene, spironolactone)
Angiotensin-converting enzyme (ACE) inhibitors ( captopril, enalapril, lisinopril, quinapril, Ramipril, benazepril)</p>
<p>Angiotensin II receptor blockers (ARBS)
(losartan, candesartan, Irbesartan, valsartan, telmisartan, eprosartan)
Calcium channel blockers (CCB)
(verapamil, diltiazem, nifedipine, felodipine, nicardipine, isradipine, amlodipine),</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-antihypertensive-cont">Classification of Antihypertensive Cont..<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-antihypertensive-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vasodilators">Vasodilators<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vasodilators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Arterial ( hydralazine, minoxidil, diazoxide fenoldopam)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Arterial and venous (nitroprusside)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sympatholytic-drugs">Sympatholytic drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sympatholytic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Alpha adrenergic blockers; (prazosin, terazosin, doxazosin, phentolamine, phenoxybenzamine)
Beta adrenergic blockers; (metoprolol, atenolol, etc )
Mixed adrenergic; ( labetalol, carvedilol)
Centrally acting alpha2 agonists (methyldopa, clonidine, guanabenz)
Adrenergic neuron blocking agents;( guanethidine, reserpine)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angiotensin-converting-enzyme-ace-inhibitors">Angiotensin-Converting Enzyme (ACE) Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-converting-enzyme-ace-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="captopril-capoten">Captopril (Capoten)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#captopril-capoten" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Other Medications: Enalapril (Vasotec), Enalaprilat (Vasotec IV), Fosinopril (Monopril), Lisinopril (Prinivil), Ramipril (Altace)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>ACEIs prevents conversion of angiotensin I to angiotensin II which is a potent vasoconstrictor. this causes vasodilation, reduces peripheral resistance, and decreases secretion of aldosterone (thereby resulting in decrease sodium and water retention and extracellular volume).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="merits-of-aceis">Merits of ACEIs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#merits-of-aceis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>Safe for asthmatics, diabetics</p>
</li>
<li>
<p>Absence of rebound hypertension upon abrupt withdrawal.</p>
</li>
<li>
<p>Total absence of postural hypotension.</p>
</li>
<li>
<p>maintains renal blood flow.
*devoid of electrolyte imbalance.</p>
</li>
<li>
<p>Hypertension</p>
</li>
<li>
<p>Heart failure</p>
</li>
<li>
<p>Myocardial infarction (To decrease mortality and to decrease risk of heart failure and left ventricular dysfunction)</p>
</li>
<li>
<p>Diabetic and nondiabetic nephropathy</p>
</li>
<li>
<p>For clients at high risk for a cardiovascular event, Ramipril can be used to prevent MI, stroke, or death.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cough related to inhibition of kinase II (alternative name for ACE) which results in increase in bradykinin
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> First-dose orthostatic hypotension.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hyperkalemia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Rash and dysgeusia (altered taste), primarily with captopril
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Angioedema.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Neutropenia (rare but serious complication of captopril)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These medications are Pregnancy Risk Category D during the second and third trimester, related to fetal injury.
renal stenosis when present bilaterally or in a single remaining kidney.
history of angioedema following use of ACE inhibitor.
Use cautiously in clients with renal impairment and
collagen vascular disease because they are at greater risk for developing neutropenia. Closely monitor these clients for signs of infection.
hypotension</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diuretics can contribute to first-dose hypotension
Antihypertensive medications may have an additive hypotensive effect.
Potassium supplements and potassium-sparing diuretics increase the risk of hyperkalemia.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> ACE inhibitors can increase levels of lithium carbonate (Eskalith)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Use of NSAIDs may decrease the antihypertensive effect of ACE inhibitors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Administer ACE inhibitors orally except enalapril, which is the only ACE inhibitor for IV use.</li>
<li>Advise clients that the medication may be prescribed as a single formulation or in combination with hydrochlorothiazide.</li>
<li>Advise clients that blood pressure has to be monitored after the first dose for at least 2 hr . to detect hypotension.</li>
<li>Instruct clients that captopril should be taken at least 1 hr . before meals. All other ACE inhibitors can be taken with or without food.
*Advise clients to notify the provider if cough, rash, dysgeusia (lack of taste), and/or signs of infection occur</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angiotensin-ii-receptor-blockers-arbs">Angiotensin II Receptor Blockers (ARBs)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-ii-receptor-blockers-arbs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="losartan-cozaar">Losartan (Cozaar)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#losartan-cozaar" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Other Medications: Valsartan (Diovan), Irbesartan (Avapro), Candesartan (Atacand), Olmesartan (Benicar)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These medications block the action of angiotensin II in the body.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="this-results-in">This results in:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#this-results-in" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Vasodilation (mostly arteriole)</li>
<li>Excretion of sodium and water, and retention of potassium (through effects on the kidney)</li>
</ul>
<p>*Hypertension,
*Heart failure and prevention of mortality following MI,</p>
<ul>
<li>Stroke prevention ,</li>
<li>Delay progression of diabetic nephropathy</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="complications">Complications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The major difference between ARBs and ACE inhibitors is that cough and hyperkalemia are not side effects of ARBs</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="angioedema">* Angioedema<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angioedema" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hypersensitivity</li>
<li>Pregnancy</li>
<li>renal stenosis when present bilaterally or in a single remaining kidney</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="considerations">Considerations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>monitor BP, HR, Weight, Edema, Blood Urea Nitrogen, Serum Creatinine.</li>
<li>can be used in patients intolerant to aceis (due to cough)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="calcium-channel-blockers">CALCIUM CHANNEL BLOCKERS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calcium-channel-blockers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Nifedipine (Adalat, Procardia)</li>
<li>Verapamil (Calan)</li>
<li>Amlodipine (Norvasc)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-medications">Other Medications:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-medications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Amlodipine (Norvasc)</li>
<li>Felodipine (Plendil)</li>
<li>Nicardipine (Cardene, Cleviprex)</li>
<li>Diltiazem (Cardizem)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action-of-ccb">Mechanism of action of CCB<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-ccb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Inhibits calcium influx in the smooth muscles and the myocardium.</li>
<li>Blocking of calcium channels in blood vessels leads to vasodilation of peripheral arterioles and arteries/arterioles of the heart, slows down heart conduction and reduction of blood pressure.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nifedipine-adalat">NIFEDIPINE (ADALAT)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nifedipine-adalat" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>give rise to coronary vasodilation.</li>
<li>Enhances coronary blood flow.</li>
<li>Reduces total periphery resistance, reduces systolic and diastolic pressure</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-use">Therapeutic use<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Chronic angina</li>
<li>Congestive heart failure</li>
<li>Acute myocardial infarction</li>
<li>Peripheral vascular disorders</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-drug-reaction">Adverse drug reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-drug-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Palpitation, nausea, vomiting, flushing, headache, edema.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="amlodipine">Amlodipine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#amlodipine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Serves as a long acting calcium channel blocker.</li>
</ul>
<p>Therapeutic use</p>
<ul>
<li>Treatment of essential hypertension.</li>
<li>Angina pectoris</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-drug-reaction">Adverse drug reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-drug-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Palpitation,epixtasis,cough,nocturia,musclecramps,breathless,importen ce, conjunctivitis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="verapamil">Verapamil<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#verapamil" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Enhances coronary blood flow rate,vasodilation.</li>
<li>Exerts anti arrhythmic action.</li>
<li>Reduces peripheral resistance.</li>
</ul>
<p>Therapeutic uses</p>
<ul>
<li>Supraventricular tachycardia.</li>
<li>Acute coronary spasms</li>
<li>Angina pectoris</li>
<li>Hypertension with myocardial infarction</li>
</ul>
<ul>
<li>Dizziness, vertigo, constipation, hypotension, nausea, pedal edema</li>
</ul>
<p>Advantages of calcium channel blockers
Exhibits rapid onset and longer duration of action hence administered once a day.
Do not exhibit cardiac depression.
Do not cause adverse effects on the fetus.
Cause no sedation.
Recommended for patients having angina and asthma.
Do not cause male impotence.
Mostly indicated for the elderly, pregnant and asthmatic.
safe with history of renal impairment.
Do not exhibit action on electrolyte balance.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="considerations">Considerations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Monitor BP, HR, rhythm,</li>
<li>Control calcium supplement.</li>
<li>Inform patient not to stop drug abruptly.</li>
<li>Patient to report signs of adverse effects such as irregular heart beat, shortness of breath, oedema in the hands and feet, dizziness, constipation, nausea and hypotension.</li>
<li>Discontinue in breast feeding because they are excreted in breast milk and have potential for adverse effects in neonates.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="direct-acting-vasodilators">DIRECT ACTING VASODILATORS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#direct-acting-vasodilators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hydralazine">HYDRALAZINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hydralazine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Hydralazine (APRESOLINE) causes direct relaxation of the arterio smooth muscle secondary to a fall in the intracellular calcium. this is associated with powerful stimulation of the sympathetic nervous system, due to baroreceptor mediated reflexes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="toxicity-and-precaution">Toxicity and Precaution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#toxicity-and-precaution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These includes; headache, nausea, flushing, hypotension, palpitation, tachycardia, dizziness and angina pectoris.</li>
<li>Myocardial ischemia (increased oxygen demand)</li>
<li>Immunological reactions, drug induced lupus syndrome. this occurs after six months of treatment with hydralazine.</li>
<li>symptoms include, arthralgia, arthritis and fever.</li>
<li>The treatment can result in an illness that resembles serum sickness, hemolytic anaemia, vasculitis, and glomerulonephritis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Due to adverse effect profile, hydralazine is no longer a first line drug in the treatment of hypertension.</li>
<li>Used in patients with CCF(in combination with nitrates for patients who cannot tolerate ACE inhibitors.</li>
<li>Treatment of hypertension emergencies in pregnancy.
*(especially preeclampsia).</li>
<li>The usual dose is twenty five to 100 mgs twice a day</li>
<li>He maximum recommended dose of hydralazine is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">200 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Parenteral administration in coronary artery disease.
Elderly patients</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="alpha-adrenergic-blockers-sympatholytics">ALPHA ADRENERGIC BLOCKERS (SYMPATHOLYTICS)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#alpha-adrenergic-blockers-sympatholytics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Medication: prazosin (Minipress)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> doxazosin mesylate (Cardura)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> It inhibits Alpha adrenergic receptor causing Venous and arterial dilation leading to reduction in total peripheral vascular resistance.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Smooth muscle relaxation of the prostatic capsule and bladder neck</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Primary hypertension.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Doxazosin mesylate (Cardura) may be used to decrease symptoms of benign prostatic hypertrophy (BPH), which include urgency, frequency, and dysuria.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="first-dose-orthostatic-hypotension">First-dose orthostatic hypotension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#first-dose-orthostatic-hypotension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Start treatment with low dosage of medication.
First dose may be given at night.
Monitor blood pressure for 2 hr . after the initiation of treatment.
Instruct clients to avoid activities requiring mental alertness for the first 12 to 24 hr .
Instruct clients to change positions slowly and to lie down if feeling dizzy, lightheaded, or faint</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Pregnancy
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> clients with hypersensitivity to medication
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Antihypertensive medications may have an additive hypotensive effect
Instruct clients to observe for signs of hypotension (dizziness, lightheadedness, faintness).
Instruct clients to lie down if these symptoms occur, and to change positions slowly.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> NSAIDs and clonidine may decrease the antihypertensive effects of prazosin.
Advise clients to avoid OTC NSAIDs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions-during-administration">Contraindications/Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Obtain baseline blood pressure and heart rate.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Instruct clients that the medication can be taken with food.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Recommend that clients take the initial dose at bedtime to decrease "first-dose" hypotensive effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="centrally-acting-alpha2-agonists-clonidine-catapres">CENTRALLY ACTING ALPHA2 AGONISTS Clonidine (Catapres)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#centrally-acting-alpha2-agonists-clonidine-catapres" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>guanfacine HCl (Tenex),</li>
<li>methyldopa (Aldomet)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>These medications act within the CNS to decrease sympathetic outflow resulting in decreased stimulation of the adrenergic receptors (both alpha and beta receptors) of the heart and peripheral vascular system.</li>
<li>Decrease in sympathetic outflow to the myocardium results in bradycardia and decreased cardiac output (CO).</li>
<li>Decrease in sympathetic outflow to the peripheral vasculature results in vasodilation, which leads to decreased blood pressure.</li>
</ul>
<p>Primary hypertension (administered alone, with a diuretic, or with another antihypertensive agent)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Severe cancer pain (administered parenterally by epidural infusion)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="investigational-use">Investigational use<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#investigational-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Migraine headache
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Flushing from menopause
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Management of ADHD and Tourette's syndrome
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Management of withdrawal symptoms from alcohol, tobacco, and opioids</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Drowsiness and sedation
*Dry mouth</li>
<li>Rebound hypertension</li>
</ul>
<p>Contraindication
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Clonidine is Pregnancy Risk Category C.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Avoid use during lactation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> This medication is contraindicated for clients taking anticoagulant medications
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Avoid use of transdermal patch on affected skin in scleroderma and systemic lupus erythematosus (SLE).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Use cautiously in clients with cerebrovascular disease, recent MI, diabetes mellitus, major depressive disorder, or chronic renal failure</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects-cont">Side/Adverse Effects cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Antihypertensive medications may have an additive hypotensive effect.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Concurrent use of prazosin (Minipress), MAOI s, and tricyclic antidepressants can counteract the antihypertensive effect of clonidine.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Additive CNS depression can occur with concurrent use of other CNS depressants, such as alcohol.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Administer medication by oral, epidural, and transdermal routes.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Medication is usually administered twice a day in divided doses. Take larger dose at bedtime to decrease the occurrence of daytime sleepiness.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Transdermal patches are applied every seven days. Advise clients to apply patch on hairless, intact skin on torso or upper arm.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="methyldopa-aldomet">Methyldopa (ALDOMET)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#methyldopa-aldomet" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Acts through its metabolites (amethylnorepinephrine)which stimulates central alpha adrenergic receptors, thus increasing total peripheral resistance.</li>
<li>It does not affect glomerular filtration, cardiac output or heart rate.</li>
</ul>
<p>Therapeutic effects
Moderate to severe hypertension
Adverse effects
GIT upsets, sedation, depression, nasal stuffiness, myocarditis edema, orthostatic hypotension, diarrhea, dry mouth, erectile dysfunction, eosinophilia, hemolytic anemia, fever.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Hypersensitivity, activity liver disease, those who developed liver cirrhosis with previous treatment of methyldopa.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="caution">Caution;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#caution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Patients taking diuretics and antihypertensive.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Those taking levodopa because of potential for additive antihypertensive effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="consideration">Consideration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#consideration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> patient to avoid hazardous task.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Lower dose in impaired renal disease.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Monitor liver functions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="caution-cont">Caution cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#caution-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Monitor HB, RBCs for signs of anemia.</li>
<li>Monitor weight, fluid input and out put.</li>
<li>Signs of drug induced depression,</li>
<li>Take BP in different patients position during dose adjustments, warn of signs and symptoms of adverse effects and toxicity</li>
<li>Tolerance may develop 2to 3 weeks after start of treatment.</li>
<li>Urine may darken on exposure to air(as drug is broken down to its metabolites)</li>
<li>Dose increase should be made with the evening dose to minimize the effects of drowsiness.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="beta-adrenergic-blockers-sympatholytics">BETA ADRENERGIC BLOCKERS (SYMPATHOLYTICS)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beta-adrenergic-blockers-sympatholytics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cardioselective: Beta1</p>
<ul>
<li>Metoprolol (Lopressor)</li>
<li>Atenolol (Tenormin)</li>
<li>Metoprolol succinate (Toprol XL)</li>
<li>Esmolol HCL (Brevibloc)</li>
</ul>
<p>Nonselective: (Beta1 and Beta2)</p>
<ul>
<li>Propranolol (Inderal)</li>
<li>Nadolol (Corgard)</li>
<li>Labetalol (Normodyne)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They block beta- adrenergic receptors in the myocardium and in the electrical conduction system of the heart.
*Decreased heart rate
*Decreased myocardial contractility
*Decreased rate of conduction through the AV node</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>hypertension, Angina, arrhythmias, heart failure and myocardial infarction.
Other uses may include: Treatment of hyperthyroidism, migraine headache, pheochromocytoma, and glaucoma</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse">Adverse<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="effects">effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Bradycardia, fatigue, dizziness, nightmares, depression, memory loss, hallucination, impotence, cold extremities, elevated serum cholesterol.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>severe hypotension, bradycardia, congestive heart failure, asthma, diabetics, critically abnormal lipid profile</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="consideration">Consideration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#consideration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Explain the rationale of therapy and importance of taking drugs as prescribed.</li>
<li>Patient should not discontinue drugs abruptly because it can cause MI or angina</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="consideration-cont">Consideration cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#consideration-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Advise clients to avoid sudden changes in position to prevent occurrence of orthostatic hypotension
Administer medications orally, usually once or twice a day.
Administer the following medications by IV route: atenolol, metoprolol, labetalol, propranolol.
Teach clients to self monitor heart rate and blood pressure at home on a daily basis.
Monitor weight &amp; signs of hypovolemic shock especially in diabetic patients.
Glucagon is prescribed to reverse signs of overdose.
Dose are lowered in geriatrics due to delayed metabolism and enhanced side effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medications-for-hypertensive-crisis">Medications for Hypertensive Crisis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medications-for-hypertensive-crisis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nitroprusside sodium (Nitropress)
Other Medications:
Nitroglycerin (Nitrostat IV)
Nicardipine (Cardene)
Clevidipine (Cleviprex)
Enalaprilat (Vasotec IV)
Esmolol HCL (Brevibloc)
Mechanism of Action; Direct vasodilation of arteries and veins resulting in rapid reduction of blood pressure (decreased preload and afterload)
Therapeutic Uses; Hypertensive emergencies</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="excessive-hypotension">Excessive hypotension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#excessive-hypotension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Administer medication slowly because rapid administration will cause blood pressure to go down rapidly.</li>
<li>Monitor the client's blood pressure and ECG.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="interactions">Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nitroprusside should not be administered in the same infusion as any other medication.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Prepare medication by adding to diluent for IV infusion.</li>
<li>Note color of solution. Solution may be light brown in color. Discard solution of any other color.</li>
<li>Protect IV container and tubing from light.</li>
<li>Discard medication after 24 hr .</li>
<li>Monitor vital signs and ECG continuously</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cardiac-glycoside">CARDIAC GLYCOSIDE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiac-glycoside" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="two-main-types">Two main types<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#two-main-types" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cardenolides (digitalis, convallaria, oleandra)
*Bufadienolides (Helleborus, Poison Arrow Frog)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Cardiac glycoside slows down the heart rate and increase the force of contraction</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-action">Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Enhances myocardial contractility and is used in congestive cardiac failure.</li>
<li>Enhances cardiac output, minimizes dilated cardiac size, blood volume and venous pressure.</li>
<li>They modulate autonomic nervous system activity, and this contributes to their efficacy in management of heart failure.</li>
<li>Diuretic effect, reduce oedema.</li>
<li>It is usually given only when diuretics and ACEIs have failed.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="indications">Indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Congestive heart failure, heart failure with atrial fibrillation, or pts who remain symptomatic despite therapy with ACE inhibitors and b Adrenergic receptor antagonists
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Left ventricular failure.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Atrial fibrillation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="digoxin">Digoxin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digoxin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is the most commonly used digitalis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="forms">Forms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#forms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tablets (Lanoxin)
Capsules (lanoxicaps)
Parenteral digoxin is available for intravenous administration and maintenance doses can be given intravenously when oral dosin is impractical.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="digoxin-cont">Digoxin Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digoxin-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="positive-inotropic-effect">Positive inotropic effect<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#positive-inotropic-effect" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> increased force of myocardial contraction Increased force and efficiency of myocardial contraction improves the heart's effectiveness as a pump,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> improving stroke volume and cardiac output.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Increase perfusion of the kidneys which facilitates excretion of fluid by the kidneys</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="negative-chronotropic-effect">Negative chronotropic effect<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#negative-chronotropic-effect" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> decreased heart rate ,
At therapeutic levels, digoxin slows the rate of SA node depolarization and the rate of impulses through the conduction system of the heart.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> A decreased heart rate gives the ventricles more time to fill with blood coming from the atria, which leads to increased SV and increased CO.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="digoxin-cont">Digoxin cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digoxin-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Treatment of heart failure</li>
<li>Dysrhythmias (atrial fibrillation)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-adverse-effects">Side/adverse effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Dysrhythmias (caused by interfering with the electrical conduction in the myocardium)</li>
<li>Cardiotoxicity leading to bradycardia.</li>
<li>GI effects include anorexia (usually the first sign), nausea, vomiting, and abdominal pain.</li>
<li>Teach clients to monitor for these effects and report to the provider if they occur.</li>
<li>CNS effects include fatigue, weakness, vision changes (diplopia, blurred vision, yellow-green or white halos around objects).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="digoxin-cont">Digoxin cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digoxin-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>In Pregnancy</li>
<li>clients with disturbances in ventricular rhythm, including ventricular fibrillation, ventricular tachycardia, and second- and third-degree heart block.</li>
<li>Use cautiously in clients who have hypokalemia, partial AV block, advanced heart failure, and renal insufficiency.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medication-interaction">Medication Interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Thiazide diuretics, such as hydrochlorothiazide (HCTZ), and loop diuretics, such as furosemide (Lasix), may lead to hypokalemia, which increases the risk of developing dysrhythmias</li>
<li>ACE inhibitors and ARBs increase the risk of hyperkalemia, which can lead to decreased therapeutic effects of digoxin.</li>
<li>Sympathomimetic medications such as dopamine (Intropin) complement the inotropic action of digoxin and increase the rate and force of heart muscle contraction.</li>
<li>Quinidine increases the risk of digoxin toxicity when used concurrently.</li>
<li>Verapamil (Calan) increases plasma levels</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-affecting-the-respiratory-system-bronchodilators">DRUGS AFFECTING THE RESPIRATORY SYSTEM (Bronchodilators)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-affecting-the-respiratory-system-bronchodilators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="overview">Overview<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The obstruction occurs either by inflammation or airway hyper-responsiveness leading to bronchoconstriction.</p>
<ul>
<li>Medication management usually addresses both inflammation and bronchoconstriction</li>
<li>These same medications may be used in symptomatic treatment of chronic obstructive pulmonary disease (COPD</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="overview-cont">Overview Cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#overview-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Advise clients to take the medication as prescribed. If a dose is missed, the next dose should NOT be doubled.</li>
<li>Check pulse rate and rhythm before administration of digoxin and record. Notify the provider if heart rate is less than 60/min in an adult, less than 70/min in children, and less than 90/min in infants. Administer digoxin at the same time daily.</li>
<li>Monitor digoxin levels periodically during treatment and maintain therapeutic levels between 0.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.0</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">2.0 \mathrm{ng} / \mathrm{mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">mL</span></span></span></span></span></span> to prevent digoxin toxicity.</li>
<li>Avoid taking OTC medications to prevent adverse and side effects and medication interactions.</li>
<li>Instruct clients to observe symptoms of hypokalemia, such as muscle weakness, and to notify the provider if symptoms occur.</li>
<li>Instruct clients to observe symptoms of digoxin toxicity (anorexia, fatigue, weakness), and to notify the provider if symptoms occur.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-digoxin-toxicity">Management of Digoxin Toxicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-digoxin-toxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Digoxin and potassium-sparing medication should be stopped immediately.</li>
<li>Monitor K+ levels. For levels less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">3.5 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.5</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>, administer potassium intravenously or by mouth. Do not give any further <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">K</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{K}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">K</span><span class="mord">+</span></span></span></span></span> if the level is greater than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">5.0 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5.0</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>.</li>
<li>Treat dysrhythmias with phenytoin (Dilantin) or lidocaine.</li>
<li>Treat bradycardia with atropine.</li>
<li>For excessive overdose, activated charcoal, cholestyramine, or Digibind can be used to bind digoxin and prevent absorption.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bronchodilators-cont">Bronchodilators Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bronchodilators-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medications-include">Medications include:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medications-include" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-bronchodilator">Classification of Bronchodilator ;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-bronchodilator" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Beta2-adrenergic agonists short acting; salbutamol,</li>
<li>Beta2-adrenergic agonists long acting; salmeterol and formoterol</li>
<li>Methyl xanthine's e.g. theophylline</li>
<li>Inhaled anticholinergics e.g. tiotropium</li>
<li>Anti-inflammatory agents such as glucocorticoids, mast cell stabilizers, and leukotriene modifiers.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="beta2-adrenergic-agonists">Beta2-Adrenergic Agonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beta2-adrenergic-agonists" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Albuterol (Proventil, Ventolin)</li>
<li>Formoterol (Foradil Aerolizer)</li>
<li>Salmeterol (Serevent)</li>
<li>Terbutaline (Brethine)</li>
<li>Albuterol ( Proventil, Ventolin)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Beta2-adrenergic agonists act by selectively activating the beta2receptors in the bronchial smooth muscle, resulting in bronchodilation. As a result of this: Bronchospasm is relieved, Histamine release is inhibited, Ciliary motility is increased.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>Medication</th><th>Route</th><th>Therapeutic uses</th></tr></thead><tbody><tr><td>Albuterol (Proventil, Ventolin)</td><td>- Inhaled, short-acting Oral, long-acting</td><td>- Prevention of asthma attack (exerciseinduced) - Treatment for ongoing asthma attack - Long-term control of asthma</td></tr><tr><td>Formoterol (Foradil Aerolizer) Salmeterol (Serevent)</td><td>- Inhaled, long-acting</td><td>- Long-term control of asthma</td></tr><tr><td>Terbutaline (Brethine)</td><td>Oral, long-acting</td><td>- Long-term control of asthma</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Inhaled agents (short and long acting) have minimal adverse effects.</li>
<li>Oral agents can cause tachycardia and angina because of activation of alpha1 receptors in the heart.</li>
<li>Tremors caused by activation of beta2 receptors in skeletal muscle.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Beta2-adrenergic agonists are Pregnancy Risk Category C.</li>
<li>These agents are contraindicated in clients with tachydysrhythmia.
*Use cautiously in clients who have diabetes, hyperthyroidism, heart disease, hypertension, and angina.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug Interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Use of beta-adrenergic blockers (propranolol) can negate effects of both medications.
*MAOIs and tricyclic antidepressants can increase the risk of tachycardia and angina.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions">Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Instruct clients to follow manufacturer's instructions for use of device: metered-dose inhaler (MDI), dry-powder inhaler(DPI), and nebulizer.
When a client is prescribed an inhaled beta2-agonist and an inhaled glucocorticoid, advise the client to inhale the beta2-agonist before inhaling the glucocorticoid.
The beta2-agonist promotes bronchodilation and enhances absorption of the glucocorticoid.
Advise clients not to exceed prescribed dosages.
Ensure that clients know the appropriate dosage schedule (if the medication is to be taken on a fixed or a when-necessary schedule).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-cont">Precautions Cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Formoterol and salmeterol are both long-acting beta2-agonist inhalers. These inhalers are used every 12 hr . for long-term control and are not to be used to abort an asthma attack. A short-acting beta2agonist should be used if clients need to treat an acute attack.</li>
<li>Advise clients to observe for signs of an impending asthma attack and to keep a log of the frequency and intensity of attacks.</li>
<li>Instruct clients to notify the provider if there is an increase in the frequency and intensity of asthma attacks.</li>
</ul>
<p>Theophylline (Theolair, Theo-24)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Theophylline causes relaxation of bronchial smooth muscle, resulting in bronchodilation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Oral theophylline is used for long-term control of chronic asthma.
Route of administration: oral or IV (emergency use only)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Mild toxicity reaction may include GI distress and restlessness.</p>
<ul>
<li>More severe reactions can occur with higher therapeutic levels and can include dysrhythmias and seizures.</li>
</ul>
<p>Contraindications/Precautions</p>
<ul>
<li>In Pregnancy</li>
<li>Use cautiously in clients who have heart disease, hypertension, liver and renal dysfunction, and diabetes.</li>
<li>Use cautiously in children and older adults.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="inhaled-anticholinergics">INHALED ANTICHOLINERGICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inhaled-anticholinergics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ipratropium (Atrovent)
Tiotropium (Spiriva)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These medications block muscarinic receptors of the bronchi, resulting in bronchodilation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These medications are used to relieve bronchospasm associated with chronic obstructive pulmonary disease (COPD)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> These medications are used for allergen-induced and exerciseinduced asthma.
Route of administration: inhalation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">SIDE/ADVERSE EFFECTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Local anticholinergic effects (dry mouth, hoarseness)
Advise clients to sip fluids and suck on hard candies to control dry mouth.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Inhaled anticholinergics are Pregnancy Risk Category B.</li>
<li>These agents are contraindicated in clients who have an allergy to peanuts because the medication preparations may contain soy lecithin.
*Use cautiously in clients who have narrow-angle glaucoma and benign prostatic hypertrophy (due to anticholinergic effects).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions-interactions">Drug Interactions Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Caffeine increases CNS and cardiac adverse effects of theophylline.</li>
<li>Caffeine can also increase theophylline levels.</li>
<li>Advise clients to avoid consuming caffeinated beverages (coffee, caffeinated colas).</li>
<li>Phenobarbital and phenytoin decrease theophylline levels.</li>
<li>Cimetidine (Tagamet), ciprofloxacin (Cipro), and other fluoroquinolone antibiotics increase theophylline level.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="glucocorticoids">GLUCOCORTICOIDS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glucocorticoids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Inhalation: beclomethasone dipropionate (QVAR)
Oral: prednisone (Deltasone)
Inhalation:
Budesonide (Pulmicort Flexhaler)
Fluticasone propionate and salmeterol (Advair)
Fluticasone propionate (Flovent)
Triamcinolone acetonide (Azmacort)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="systemic">Systemic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#systemic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Oral Prednisolone E 30 to 40mg for initial to 7 days,</li>
<li>IV/IM dexamethasone</li>
<li>IV Hydrocortisone sodium succinate (Solu-Cortef) (</li>
<li>IV Methylprednisolone sodium succinate (Solu-Medrol)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These medications prevent inflammation, suppress airway mucus production, and promote responsiveness of beta2 receptors in the bronchial tree.</li>
<li>The use of glucocorticoids does not provide immediate effects, but rather promotes decreased frequency and severity of exacerbations and acute attacks.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Short-term IV agents are used for status asthmaticus.
*Inhaled agents are used for long-term prophylaxis of asthma.</li>
<li>Short-term oral therapy is used to treat symptoms following an acute asthma attack.</li>
<li>Long-term oral therapy is used to treat chronic asthma.</li>
<li>Replacement therapy is used for primary adrenocortical insufficiency.</li>
<li>Promote lung maturity and decrease respiratory distress in fetuses at risk for preterm birth</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="beclomethasone-dipropionate">Beclomethasone dipropionate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beclomethasone-dipropionate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Difficulty speaking, hoarseness, and candidiasis
Advise clients to use a spacer with MDI.
Advise clients to rinse mouth or gargle with water or salt water after use.
Advise clients to monitor for redness, sores, or white patches and to report to provider if they occur.
Candidiasis may be treated with nystatin oral suspension.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prednisolone-when-used-for-more-than-10-days">Prednisolone When Used for More Than 10 days<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prednisolone-when-used-for-more-than-10-days" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Suppression of adrenal gland function, such as a decrease in the ability of the adrenal cortex to produce glucocorticoids: Can occur with inhaled agents and oral agents</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="taper-the-client-s-dose">Taper the client's dose.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#taper-the-client-s-dose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Bone loss (can occur with inhaled agents and oral agents)</li>
<li>Myopathy as evidenced by muscle weakness</li>
<li>Hyperglycemia and glycosuria</li>
<li>Myopathy as evidenced by muscle weakness a</li>
<li>Peptic ulcer disease</li>
<li>Infection</li>
<li>Disturbances of fluid and electrolytes (fluid retention as evidenced by weight gain, and edema and hypokalemia as evidenced by muscle weakness)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions-of-pdl">Contraindications/Precautions of PDL<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions-of-pdl" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Pregnancy risk category C</li>
<li>Contraindicated in clients who have received a live virus vaccine</li>
<li>Contraindicated in clients with systemic fungal infections</li>
<li>Use cautiously in children, and in clients who have diabetes, hypertension, peptic ulcer disease, and/or renal dysfunction.</li>
<li>Use cautiously in clients taking NSAIDs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Concurrent use of potassium-depleting diuretics increases the risk of hypokalemia.</li>
<li>Concurrent use of NSAIDs increases the risk of GI ulceration. Concurrent use of glucocorticoids and hypoglycemic agents (oral and insulin) will counteract the effects.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Instruct clients to use glucocorticoid inhalers on a regular, fixed schedule for longterm therapy of asthma.</li>
<li>Glucocorticoids are not to be used to treat an acute attack.</li>
<li>Administer using an MDI device, DPI, or nebulizer.</li>
<li>When a client is prescribed an inhaled beta2-agonist and an inhaled glucocorticoid, advise the client to inhale the beta2-agonist before inhaling the glucocorticoid. The beta2-agonist promotes bronchodilation and enhances absorption of the glucocorticoid.</li>
<li>Oral glucocorticoids are used short-term, 3 to 10 days following an acute asthma attack.</li>
<li>If client is on long-term oral therapy, additional dosages of oral glucocorticoids are required in times of stress (infection, trauma).</li>
<li>Clients who discontinue oral glucocorticoid medications or switch from oral to inhaled agents require additional doses of glucocorticoids during periods of stress.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mastcell-stabilizers-anti-inflatory-drugs">MASTCELL STABILIZERS ANTI INFLATORY DRUGS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mastcell-stabilizers-anti-inflatory-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cromolyn-sodium-intal">(cromolyn sodium (Intal)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cromolyn-sodium-intal" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Others are: nedocromil sodium (Tilade)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Anti-inflammatory action</li>
<li>These medications stabilize mast cells, which inhibits the release of histamine and other inflammatory mediators.</li>
<li>These medications suppress inflammatory cells (eosinophils, macrophages).
Complications Safest of all asthma medications, Safe to use for children</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Management of chronic asthma
*Prophylaxis of exercise-induced asthma</li>
<li>Prevention of allergen-induced attack</li>
<li>Allergic rhinitis by intranasal route</li>
<li>Route of administration: inhalation</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>These agents are Pregnancy Risk Category B.</li>
<li>Fluorocarbons in aerosols make this medication contraindicated for clients who have coronary artery disease, dysrhythmias, and status asthmaticus.</li>
<li>Use cautiously in clients with liver and kidney impairment.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="leukotriene-modifiers">LEUKOTRIENE MODIFIERS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#leukotriene-modifiers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>leukotriene receptor antagonist ;</p>
<ul>
<li>Montelukast (Singulair), Zileuton (Zyflo),Zafirlukast (Accolate)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Leukotriene modifiers prevent the effects of leukotrienes, thereby suppressing inflammation, bronchoconstriction, airway edema, and mucus production.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Leukotriene modifiers are used for long-term therapy of asthma in adults and children 15 years and older and to prevent exercise-induced bronchospasm.</p>
<p>Route of administration: oral</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Use cautiously in clients with liver dysfunction</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Zileuton and zafirlukast inhibit metabolism of warfarin (Coumadin), leading to increased warfarin levels.</li>
<li>Zileuton and Zafirlukast inhibit metabolism of theophylline, leading to increased theophylline levels.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Advise clients to take zileuton as prescribed. Zileuton can be given with or without food.</li>
<li>Advise clients that zafirlukast should not be given with food, and to administer it 1 hr . before or 2 hr . after meals.</li>
<li>Advise clients to take Montelukast once daily at bedtime.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="git-drugs-peptic-ulcer-disease">GIT DRUGS( PEPTIC ULCER DISEASE)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#git-drugs-peptic-ulcer-disease" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acid peptic disease includes:</p>
<ul>
<li>peptic ulcers (gastric ulcer, duodenal ulcer , NSAIDS induced ulcers)</li>
<li>gasro oesophageal reflux disease,</li>
<li>hypersecretory states like Zollinger Ellison Syndrome (ulcerogenic tumour of the islets of Langerhans.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-therapy">Principles of therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The aim of therapy is to;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋆</mo></mrow><annotation encoding="application/x-tex">\star</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4653em;"></span><span class="mord">⋆</span></span></span></span></span> relieve symptoms,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋆</mo></mrow><annotation encoding="application/x-tex">\star</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4653em;"></span><span class="mord">⋆</span></span></span></span></span> induced ulcer healing and cure in the long run
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋆</mo></mrow><annotation encoding="application/x-tex">\star</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4653em;"></span><span class="mord">⋆</span></span></span></span></span> Decreased risk of complications
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋆</mo></mrow><annotation encoding="application/x-tex">\star</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4653em;"></span><span class="mord">⋆</span></span></span></span></span> Stopping reoccurrence .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-agents-used-in-treatment-of-peptic-ulcer">Classification Of Agents Used in Treatment of Peptic Ulcer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-agents-used-in-treatment-of-peptic-ulcer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="inhibition-of-acid-secretion">Inhibition Of Acid Secretion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inhibition-of-acid-secretion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> H2 receptor agonist e.g. cimetidine, ranitidine, famotidine roxatidine.
Proton pump inhibitors e.g. omeprazole, pantoprazole, esomeprazole, lansoprazole.
Anticholinergics e.g. pirenzepine.
Prostaglandin analogue e.g. misoprostol.
Neutralization of gastric acids
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Sodium bicarbonate systemic
Non systemic: magnesium hydroxide, aluminium hydroxide, magnesium trisilicate.</p>
<p>Mucosal protective agents e.g. sucralfate, colloidal bismuth.</p>
<ul>
<li>Anti helicobacter pylori drugs (ANTIBIOTICS) e.g. Clarithromycin, Ampicillin, Metronidazole, Tetracycline, Tinidazole</li>
</ul>
<p>Anti H. pylori drugs</p>
<ul>
<li>Amoxicillin (Amoxil)</li>
<li>Bismuth (Pepto-Bismol)</li>
<li>Clarithromycin (Biaxin)</li>
<li>Metronidazole (Flagyl)</li>
<li>Tetracycline</li>
</ul>
<p>Expected Pharmacological Action</p>
<ul>
<li>Eradication of H. pylori bacteria</li>
<li>Therapy should include: Combination of 2 or 3 antibiotics for 14 days</li>
</ul>
<p>The disease process is only altered by the use of antibiotics. All other medications make an environment that is conducive to healing</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="two-weeks-regimen">Two weeks Regimen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#two-weeks-regimen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Tetracycline 500mg QID and metronidazole 200mg BID and Bismuth sub salylicylate.</li>
<li>Amoxicillin 100mg BID and clarithromycin 500mg BID+ Lansoprazole 30mgs BID.</li>
<li>Clarithromycin 500mg TDS +Omeprazole.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="one-week-regimen">ONE WEEK REGIMEN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#one-week-regimen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Clarithromycin 250mg BID + Metronidazole 400mgs + Omeprazole 20mgs BID.
Amoxicillin 500mg Bid + Clarithromycin 250mg Bid+ Omeprazole 20mg</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="histamine2-receptor-antagonists">Histamine2 -Receptor Antagonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#histamine2-receptor-antagonists" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*Ranitidine hydrochloride (Zantac)
*Cimetidine (Tagamet)</p>
<ul>
<li>Nizatidine (Axid)</li>
<li>Famotidine (Pepcid)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Histamine2-receptor antagonists suppress the secretion of gastric acid by selectively blocking H 2 receptors in parietal cells lining the stomach.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>0Gastric and peptic ulcers,
0 Gastroesophageal reflux disease (GERD),
0 Hypersecretory conditions, such as Zollinger-Ellison syndrome.
0 Histamine2-receptor antagonists are used in conjunction with antibiotics to treat ulcers caused by H. pylori.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cimetidine may block androgen receptors, resulting in decreased libido and impotence.</li>
<li>Cimetidine may cause CNS effects (lethargy, depression, confusion)</li>
<li>Ranitidine, nizatidine, and famotidine have few adverse effects and interactions.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These medications are Pregnancy Risk Category B</li>
<li>Use in older adults can cause antiadrenergic effects (e.g., impotence) and CNS effects (e.g., confusion).</li>
<li>H2-receptor antagonists decrease gastric acidity, which promotes bacterial colonization of the stomach and the respiratory tract. Use cautiously in clients who are at a high risk for pneumonia, such as clients with chronic obstructive pulmonary disease (COPD).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cimetidine can inhibit medication metabolizing enzymes and thus increase the levels of warfarin, phenytoin (Dilantin), theophylline, and lidocaine.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Concurrent use of antacids can decrease absorption of histamine2 -receptor antagonists.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="proton-pump-inhibitor">Proton Pump Inhibitor<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#proton-pump-inhibitor" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*omeprazole (Prilosec)</p>
<ul>
<li>Pantoprazole (Protonix)</li>
<li>Lansoprazole (Prevacid)
*Rabeprazole sodium (AcipHex)</li>
<li>Esomeprazole (Nexium)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Proton pump inhibitors reduce gastric acid secretion by irreversibly inhibiting the enzyme that produces gastric acid.
*Proton pump inhibitors reduce basal and stimulated acid production.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Gastric and peptic ulcers,</li>
<li>GERD,</li>
<li>h\Hypersecretory conditions such as Zollinger-Ellison syndrome.</li>
</ul>
<p>Complications
Insignificant side effects and adverse effects with short-term treatment
Low incidence of headache, diarrhea, and nausea/vomiting</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These medications are Pregnancy Risk Category C.</li>
<li>Use cautiously with children and women who are breastfeeding.</li>
<li>Contraindicated for clients hypersensitive to medication</li>
<li>These medications increase the risk for pneumonia. Omeprazole decreases gastric acid pH , which promotes bacterial colonization of the stomach and the respiratory tract. Use cautiously in clients at high risk for pneumonia, such as clients with COPD.</li>
<li>Long-term use of proton pump inhibitors increases the risk of gastric cancer and osteoporosis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*Digoxin (Lanoxin) levels may be increased when used concurrently with omeprazole.</p>
<ul>
<li>Monitor digoxin levels carefully if prescribed concurrently.
*Absorption of ketoconazole (formerly Nizoral), itraconazole (Sporanox), and atazanavir (Reyataz) is extremely decreased when taken concurrently with proton pump inhibitors.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Do not crush, chew, or break sustained-release capsules.</li>
<li>Clients may sprinkle the contents of the capsule over food to facilitate swallowing.</li>
<li>Clients should take omeprazole once a day prior to eating in the morning.</li>
<li>Encourage clients to avoid alcohol and irritating medications such as NSAIDs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-cont">Precautions During Administration cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Active ulcers should be treated for 4 to 6 weeks.</li>
<li>Pantoprazole (Protonix) can be administered to clients intravenously. In addition to low incidence of headache and diarrhea, there may be irritation at the injection site leading to thrombophlebitis. Monitor the client's IV site for signs of inflammation (redness, swelling, local pain) and change the IV site if indicated.</li>
<li>Teach clients to notify the provider for any sign of obvious or occult GI bleeding such as coffee-ground emesis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anticholinergics">ANTICHOLINERGICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anticholinergics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="piperazine">Piperazine :<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#piperazine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is a selective M1 receptor blocker
Produces less effects.
Reduces acid secretion by 40 to fifty percent
Has a small therapeutic window</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prostaglandins-analogue">Prostaglandins Analogue<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prostaglandins-analogue" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>They have o cytoprotective role by inhibiting acid secretion by increasing mucus and bicarbonate secretion.</li>
<li>Inhibit gastrin secretion and increase mucosal blood flow.</li>
</ul>
<p>Misoprostol</p>
<ul>
<li>A synthetic pge1 analogue and inhibits acid output.</li>
<li>ulcer heal in 4 to six weeks but relieving pain</li>
</ul>
<p>Therapeutic Use
prevent ulceration and bleeding induced by NSAIDS</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mucosal-protectant">MUCOSAL PROTECTANT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mucosal-protectant" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sucralfate-carafate">Sucralfate (Carafate)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sucralfate-carafate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The acidic environment of the stomach and duodenum changes sucralfate into a thick substance that adheres to an ulcer. This protects the ulcer from further injury that may be caused by acid and pepsin.
This viscous substance can stick to the ulcer for up to 6 hr .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>promotes healing of duodenal and gastric ulcers</li>
<li>Poorly absorbed systemically, not used frequently due to a large doses.</li>
<li>Should not be used with antacids, H2 Antagonist, PPIs as it is dependent on gastric PH.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="colloidal-bismuth-compounds">Colloidal Bismuth Compounds<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#colloidal-bismuth-compounds" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Promote healing of duodenal and gastric ulcers.</li>
<li>Act by binding to an ulcer, denaturing the protein and creating a physical barrier.</li>
<li>Inhibition of pepsin, activation of mucous production, increase of prostaglandins.</li>
<li>It is effective in healing of duodenal and gastric ulcers.</li>
<li>Effective in non ulcer gastritis, caused by H.pylori</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="considerations">Considerations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Take before meals and at bed time for 4 to 8 weeks.</li>
<li>Poor acceptance due to blackening of tongue, dentures and stool inconvenience of dosing used as a regimen of multiple therapy for H.Pylori not used alone.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="laxatives">LAXATIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This are drugs tha promote deafacation
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋄</mo></mrow><annotation encoding="application/x-tex">\diamond</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋄</span></span></span></span></span> laxatives; mild action
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋄</mo></mrow><annotation encoding="application/x-tex">\diamond</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋄</span></span></span></span></span> Purgative; strong action
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋄</mo></mrow><annotation encoding="application/x-tex">\diamond</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋄</span></span></span></span></span> Classification</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bulk-forming-purgatives">Bulk Forming Purgatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bulk-forming-purgatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Magnesium sulphate, magnesium hydroxide, sodium phosphate, lactulose, sodium tartrate, osmotic cathartic.
Vegetable fibres, bran
Hydrophillic colloids, methyl cellulose</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="irritants-and-stimulants">Irritants and stimulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#irritants-and-stimulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Diphenylmethanes; phenolphthalein, Bisacodyl</li>
<li>Anthraquinone derivatives; senna, cascara</li>
<li>Fixed oil; castor oil</li>
<li>Stool softeners; docusate, mineral oil, glycerin suppositories</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action-of-laxatives">Mechanism of action of laxatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Laxatives cause retention of fluid in colonic contents increasing bulk and softness of stool and its transit.</li>
<li>They may decrease absorption of water and electrolyte by acting on intestinal mucosa.</li>
<li>They may enhance intestinal motility reducing absorption of water.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bulk-forming-purgatives">Bulk Forming Purgatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bulk-forming-purgatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="osmotic-or-saline-cathartics">Osmotic or saline cathartics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#osmotic-or-saline-cathartics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> They are poorly absorbed hold water through osmosis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> In addition the ions stimulate secretion and motility.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Main used salts are; magnesium sulphate, sodium sulphate, magnesium hydroxide, sodium potassium tartrate.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Sodium salts contraindicated in congestive heart failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="considerations">Considerations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cause after constipation therefore not used routinely</li>
<li>Preferred for pre-operative care before colonoscopy and in poisoning.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="lactulose">Lactulose<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lactulose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>A synthetic disaccharide containing fructose and galactose absorbed in the GIT.</li>
<li>Produces soft stools within 1-3 days</li>
<li>Side effects; abnominal cramps, flatulence,</li>
<li>Contraindicated in patients requiring galactose free diet.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vegetable-fibres">Vegetable fibres<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vegetable-fibres" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Dietary fibres derived from whole grains, vegetables and fruits. They contains the indigestible portion of cell wall.</li>
<li>Dietary fibre act by binding water and ions in the intestine softens stool and promotes peristables. Also increases faecel mass.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vegetable-fibres">Vegetable fibres<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vegetable-fibres" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indications">Indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Prevention and treatment of functional constipation.</li>
<li>Used for symptomatic relief of mild diarrhea</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-effects">Adverse effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Flatulance
Intestinal obstruction, oesophageal obstruction may occur.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraidication">Contraidication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraidication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Stenosis
Ulceration</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="irritant-and-stimulant-purgatives">Irritant and stimulant purgatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#irritant-and-stimulant-purgatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>They promote accumulation of water and electrolytes in the lumen.</li>
<li>Enhance intestinal motility</li>
<li>Increased water secretion is through activation of cAMP and synthesis of prostaglandins</li>
<li>Phenolpthalein and bisacodly are widely used.</li>
<li>Castor oil is hydrolysed to glycerol and ricinoleic acid which stimulates peristalsis. Effect in the small intestines causes rapid complete evacuation.</li>
<li>Side effects include; Cramping, dehydration.</li>
<li>Regular use bordestroys mucosa.</li>
<li>Should be avoided in pregnant women, can intiate labour.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="stool-softeners">Stool softeners<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#stool-softeners" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="docusates">Docusates<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#docusates" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Used as an emulsifying, wetting and dispersing agent.</li>
<li>soften stool with 1-3days</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="liquid-paraffin">Liquid paraffin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#liquid-paraffin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>It's a mineral oil.</li>
<li>Pharmacologically inert and acts as lubricants and softens stool.</li>
</ul>
<p>Adverse effects of liquid paraffin</p>
<ul>
<li>Leakage of oil past anal sphincter</li>
<li>Affect absorption of fat soluble vitamins.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="glcerin">Glcerin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glcerin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Used as a suppository, produces effects within 30mins.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="indication-of-laxatives">Indication of laxatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication-of-laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Constipation not responding to non- pharmacological measures: fibre rich diet, regular exercise, regular bowel movements, ( bulk laxatives are the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> choice).</li>
<li>Before and after surgery to produce soft stool in patients with haemorrhoids and fissures.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications">Contraindications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Undiagnosed abnominal pain
Appendicitis
Intestinal obstruction
Should be avoided during later stages of preganancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-diarrhoeal-agents">Anti- Diarrhoeal Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-diarrhoeal-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Diarrhoea is marked by frequent passage of unformed or liquid stools.</li>
</ul>
<p>Treatment of diarrhoea
Fluid and electrolyte replacement
Nutritional management
Drug therapy</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy">Drug Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="anti-diarrhea-drugs-include">Anti-diarrhea drugs include;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-diarrhea-drugs-include" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Antimotility drugs
Antisecretory drugs
Adsorbents
Antibacterial agents</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="atimotility-drugs">Atimotility drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#atimotility-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>E.g loperamide, diphenoxylate</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="loperamide">Loperamide<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#loperamide" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Acts mainly on GIT receptor.</li>
<li>Acts quickly and has a longer duration of action</li>
<li>Decreases GIT motility and is excreted unchanged indicated for non infective diarrhea, mild travellors diarrhea.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-effects">Adverse effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Skin rash , abdominal cramps with excessive use paralytic ileus</li>
<li>Contraindication; below 4years, infective diarrhea, ulcerative colitis</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antisecretory-drugs">Antisecretory drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antisecretory-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="racecadotril">Racecadotril<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#racecadotril" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Enkephalinase inhibitor that increases endogenous enkephalin level and reduce intestinal hyper tension of water and electrolytes.</li>
<li>Used for systematic treatment of diarrhea.</li>
<li>Has no side effects like bloating and after constipation.</li>
<li>Should not be used in pregnancy, lactation and children.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adsorbents">Adsorbents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adsorbents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Include kaolin, pectin, methylcellulose , magnesium aluminium silicate.
They act by absorbing microorganisms and/ toxins by altering normal flora or by protecting the mucosa of the intestines.
Their efficacy is doubtful</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimicrobial-agents">Antimicrobial agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimicrobial-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Cholera; tetracyclines, norfloxacin/ciprofloxacin</li>
<li>Infections with camphylobacter; erythromycin and flouroquinolones</li>
<li>Amoebiasis or giardiasis; metronidazole, diloxanide furoate, ornidazole
*Shigella spcs, ciprofloxacin, norfloxacin or cotrimoxazole.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous">Miscellaneous<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Contain viable lactic acid bacilli.</li>
<li>Improve intestinal microflora</li>
<li>Known as probiotics</li>
<li>Useful in rotavirus diarrhoea and anti biotic induced diarrhoea</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="d-anti-emetics">D.ANTI EMETICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-anti-emetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Vomitting is reflex action that results in forceful evacuation of gatric contents.</li>
<li>Conditions pregnancy, ulcers, motion sickness, chemotherapy.</li>
</ul>
<p>Anti emetics
Applied to suppress or prevent vomiting.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification">Classification<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Anti muscarinic: scopolamine (hyoscine), dicyclomine
H1 antagonist: promethazine, doxylamine,
Prokinetic drugs; metoclopramide, domperidone, cisapride, mosapride.
Neuroleptics; phenothiazines, chlorpromazine
Adjuvant antiemetics; dexamethasone, benzodiazepines</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1-prokinetic-drugs">1. Prokinetic drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-prokinetic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-metroclopramide">a. Metroclopramide<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-metroclopramide" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Effective for all types of vomiting, post- operatively, radiation, chemotherapy.</li>
<li>Less effective in motion sickness.</li>
<li>Blocks dopamine receptors, enters CNS</li>
</ul>
<p>Side effects: extrapyramidal effects, dystonia, dyskinesia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indications">Indications;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Anti emetic</li>
<li>Dyspesia</li>
<li>facilitate lactation</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prokinetic-drugs-cont">Prokinetic drugs Cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prokinetic-drugs-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>b, Domperidone</p>
<ul>
<li>Peripheral D2 receptor agonist .</li>
<li>Causes less extra pyramidal effects, doesnot cross the blood brain barrier.</li>
<li>Lower efficacy than metoclopramide</li>
</ul>
<p>Uses; levodopa or bromocriptine induced vomiting.
Side effects; increased prolactin, galactorrhoea, dry mouth, rashes. Headache.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2-anti-muscarinic">2. Anti muscarinic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-anti-muscarinic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="scopolamine-hyoscine">Scopolamine (hyoscine)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#scopolamine-hyoscine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Alkaloid related to atropine</li>
<li>Most effective in prophylaxis of motion sickness</li>
<li>Antimuscarinic action blocks afferent pathways for vomiting reflex.</li>
<li>Has short duration of action</li>
<li>Produces anticholinergic effects; blurred vision, dry mouth, sedation.</li>
<li>Not effective with vomiting of other aetiologies.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="3-neuroleptics">3. Neuroleptics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-neuroleptics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Phenothiazines: chlorpromazine
potent anti emetics in vomiting due to drug toxicity, chemotherapy.
They act by blocking the D2 receptors in the medulla oblongata chemoreceptor trigger zone.
Not effective in motion sickness
Dosage is lower than antipsychotics</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-effects">Side effects;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Sedation, extrapyramidal effects; dyskinesia, dystonia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="4-h1-antagonist">4. H1 Antagonist<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-h1-antagonist" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Doxylamie useful in motion sickness</li>
<li>Modest effect on chemotherapy</li>
<li>Reduce extra pyramidal effects of D2 receptor antagonist.</li>
<li>Are antagonist therefore avoided in pregnancy.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adjuvant-antiemetics">Adjuvant Antiemetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adjuvant-antiemetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="corticosteroids">Corticosteroids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#corticosteroids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>dexamethasone, methylprednisolone, used to control chemotherapy vomiting.
Act by blocking prostaglandins.
Cause insomnia and hyperglycemia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cannabinoids">Cannabinoids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cannabinoids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>tetrahydrocannabinol</p>
<ul>
<li>active principle of marijuana</li>
<li>Reduce chemotherapy emesis.</li>
<li>For patients intolerant or refractory to others antiemetics</li>
</ul>
<p>Side effects; hallucinations. Disorientation, vertigo, sedation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hematologic-drugs-anti-coagulants">HEMATOLOGIC DRUGS - ANTI COAGULANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hematologic-drugs-anti-coagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Anti coagulant refers to any substance which inhibits normal blood clotting, lowers coagulability of blood.</li>
<li>The anti coagulant interfere with normal coagulation process by interfering with the clotting cascade and thrombin formation.</li>
<li>These agents are used to inhibit clot formation but they do not dissolve existing clots.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-anticoagulants">Classification of Anticoagulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-anticoagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Parenteral anticoagulants:</li>
</ul>
<p>Heparin
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Low molecular weight heparin; enoxaparin, dalteparine, nadroparin, arteparin.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Semisynthetic heparinoid; heparin sulphate, dextran sulphate, ancrod, danaparoid.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Others; lepirudin, bivalirudin, argatroban</p>
<ul>
<li>Oral anticoagulant; warfarin, acenocoumarin, dicoumarol</li>
<li>Fibrinolytic; streptokinase urokinase, alteplase</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="heparin">HEPARIN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#heparin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>mechanism of action: heparin acts prophylactically to prevent the formation of clots in the vasculate.it activates anti thrombin III which inhibits thrombin and clotting factor IX, X, XI, XII, consequently conversion of fibrinogen to fibrin does not occur and the formation of a fibrin clot is prevented</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Heparin sodium, LMWH, fondaparinux sodium</p>
<ul>
<li>In conditions necessitating prompt anticoagulant activity (evolving stroke, pulmonary embolism, massive deep venous thrombosis)</li>
<li>As an adjunct for clients having open heart surgery or renal dialysis</li>
<li>As low-dose therapy for prophylaxis against postoperative venous thrombosis (for example, hip/knee replacement surgery, abdominal surgery)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="administration">Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These medications cannot be absorbed by the intestinal tract and must be given by subcutaneous injection or IV infusion.</li>
<li>Heparin sodium: Subcutaneously every 12 hr ., continuous or intermittent IV infusion</li>
<li>Enoxaparin, dalteparin sodium, tinzaparin: Subcutaneously every 12 hr . for 2 to 8 days</li>
<li>Fondaparinux sodium: Subcutaneously every 12 hr . for 5 to 9 day.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hemorrhage secondary to heparin overdose</li>
<li>thrombocytopenia,</li>
<li>Hypersensitivity reactions (chills, fever, urticaria)</li>
<li>Administer a small test dose prior to the administration of heparin. Toxicity/overdose</li>
<li>Administer protamine sulfate, which binds with heparin and forms a heparin-protamine complex that has no anticoagulant properties.</li>
<li>Protamine sulfate should be administered slowly intravenously, no faster than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> or 50 mg in 10 min .</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="enoxaparin">Enoxaparin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#enoxaparin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hemorrhage Monitor vital signs <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> Advise clients to observe for signs and symptoms of bleeding, such as increased heart rate, decreased blood pressure, bruising, petechiae, hematomas, black tarry stools. - Monitor platelet count. Instruct client to avoid aspirin.</li>
<li>Neurologic damage from hematoma formed during spinal or epidural anesthesia</li>
<li>Thrombocytopenia, as evidenced by low platelet count , Monitor platelets. Discontinue medication for platelet count less than 100,000/mm3 .</li>
<li>Toxicity/overdose; Administer protamine sulfate</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">- Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Parenteral anticoagulants are contraindicated in clients with low platelet counts (thrombocytopenia) or uncontrollable bleeding.</li>
<li>These medications should not be used during or following surgeries of the eye(s), brain, or spinal cord; lumbar puncture; or regional anesthesia.</li>
<li>clients who have hemophilia, increased capillary permeability, dissecting aneurysm, peptic ulcer disease, severe hypertension, hepatic or renal disease, or threatened abortion</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Anti-platelet agents such as aspirin, NSAIDs, and other anticoagulants may increase risk for bleeding..</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="oral-anti-coagulants">ORAL ANTI COAGULANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oral-anti-coagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These are the most commonly used oral anti coagulants;</li>
<li>Warfarin,</li>
<li>Dicoumarol,</li>
<li>Acenocoumarol</li>
</ul>
<p>Mechanism of action
Vitamin K antagonist; these agents inhibit the liver synthesis of vitamin K clotting factor II,VII, IX, X.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advantages-over-heparin">Advantages over heparin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advantages-over-heparin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Bioavailability is almost 100 percent.
Low volume distribution,
Long half life.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Produces delayed action,
possibility of genetic resistance</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-indication">Clinical indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Treatment deep venous thrombosis.
Pulmonary embolism
Prevent blood clotting in patients with thrombophlebitis, pulmonary embolism and embolism from arterial fibrillation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindication-precaution">Contraindication /precaution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication-precaution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Not given to pregnant women because it crosses the placenta barrier, it is teratogenic, and can cause an a abortion.</li>
<li>Not given to patients with bleeding disorders e.g. hemophilia, peptic ulcer, sever renal/ liver disease and eclampsia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="monitoring">Monitoring<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#monitoring" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Monitor prothrombin time usually done before administering the dose.</li>
<li>The PT SHOULD BE 1.5-2.5 times the reference value to be therapeutic</li>
<li>If it is below the recommended range warfarin should be increased.</li>
<li>If it above the recommended range warfarin should be decreased.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects-of-warfarin">Adverse effects of warfarin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects-of-warfarin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hematologic effects: increased bleeding, thrombocytopenia</li>
<li>Anorexia, nausea, vomiting, diarrhoea and dermatitis.</li>
<li>Hemorrhage</li>
<li>Interference with bone formation in early pregnancy</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="potentiation-activity">Potentiation activity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#potentiation-activity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Inhibition of metabolism: chloramphenicol, ciprofloxacin, cotrimoxazole, cimetidine.</li>
<li>Displacement from plasma protein; ethacrynic acid.</li>
<li>Platelet function inhibition; NSAIDs (Aspirin)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="retarded-activity">retarded activity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#retarded-activity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>inhibition of absorption; Sucralfate</li>
<li>Enzyme induction; barbiturates, carbamazepine, rifampicin</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acenocoumarol">Acenocoumarol<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acenocoumarol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>take 2-3 DAYS.</li>
</ul>
<p>Indication</p>
<ul>
<li>Arterial fibrillation,</li>
<li>pulmonary embolism,</li>
<li>prophylaxis following insertion of heart valve.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-drug-reaction">Adverse drug reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-drug-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Alopecia, diarrhoea, hepatic dysfunction, pancreatitis vomiting</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-of-warfarin">Precautions during Administration of warfarin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-of-warfarin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Administration is usually oral, once daily.</li>
<li>Obtain the client's baseline vital signs.</li>
<li>Monitor PT levels (therapeutic level 18 to 24 sec ) and INR levels (therapeutic levels 2 to 3 ). INR levels are the most accurate. Hold dose and notify the provider if these levels exceed therapeutic ranges.</li>
<li>Obtain baseline and monitor CBC, platelet count, and Hct levels.</li>
<li>Instruct clients that anticoagulant effects may take 8 to 12 hr and full therapeutic effect is not achieved for 3 to 5 days. For clients in the hospital setting, explain the need for continued heparin infusion when starting oral warfarin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-of-warfarin">Precautions during Administration of warfarin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-of-warfarin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Advise clients that anticoagulation effects can persist for up to 5 days following discontinuation of medication because of long half-life.
Advise clients to avoid alcohol and over-the-counter and nonprescription medications to prevent adverse effects and medication interactions, such as risk of bleeding.
Advise clients to employ nonmedication measures to avoid development of thrombi, including avoiding sitting for prolonged periods of time, not wearing constricting clothing, and elevating and moving legs when sitting.
Advise clients to wear a medical alert bracelet indicating warfarin use.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-of-warfarin">Precautions during administration of warfarin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-of-warfarin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Be prepared to administer vitamin K for warfarin overdose.</li>
<li>Teach clients to self-monitor PT and INR at home as appropriate.</li>
<li>Advise clients to record dosage, route, and time of warfarin administration on a daily basis.</li>
<li>Plan for frequent PT monitoring for clients who are prescribed medications that interact with warfarin. The client is at greatest risk for harm when the interacting medication is being deleted or added. Frequent PT monitoring will allow for dosage adjustments as necessary.</li>
<li>Advise clients to notify the provider regarding warfarin use.</li>
<li>Advise clients to use a soft-bristle toothbrush to prevent gum bleeding</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="thrombolytic-fibrinolytic-medications">Thrombolytic /Fibrinolytic Medications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#thrombolytic-fibrinolytic-medications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Two phenomena which causes hemostasis include,</p>
<ul>
<li>Coagulation of blood .</li>
<li>Formation of a thrombus</li>
</ul>
<p>Formation of a thrombus is restricted through:</p>
<ol>
<li>Fibrin inhibition: anti thrombin III, Ant plasmin, Antitrypsin, Macroglobulin</li>
<li>Fibrinolysis: tissue plasminogen activator and CF XII activate fibrin bound plasminogen to active plasmin, restrict formation of a thrombus.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action-of-fibrinolytic">Mechanism of action of Fibrinolytic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-fibrinolytic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Thrombolytic/fibrinolytic medications dissolve clots that have already formed. Clots are dissolved by conversion of plasminogen to plasmin, which destroys fibrinogen and other clotting factors. The result is clot disintegration.</p>
<p>The commonly used fibrinolytic include:
Streptokinase (Streptase)
Urokinase
Alteplase (Activase, tPA),
Anistreplase
Reteplase (Retavase)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="streptokinase">Streptokinase<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#streptokinase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>streptokinase is a semi synthetic that acts systematically to dissolve the blood clot by activating plasminogen to plasmin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-indication">Clinical indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Acute myocardial infarction</li>
<li>Deep vein thrombosis (DVT)</li>
<li>Massive pulmonary emboli</li>
<li>thrombo embolic stroke (alteplase)</li>
<li>Peripheral arterial thrombosis</li>
<li>To open clotted iv catheters</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reaction">Adverse reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic reaction (urticaria, itching, flushing, bronchospasms); possible severe anaphylactic reaction.
*Serious risk of bleeding from different sites (within brain, needle puncture sites, wounds)</li>
<li>Hypotension</li>
<li>Arrhythmias</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Any prior intracranial hemorrhage (hemorrhagic stroke)</li>
<li>Active internal bleeding</li>
<li>History of significant closed head or facial trauma in the past 3 months</li>
<li>Acute pericarditis</li>
<li>Brain tumors</li>
<li>Use cautiously in clients who have severe hypertension, a recent episode of ischemic stroke ( 6 months prior to start of treatment), or a recent major surgery (2 to 4 weeks prior to start of treatment).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="urokinase">Urokinase<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#urokinase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Isolated from human renal cells from tissue cultures.</li>
<li>Helps in direct conversion of plasminogen to plasmin.</li>
</ul>
<p>Therapeutic uses
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Myocardial infarction.
Venous thrombosis.
Pulmonary embolism.
Adverse reaction</p>
<ul>
<li>Fever.
*Hemorrhage.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="alteplase">Alteplase<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#alteplase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Recombinant tissue plasminogen activator (t-PA)
*helps in Critical activation of plasminogen bound in fibrin clot.</li>
</ul>
<p>Reduces the risk of systemic bleeding to an appreciable extent.</p>
<ul>
<li>Half life 4-8 minutes</li>
<li>More efficacious than others</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-use">Therapeutic use<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Lysis of occlusive coronary artery thrombi associated with myocardial infarction.
Deep venous thrombosis.
Ischemic cerebrovascular disease</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reaction">Adverse reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Nausea</li>
<li>Fever</li>
<li>Rash, pruritic</li>
<li>Mild hypertension</li>
<li>Localized bleeding</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-of-thrombolytic-agents">Precautions during Administration of thrombolytic agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-of-thrombolytic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Use of thrombolytic agents must take place within 4 to 6 hr . of onset of symptoms
monitor in a setting that provides for close supervision and continuous monitoring during and after administration of the medication.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Obtain baseline platelet counts, hemoglobin (Hgb), hematocrit (Hct), a PTT, PT, INR, and fibrinogen levels, and monitor periodically.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Obtain baseline vital signs (heart rate, blood pressure) and monitor frequently per protocol.</p>
<ul>
<li>Special care includes continuous monitoring of hemodynamic status to assess for therapeutic and adverse effects of thrombolytic (relief of chest pain, signs of bleeding). Follow facility protocol.</li>
<li>Provide for client safety per facility protocol.</li>
<li>Ensure adequate IV access for administration of emergency medications and availability of emergency equipment.</li>
<li>Do not mix any medications in IV with thrombolytic agents.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-cont">Precautions during administration cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Minimize bruising or bleeding by limiting venipunctures and subcutaneous/intramuscular injections.</li>
<li>Discontinue thrombolytic therapy if life-threatening bleeding occurs. Treat blood loss with whole blood, packed red blood cells, and/or fresh frozen plasma. IV aminocaproic acid (Amicar) should be available for administration in the event of excessive fibrinolysis.</li>
<li>Following thrombolytic therapy, administer heparin or aspirin as prescribed to decrease the risk of rethrombosis.</li>
<li>Following thrombolytic therapy, administer beta blockers as prescribed to decrease myocardial oxygen consumption and to reduce the incidence and severity of reperfusion arrhythmias.</li>
<li>Administer H2 antagonists, such as ranitidine (Zantac), or proton pump inhibitors, such as omeprazole (Prilosec), as prescribed to prevent GI bleeding.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-platelets-drugs">Anti Platelets Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-platelets-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These are agents that decrease the formation of platelet plug by decreasing their responsiveness to various stimuli that would cause them to risk and combine together on a vessel wall.
This include;</li>
<li>Acetyl salicylic acid (aspirin)</li>
<li>Thienopyridine analogues</li>
</ul>
<p>Ticlopidine,
Clopidogrel</p>
<ul>
<li>Glycoprotein receptor antagonist:</li>
</ul>
<p>Abciximab
Eptifibatide and Tirofiban</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action-of-platelet-inhibitors">Mechanism of action of platelet inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-platelet-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These agents inhibit the aggregation of platelets in the clotting process by blocking receptor sites on the platelets membrane, preventing platelet to platelet interaction, there by prolonging the bleeding time.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acetyl-salicylic-acid-aspirin">Acetyl salicylic acid (aspirin)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acetyl-salicylic-acid-aspirin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Universally accepted anti platelet drug.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Irreversibly causes inhibition of cyclooxygenase (COX) that leads to formation of thromboxane A2 and prostacyclin.</li>
<li>TXA2 is the key platelet activator inhibition of platelets action.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Primary prevention of acute myocardial infarction</li>
<li>Prevention of reinfarction in clients following an acute myocardial infarction</li>
<li>Prevention of stroke</li>
<li>Acute coronary syndromes (abciximab, tirofiban, eptifibatide)</li>
<li>Intermittent claudication (cilostazol, pentoxifylline, dipyridamole)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="route-of-administration">Route of administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#route-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Aspirin: Oral
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Abciximab: IV
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Clopidogrel: Oral
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Pentoxifylline: Oral</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Aspirin GI effects (nausea, vomiting, dyspepsia) Advise clients to use enteric-coated tablets and to take aspirin with food. Concurrent use of a proton pump inhibitor, such as omeprazole (Prilosec), may be appropriate.
Hemorrhagic stroke
Prolonged bleeding time, gastric bleed, thrombocytopenia
Tinnitus, hearing loss</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Advise clients that prevention of strokes, myocardial infarctions, and reinfarction can be accomplished with low-dose aspirin ( 81 mg ).
Aspirin 325 mg should be taken during initial acute episode of myocardial infarction</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="thienopyridine-analogues">Thienopyridine analogues<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#thienopyridine-analogues" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clopidogre-and-ticlopidine">Clopidogre and ticlopidine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clopidogre-and-ticlopidine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Clopidogre and ticlopidine reduces platelets aggregation by inhibiting the ADP pathway of platelets.</li>
<li>These drugs achieved their antiplatelet effects by irreversibly blocking the ADP receptor on platelets.</li>
<li>unlike aspirin, these drugs have no effects on prostaglandin metabolism.</li>
<li>Important for aspirin intolerant</li>
<li>Use of clopidogre or ticlopidine to prevent thrombosis is now considered standard practice in patients undergoing placement of coronary stent.</li>
<li>Clopidogrel plus aspirin is used for long term treatment of severe cases of coronary syndromes.
*Rashes caused by ticlopidine.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hemostatic-agents-coagulants">Hemostatic Agents/ coagulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hemostatic-agents-coagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Haemostatic agents help to stop bleeding at the local site.thus enhancing and promoting coagulation and formation of network fibrin around the wound.
These drugs are :
Aminocaproic acid and tranexamic</p>
<ul>
<li>These are fibrin stabilizers that maintain or stabilize the clot in the bleeding vessels.</li>
</ul>
<p>Protamine sulfate</p>
<ul>
<li>This agent antagonizes the anticoagulant effects of heparin.</li>
<li>It is derived from fish testis and is high in arginine content.</li>
<li>The positive charge interacts with the negative charge of heparin to form a stable inactive complex.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-for-various-bleeding-conditions">Drugs for Various Bleeding Conditions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-for-various-bleeding-conditions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Epistasis - adrenaline</li>
<li>Overdose of fibrinolytic, bleeding post surgery - aminocaproic acid</li>
<li>Menorrhagia, metrorrhagia - adrenochrome, ethamesylate.</li>
<li>PPH - carboprost</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vitamin-k">Vitamin K<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vitamin-k" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Is a fat soluble vitamin occurs in two forms :
vitamin K1 (phytonadione):leafy vegetables
Vitamin k2 (menadione): GIT through microbes.
Bile salts are required for absorption of vitamin K from the intestines.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vit-k-cont">VIT .K cont.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vit-k-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Deficiency occurs due to two conditions</p>
<ul>
<li>Prolonged gut sterilization. VIT. K2</li>
<li>Obstructive jaundice. VIT. K1, K2.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phytonadione">Phytonadione<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phytonadione" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>may be given orally, IM, IV
if given orally give with bile salts.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="menadione-sodium-bisulphate">Menadione sodium bisulphate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#menadione-sodium-bisulphate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Oral, IM ,IV, or SC
does not require bile salts
Takes longer duration
Vitamin K is given to antagonize oral anticoagulants.
The response to vitamin K is slow, requiring about 24 hours thus, if immediate hemostasis or bleeding control is required, fresh frozen plasma should be ordered.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Vitamin K deficiency.
Treatment of hemorrhagic disease of the newborn.
newborn and premature to cover the reduced intestinal synthesis.
Prolonged anti microbial therapeutic activity.
Obstructive jaundice.
malabsorption</p>
<p>A hematinic is a nutrient required in the formation of blood cells the main hematinic are iron, B12 and Folate. deficiency can lead to anemia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iron-and-iron-salts">Iron and iron salts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iron-and-iron-salts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Iron deficiency is the most common nutritional anaemia in humans</li>
<li>It result from inadequate iron intake, malabsorption, blood loss, or an increased requirement as with pregnancy.</li>
<li>When severe it results in microcytic hypochromic anemia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ferrous-sulphate">Ferrous sulphate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ferrous-sulphate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Iron is given orally as a ferrous salt <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">G</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{MG}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm">MG</span></span></span></span></span></span> is administered daily for the treatment of anemia .
Iron is absorbed readily in presence of gastric acid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ferrous-sulphate-cont">Ferrous Sulphate Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ferrous-sulphate-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>It is given before meals though many patients cannot tolerate it due to its irritating effects.</li>
<li>After sometime the patient shows improved appetite, increased erythrocyte cell count and decreased microcytic hypochromic anaemia</li>
<li>At lest six months of therapy is necessary to restore iron levels to storage site.</li>
<li>It can be given parenterally as iron dextran or iron sucrose that is by slow im or iv.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="unwanted-effects">Unwanted Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#unwanted-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Oral can cause GIT discomfort
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Liquid form for infants can stain teeth.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Allergic reactions are possible with chills, urticaria, sweating, fever and even anaphylaxis after parenteral administration.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Patients pass black or dark stool this in harmless results of unabsorbed iron.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="folic-acid">Folic Acid<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#folic-acid" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Folic acid is essential in the production of DNA and erythropoiesis (RBC, WBC, and platelets).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Treatment of megaloblastic (macrocytic) anemia secondary to folic acid deficiency</li>
<li>Prevention of neural tube defects during pregnancy; therefore it is needed in all women of child-bearing age who may become pregnant.</li>
<li>Treatment of malabsorption syndrome such as sprue</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions .<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Indiscriminate use of folic acid is inappropriate because of the risk of masking signs of vitamin B12 deficiency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Decreased folate levels with concurrent use of sulfonamides, sulfasalazine, or methotrexate.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Assess clients for signs and symptoms of megaloblastic anemia (pallor, easy fatigability, palpitations, paresthesia of hands or feet).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Obtain the client's baseline folic acid levels, RBC and reticulocyte counts, Hgb, and Hct levels. Monitor periodically.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Advise clients with folic acid deficiency to concurrently increase intake of food sources of folic acid, such as green leafy vegetables and liver. Monitor clients for risk factors indicating that folic acid therapy may be needed, such as heavy alcohol use and child-bearing age.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="insulin-oral-hypoglycemic-agents">Insulin, oral hypoglycemic agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#insulin-oral-hypoglycemic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="overview">Overview<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Diabetes mellitus is a chronic illness that results from an absolute or relative deficiency of insulin.</li>
<li>Various insulins are available to manage diabetes. These medications differ in their onset, peak, and duration.</li>
<li>Oral hypoglycemic agents work in various ways to increase available insulin or modify carbohydrate metabolism.</li>
<li>Newer injectable medication are used to supplement insulin or oral agents to manage glucose control.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="diabetes-mellitus-and-effects-of-insulin">Diabetes Mellitus and Effects of Insulin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diabetes-mellitus-and-effects-of-insulin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>DM consists of agroup of disorders characterized hyperglycemia, altered metabolism of lipids, carbohydrates and proteins and increased complications from vascular diseases.</li>
<li>Most patients can be classified clinically as having either type1 or type 2 DM.</li>
<li>The criteria for the diagnosis of DM include symptoms (e.g.polyuria, polydipsia, and unexplained weight loss)and a random plasma glucose concentration of greater than 200ml/dl )11.1mmol.</li>
<li>A fasting plasma glucose of greater than (126ml/dl) 7mmol</li>
<li>there two types of DM . DM TYPE 1 and DM TYPE 2</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="insulin-therapy">Insulin Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#insulin-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Insulin polypeptide hormone is the mainstay for treatment</li>
<li>Of all types of diabetes.</li>
<li>Insulin may be administered IM, IV, SC.</li>
<li>long term treatment relies on subcutaneous injections of the hormone.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Promotes cellular uptake of glucose (decreases glucose levels)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Converts glucose into glycogen
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Moves potassium into cells (along with glucose)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Insulin is used for glycemic control of diabetes mellitus (type 1, type 2, gestational) to prevent complications.</li>
<li>Clients with type 2 diabetes mellitus may require insulin when:</li>
<li>Oral hypoglycemic, diet, and exercise are unable to control blood glucose levels.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Severe renal or liver disease is present.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Painful neuropathy is present.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Undergoing surgery or diagnostic tests.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Experiencing severe stress such as infection and trauma.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Undergoing emergency treatment of diabetes ketoacidosis (DKA) and hyperosmolar hyperglycemic nonketotic syndrome (HHNS).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Requiring treatment of hyperkalemia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-insulin-classified-according-to-duration-of-action">Classification of insulin classified according to duration of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-insulin-classified-according-to-duration-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>|  classification | Generic
(trade name) | Onset | Peak | duration  |
| --- | --- | --- | --- | --- |
|  Rapid acting | Lispro insulin
(Humalog), Insulin
aspart (NovoLog),
Insulin glulisine
(Apidra) | Less than 15 min | Less than 15 min 0.5 to
1 hr. | 3 to 4 hr.  |
|  Short acting | - Regular insulin
(Novolin R) | 0.5 to 1 hr. | 2 to 3 hr. | 5 to 7 hr.  |
|  Intermediate acting | neutral protamine
Hagedorn(NPH) insulin
(Humulin N), lente
insulin | 1 to 2 hr. | 4 to 12 hr. | 18 to 24 hr.  |
|  Long acting | Ultra lente, Insulin
glargine (Luntus) | 1 hr. | None | 10.4 to 24 hr.  |</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="premixed-insulins">Premixed insulins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#premixed-insulins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>70% NPH and 30% Regular (Humulin 70/30) - mixture of intermediate acting and short-acting insulin</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> insulin lispro protamine and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> insulin lispro (Humalog 75/25) - mixture of intermediate acting and rapid-acting insulin Complications</li>
</ul>
<p>Side/Adverse Effects</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="risk-for-hypoglycemia-too-much-insulin">Risk for hypoglycemia (too much insulin)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#risk-for-hypoglycemia-too-much-insulin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Monitor clients for signs of hypoglycemia. If abrupt onset, client will experience sympathetic nervous system (SNS) symptoms (tachycardia, palpitations, diaphoresis, shakiness). If gradual onset, client will experience parasympathetic (PNS) symptoms (headache, tremors, weakness).</li>
<li>Administer glucose. For conscious clients, administer a snack of 15 g of carbohydrate ( 4 oz. orange juice, 2 oz. grape juice, 8 oz. milk, glucose tablets per manufacturer's suggestion to equal 15 g<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mclose">)</span></span></span></span></span>.</li>
</ul>
<ul>
<li>If the client is not fully conscious, do not risk aspiration. Administer glucose parenterally such as IV glucose, or SC/IM glucagon.</li>
<li>Encourage clients to wear a medical alert bracelet.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="lipohypertrophy">Lipohypertrophy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lipohypertrophy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>atrophy of the sub cutaneous fat at the site of insulin injection is probably an immune response to insulin.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> It may occur with human insulin if patients inject themselves repeatedly in the same site
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Instruct clients to systematically rotate injection sites and to allow 1 inch between injection sites.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="insulin-allergy-resistant">Insulin Allergy Resistant<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#insulin-allergy-resistant" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Identify the underlying cause.</li>
<li>If allergic reaction to porcine insulin human insulin should be used.</li>
<li>Antihistamines may provide relieve in patients with cutaneous reaction.</li>
<li>Glucocorticoids are used in patients with resistant to insulin or more severe systemic reactions</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drug interaction is often caused by ethanol, adrenergic receptor antagonist, and salicylates.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Adrenergic receptor antagonist pose a risk of hypoglycemia due to inhibition of catecholamine effects on gluconeogenesis and glycogenolysis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> These agents may also mask he autonomic symptoms associated with hypoglycemia.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Salicylates enhance cell sensitivity to glucose and potentiate insulin secretion and also have a weak insulin - like action in the periphery.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Epinephrine, glucocorticoid, atypical antipsychotic drugs such as clozapine and olanzapine, and ARVS (protease inhibitors) have direct effects on peripheral tissues that counter the effect of insulin.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Phenytoin, clonidine, ca2+channel blockers cause hyperglycemia by inhibiting insulin secretion directly or in directly via depletion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">K</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{K}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">K</span><span class="mord">+</span></span></span></span></span> (diuretics).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="oral-hypoglycemic">Oral hypoglycemic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oral-hypoglycemic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>Medications</th><th>Expected pharmacological action</th></tr></thead><tbody><tr><td>Sulfonylureas</td><td></td></tr></tbody></table>
<ul>
<li>1st generation - tolbutamide (Orinase), chlorpropamide (Diabinese)</li>
<li>2nd generation - glipizide (Glucotrol, Glucotrol XL) ,glyburide (DiaBeta, Micronase, glibenclamide) glimepiride (Amaryl) | Results in insulin release from the pancreas  |
|  Meglitinides repaglinide (Prandin) nateglinide (Starlix) | Results in insulin release from the pancreas  |
|  Biguanides
metformin HCl (Glucophage) | - Reduces the production of glucose within the liver through suppression of gluconeogenesis</li>
<li>Increases muscles' glucose uptake and use  |
|  Thiazolidinedione's (Glitazones), rosiglitazone (Avandia), pioglitazone (Actos) | - Increases cellular response to insulin by decreasing insulin resistance</li>
<li>Results in increased glucose uptake and decreased glucose production  |
|  Alpha glucosidase inhibitors acarbose (Precose), miglitol (Glyset) | - Slows carbohydrate absorption and digestion  |
|  Gliptins - Sitagliptin (Januvia | - Augments naturally occurring incretin hormones, which promote  |</li>
</ul>
<p>All classifications of oral hypoglycemic agents control blood glucose levels in clients with type 2 diabetes mellitus and are used in conjunction with diet and exercise lifestyle changes.
Metformin HCl is used to treat polycystic ovary syndrome (PCOS).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="glipizide-and-repaglinide">Glipizide And Repaglinide<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glipizide-and-repaglinide" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hypoglycemia</li>
</ul>
<p>Metformin</p>
<ul>
<li>Gastrointestinal effects (anorexia, nausea, vomiting, which frequently results in weight loss of 3 to 4 kg [6 to 8 lb<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">]</mo></mrow><annotation encoding="application/x-tex">]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mclose">]</span></span></span></span></span> )</li>
<li>Vitamin B12 and folic acid deficiency caused by altered absorption</li>
<li>Lactic acidosis (hyperventilation, myalgia, sluggishness, somnolence) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> mortality rate</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="rosiglitazone">Rosiglitazone<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rosiglitazone" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Fluid Rosiglitazone retention</li>
<li>Elevations in low density lipoproteins (LDL) cholesterol</li>
<li>Hepatotoxicity .</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/ Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="acarbose">Acarbose<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acarbose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Intestinal effects (abdominal distention and cramping, hyperactive bowel sounds, diarrhea, excessive gas).</li>
<li>Risk for anemia due to the decrease of iron absorption</li>
<li>Hepatoxicity with long-term use</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sitagliptin">Sitagliptin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sitagliptin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>generally well tolerated</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Pregnancy Risk Category C: Glipizide, repaglinide, rosiglitazone
Pregnancy Risk Category B: Metformin HCl (Glucophage), acarbose (Precose), sitagliptin (Januvia)
These oral agents are generally avoided in pregnancy and lactation, but the provider may decide to prescribe them.
Use cautiously in clients with renal failure, hepatic dysfunction, or heart failure because of the risk of medication accumulation and resulting hypoglycemia. Severity of disease may indicate contraindication.
Contraindicated in the treatment of diabetic ketoacidosis (DKA) Metformin HCl is contraindicated for clients with severe infection, shock, and any hypoxic condition.
Acarbose is contraindicated for clients with gastrointestinal disorders, such as inflammatory disease, ulceration, or obstruction.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacology">PHARMACOLOGY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mr-misati-tiberius-oiro-kitale-kmtc-campus-complete-notes">MR. MISATI TIBERIUS OIRO. KITALE KMTC CAMPUS. (Complete NOTES)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mr-misati-tiberius-oiro-kitale-kmtc-campus-complete-notes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="learning-objectives">Learning Objectives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#learning-objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>By the end of this Module, the learners should be able to administer drugs professionally to patient's.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="introduction-to-pharmacology">INTRODUCTION TO PHARMACOLOGY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#introduction-to-pharmacology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Definition of terms:</li>
</ul>
<p>Pharmacology is the study of effects of chemical substances on the function of living systems.
pharmacology is the science of drugs which includes their preparation, use and effects.
*It is also the science that deals with the origin, chemistry, effects and uses of drugs.
Pharmacy: Branch of health science that deals with preparation and dispensing of drugs.
pharmacotherapy: The study of therapeutic uses and effects of drugs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="terminology">Terminology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#terminology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Pharmacognosy: the study of drugs that come from natural sources e.g. plants, animals and minerals as well as search for new drugs from natural sources.</li>
<li>Pharmacokinetics :this is the study of the body acts on the drugs; it is characterized by absorption, distribution, metabolism(biotransformation)and excretion/elimination. It can further be described as how the body handles a drug from site of administration to the site of action and elimination.</li>
<li>Pharmacodynamics/mechanism of action: the study of how drugs act on the body.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="terminologies-cont">Terminologies Cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#terminologies-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Pharmacogenetics: the study of the effects that genetics have on an individuals response to drugs.</li>
<li>Contra-indication: A health condition/ state that will prelude the administration of a drug e.g. aspirin is contraindicated in peptic ulcer disease.</li>
<li>Half life or half time (t1/2): Time taken for plasma concentration to fall by half following its elimination in the body.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="terminologies-cont">Terminologies Cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#terminologies-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Toxicology: This branch of pharmacology which deals with the an desirable effects of chemicals on living systems from individual cells to complex body systems.</li>
<li>Drug: Any substance used in diagnosis, cure, treatment and prevention of disease/condition or any substance that brings a change in biological functions through its chemical actions. The term drug, medication, and medicine are used synonymously.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="terminologies-cont">Terminologies Cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#terminologies-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Drug interactions :effects produced when some drugs are given concurrently.</li>
<li>Desired therapeutic effect: This should indicate the mechanism of action of a drug e.g.an analgesic is for pain relief, accompanied by central nervous system depression inhibition of inflammation, neutralization of acid in the stomach, vasodilation in angina or muscle relaxation.
*Placebo: Any component of therapy that is without specific biological activity e.g. inactive substance such as normal saline or distilled water usually used in clinical trials research and for psychological treatment.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-reactions-and-interactions">Drug Reactions and Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-reactions-and-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Any physiologically active drug has the potential to cause an undesirable reaction that may induce illness in the recipient. These include toxic reaction, side effects, allergic reactions, cumulative reaction, tolerance and dependence and detrimental drug reaction.</p>
<ul>
<li>Side effects: these are physiological effects exerted by the chemicals that are not related to the desired therapeutic effects. you must therefore be familiar with serious side effect and commonly occurring effects.</li>
<li>Adverse drug reaction: this an injury occurring by taking medication .It may occur following a single dose or prolonged administration of a drug or result from a combination of two or more drugs. The study of ADR is known as pharmacovigilance.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-reactions-and-interactions-conti">Drug reactions and Interactions Conti....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-reactions-and-interactions-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Drug interaction: this is when an interactant chemical modifies the therapeutic results that are anticipated with a drug the interact may be another drug, some combination of a drug, natural or artificial components in the diet, pollutants chemical from the environment, endogenous body chemicals and Chemicals used for diagnostic laboratory test. Drug interaction may be detriment or beneficial drug and may vary from one person to another. This may affect the absorption, distribution ,metabolism or excretion of the drugs.</li>
<li>Allergic reactions: This the body's immunological response to a drug following previous exposure to the same drug.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-reactions-and-interactions-conti">Drug reactions and Interactions Conti.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-reactions-and-interactions-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Idiosyncratic reactions: this is genetically determined, un expected response to a drug. The response may take the form of extreme sensitivity to low doses or extreme insensitivity to high doses to the drug.</li>
<li>Chain reaction: Medication are often added to a regime to control side effects of other drugs. This can initiate a chain reaction e.g. cortisone is prescribed to treat a serious inflammatory condition it can cause hypertension, ulcers, diabetes and a reactivation of arrested tuberculosis.</li>
<li>Cumulative reaction: Drugs accumulate in the body whenever the dosage exceeds the amount the body can eliminate through metabolism or excretion</li>
<li>Tolerance and dependence: Tolerance occurs when a person no longer responds to the drug in the way that person initially responded as a result of continued use of the drug causing a need to increase dose of a drug to achieve the same effect.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-reactions-and-interactions-conti">Drug reactions and Interactions Conti....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-reactions-and-interactions-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>There three basic types of tolerance.
metabolic /pharmacokinetics tolerance this occurs due to increased metabolism of a drug leading to reduction in drug concentration at the receptor site.
cellular/pharmacodynamic tolerance this caused by adaptive changes that take place at the receptor site or drug action site.
cross tolerance when tolerance to one drug confers tolerance to another drug. Drugs that have the same chemical structure tend to portray cross tolerance e.g. people tolerance to one barbiturates are usually tolerant to all barbiturates e.g., phenobarbital, thiopental. However drugs of similar class can also portray crosstolerance.</li>
<li>Intolerance: low threshold to normal pharmacological response. A drug causes an exaggeration of a normal pharmacological response e.g. morphine may cause coma instead of respiratory distress which occurs with administration of a normal dose.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-reactions-and-interactions-conti">Drug reactions and Interactions Conti.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-reactions-and-interactions-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Dependence: A state arising from repeated periodic or continuous administration of a drug that results in harm to the individual or sometimes society. People feel desire or compulsion to continue using the drug and feel ill if abruptly withdrawn or an antidote is used. Substance that cause dependence are taken to induce a good feelings or avoid discomfort of their absence.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="types-dependence">Types dependence:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#types-dependence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>a. psychological dependence: usually first to appear, where the individual have a craving for the effect the drug produces motional distress like fear, anxiety and irritability occur when the drug is withdrawn.
b. Physical dependence: this dependence is usually defined in terms of withdrawal/abstinence syndrome that are physical in nature e.g. tremors, ataxia, shivering.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-reactions-and-interactions-conti">Drug reactions and Interactions Conti.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-reactions-and-interactions-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Iatrogenic responses: these are responses produced an intentionally during the cause of treatment e.g. penicillin may cause hepatic toxicity, steroid may cause Cushing's syndrome.</li>
<li>Anaphylaxis: A sudden serious life threating allergic reaction and should be treated as a medical emergency, it causes more than one of the following ; an itchy rash throat and tongue swelling, shortness of breath ,vomiting, lightheadedness and low blood sugar.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-development">Drug development<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-development" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>After a chemicals that has shown therapeutic value has been identified, it must undergoes a series of scientific test to evaluate its actual therapeutic and toxic effects. The process is controlled by legally established bodies e.g. pharmacy and poisons board and food &amp; drug administration (FDA)development IN Kenya and USA respectively. Before receiving legal approval to be marketed to the public ,drugs must pass through several sequential stages of development.
Pre-clinical trials: this phase involves testing the drug on laboratory animals to test their pharmacodynamics, pharmacokinetics and toxicology. The toxicity studies include mutagenic, carcinogenic and reproductive studies.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-development-conti">Drug Development Conti....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-development-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phase-i-clinical-pharmacology">Phase I: clinical pharmacology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phase-i-clinical-pharmacology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is first phase human volunteers, usually 20-50 (healthy volunteers or volunteer patients depending on the class of drug and its safety)are used to test the drug. Pharmacodynamics and pharmacokinetics era tested. Toxicity and therapeutic effects are further tested.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phase-ii-therapeutic-exploration">Phase II: therapeutic exploration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phase-ii-therapeutic-exploration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tests are done on patients who have the disease usually 100-200 patients are involved in the study. Pharmacodynamics and pharmacokinetics era determined as well as dosing requirements and efficacy of the drug at the given dose</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phase-iii-therapeutic-confirmation">Phase III: Therapeutic confirmation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phase-iii-therapeutic-confirmation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The drug is used on Avast clinical market 300-3000 patients are involved. Prescriber observes patients closely for drug adverse effects and therapeutic effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-development-conti">Drug Development Conti....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-development-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phase-iv-continuous-evaluation">Phase IV: continuous evaluation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phase-iv-continuous-evaluation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>the prescribers are expected to report to the regulatory bodies any unexpected effects which then evaluates this information. A drug may be withdrawn from the market if it produces toxic effects e.g. thalidomide.</p>
<ul>
<li>Orphan drug : drugs that have been discovered but are not financially viable and therefore have not been adopted by any drug company. may be useful in treating a rare disease or may have potentially dangerous adverse effects. They are often abandoned after preclinical trials or phase I studies.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sources-of-drugs">Sources of drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sources-of-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>a)Plants sources: plants have been used as a source of drugs since prehistoric times. Plants are an important source of chemicals that are developed into drugs. Any part of a plant; including leaves, roots and back can be used. Drug can be processed using the synthetic version of the active chemical found in plants e.g. dronabinol which contains the active ingredients delta-9-tetrahydrocannabinol found in marijuana.it prevents nausea and vomiting in cancer patients but does not cause adverse effects as when one smokes marijuana.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="examples-of-active-ingredients-in-plants">Examples of active ingredients in plants.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#examples-of-active-ingredients-in-plants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>i) Alkaloids: Taste bitter and are poorly absorbed in water but become soluble if dissolved in acids examples of drugs derived from alkaloids includes; atropine, caffeine, cocaine, quinine, codeine and morphine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sources-of-drugs-conti">Sources of drugs Conti....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sources-of-drugs-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ii)Glycosides: these are digitalis products e.g. digoxin, digitoxin which are gotten from digitalis purpureal or foxglove plants.
iii)Gums: these are polysaccharides exudates that can be used for bulk laxatives and dental adhesives.
iii)Resins: the most common resins is benzoin which is used as an antiseptic.
iv)Oils: These can be volatile oils like peppermint, spearmint, menthol, cinnamon, lemon camphor. They have pleasant fragrance and evaporate easily. The other types of oils is fixed oils which include castor oil used as a laxative, olive oil for cooking, emollients used in cosmetics and solvents for injections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sources-of-drugs-cont">Sources of drugs Cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sources-of-drugs-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>b) Animal sources: these are used to replace human chemicals that are not produced adequately due to disease or genetic problems e.g. insulin from pancreases of pigs and cows. Thyroid drugs and growth hormone preparations from animals hypothalamus. Despite these animal sources most of these products are being currently produced synthetically which provides purer and safer products than animal sources.
c)Inorganic sources: salts of various elements have therapeutic effect in the human body e.g., aluminum ( used as antacids),fluoride( used to prevent dental cavities and osteoporosis), gold( used for rheumatoid arthritis), iron( used for anemia) and potassium (used in potassium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">K</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{K}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">K</span><span class="mord">+</span></span></span></span></span> supplements.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sources-of-drugs-cont">Sources of drugs Cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sources-of-drugs-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>d)Synthetic sources: Many drugs are developed synthetically after chemicals in plants ,animals or other environment have been screened for signs of therapeutic activity. This eliminates side effects and increases drug potency. Drugs have genetic engineering are used to produce chemicals that have therapeutic effects.
e)Microbiological sources: example penicillins,tetracycline
f)recombinant DNA technology.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="uses-of-drugs">Uses of drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#uses-of-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>curative: this is the primary therapy e.g. in treating infections or auxiliary therapy e.g. application of anaesthetic medication.</li>
<li>suppress signs and symptoms, hence improve quality of life without attaining cure e.g. anti diabetics.</li>
<li>prevent/prophylaxis- this could be primary e.g. use of vaccines to prevent one from getting a disease or secondary to stop progression of an existing disease.</li>
<li>diagnosis- for instance the use of tuberculin test to diagnose PTB</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-nomenclature">Drug nomenclature<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-nomenclature" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nomenclature is the systematic naming of drugs especially pharmaceutical drug
Drugs in majority of circumstances have three types of names.</p>
<ol>
<li>i)Chemical/molecular/ scientific name: this is the chemical/molecular structure of a drug. It states the structure in terms of atoms and molecules accompanied by a diagram of the chemical structure. Most useful to a few technically trained personnel e.g. chemist or research pharmacist the names are unsuitable for general use since they are long. e.g. acetyl-p-aminophenol is for paracetamol or acetaminophen</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-nomenclature-conti">Drug Nomenclature Conti......<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-nomenclature-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ii)Generic/non-proprietary/approved name; this is the abbreviated and approved name. it is the official medical name assigned by the producer in collaboration with the food and drugs board and nomenclature committee. The generic name can be used by any interested party and it removes confusion of giving several names to the same drug regardless of who manufactures them once they have the same chemical structure. A generic name is not capitalized e.g. acetylsalicylic acid commonly known as aspirin,
iii) Trade name/proprietary/brand name: name given to the drug by the manufacturing and marketing company. One drug may have so many trade name e.g. acetaminophen has about 30 names some are paramol, Tylenol, Panadol etc. they are usually capitalized.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="example-of-drugs-chemical-name-generic-name-and-trade-name">Example of drugs chemical name, generic name and trade name.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#example-of-drugs-chemical-name-generic-name-and-trade-name" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>Chemical name</th><th>Generic name</th><th>Trade names</th></tr></thead><tbody><tr><td>2-(4-</td><td></td><td></td></tr><tr><td>isobutylphenyl)propan</td><td></td><td></td></tr><tr><td>oic acid</td><td>ibrufen</td><td>Brufen, advil, nurofen</td></tr><tr><td>N-acetyl-para-</td><td></td><td></td></tr><tr><td>aminophenol</td><td>Paracetamol,</td><td></td></tr><tr><td>acetaminophen</td><td>Calpol, Panadol,</td><td></td></tr><tr><td>tylenol</td><td></td><td></td></tr><tr><td>2-(2-methl-5-nitro-1h-</td><td></td><td></td></tr><tr><td>imidazol1-y)ethyl</td><td></td><td></td></tr><tr><td>benzoate.</td><td>metronidazole</td><td>Flagyl ,metrogyl</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="two-major-methods-of-dispensing-drugs">Two major methods of dispensing drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#two-major-methods-of-dispensing-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Over the counter drugs (OTC):they do not need a prescription and can be purchased at the chemical shops; examples pain relief, blood tonics, vitamin preparation, ORS, antacids, antimalarial.</li>
<li>Prescription drugs: They need a prescription and must be controlled from abuse and dependence; e.g. antibiotics, anti-hypertensives, sedatives, diabetics drugs etc.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patients-education-about-otc-drugs">Patients education -about OTC drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patients-education-about-otc-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>You need to give your attention to all the drugs the patient is taking whether prescription or OTC.</li>
<li>Caution patient not to treat themselves with OTC drugs.</li>
<li>Inform them that most of the OTC medication contain more than one active ingredient.</li>
<li>Tell he patient that interactions can occur when takes more than one OTC medication at a time or takes one with a prescription drugs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patients-education-about-drugs">Patients education about drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patients-education-about-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prescription-drugs">Prescription drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prescription-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Inform patient about special consideration and drug safety precaution.</li>
<li>Encourage: complete medication list complete adverse reaction list.</li>
<li>Patients compliance.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Pharmacokinetics is the process by which the body, sick or well, handles and affects the drug. Or is the study of the bodily absorption, distribution, metabolism, and excretion of drugs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="it-is-characterized-by-four-processes">It is characterized by four processes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#it-is-characterized-by-four-processes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Absorption ;This is the process by which a drug is transferred from the site of administration into the circulating fluids of the body e.g. Blood and lymph.</li>
<li>The rate of absorption is vital because it determines when the drug is available to exert its action.</li>
<li>Bioavailability: This is the fraction extent to which a dose of drug reaches its site of action .for example;1. hepatic metabolism and biliary excretion may occur before a drug taken orally reaches systemic circulation.(first pass effect)</li>
<li>Drug given intravenously its bioavailability is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> thus bioavailability must be considered when calculating none intravenous routes of administration.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="factors-affecting-absorption">Factors affecting absorption<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factors-affecting-absorption" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Route of drug administration.
Dose.
Dosage formulation.
Food and fluids administered with the drugs.
Status of the absorptive surface.
Rate of blood flow to the small intestines.
acidity of the stomach
Status of GI motility.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="factors-influencing-drug-administration">Factors influencing drug administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factors-influencing-drug-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> The nature of the absorbing surface.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Blood flow to the site of administration; increase in blood flow facilitates abortion ; and e.g. sublingual route and pulmonary epithelium.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> The health status of the person taking the drug. This affects the rate of absorption and transportation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> The lipid solubility of drugs the higher the solubility the more a drug is absorbed especially in the GIT.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> The PH of the drug.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Drug concentration and critical concentration.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="routes-of-drug-administration">Routes of drug administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#routes-of-drug-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>A drugs route of administration affects the rate and extend of absorption.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Enteral route : drugs given along any portion of the GIT.it is most common, safe, convenient. and economical. but it is the slowest, it can be orally, sublingually, and rectally.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Parenteral route: intradermally, subcutaneous, intramuscular, intrathecal intravenous.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Pulmonary route: administered by in halation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> topical: applied on the skin, mucus membrane of eyes, ears, nasal mucosa, bladder, vagina and the penis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="factors-to-consider-when-choosing-the-route-of-drug-administration">Factors to consider when choosing the route of drug administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factors-to-consider-when-choosing-the-route-of-drug-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>The time at which the effect of the drug is required.</li>
<li>The method most suitable for the drug required.</li>
<li>The site of drug action.</li>
<li>Patients status whether conscious or unconscious.</li>
<li>Desire off the patient.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="conti">Conti......<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>When prescribing drugs the dose may vary with certain factors ; age, route, assimilation.
ii)distribution: this is the transport of a drug in body fluids to various tissues of the body and ultimately site of action.
The rate of distribution depends on;</li>
<li>The permeability of the capillary to the drug.</li>
<li>Lipid solubility and ionization of the drug. lipid soluble drugs are more rapidly absorbed and distributed than their lipid insoluble drugs</li>
<li>Cardiac function e.g. cardiac out put and regional blood, drug are fast distributed to areas with rich blood flow(Heart, kidneys, brain) later to areas of low blood flow (muscle, fat tissue).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="conti">Conti.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Drugs are widely distributed in body water (free fraction of drug)and partly as bound to plasma proteins and or tissues.</li>
<li>Plasma protein and tissue binding of drug reservoirs that sustain pharmacological action of a drug. The bound fraction and the free fraction are usually in a state of equilibrium</li>
<li>other proteins involved in drug binding include; lipoproteins, glycoprotein and globulins.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="biological-membranes-which-limit-the-distribution-of-drugs">Biological membranes which limit the distribution of drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#biological-membranes-which-limit-the-distribution-of-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Blood brain barrier: allows distribution of only lipid soluble drugs e.g. general anesthetics, barbiturates into the brain and spinal cord.</li>
<li>Placenta barrier: lipid soluble and some lipid insoluble can diffuse through hence some drug meant for the mother may pass through and harm the baby e.g. steroids ,narcotis and anaesthetics.</li>
<li>Blood-testes barrier: this may limit some chemotherapeutic agents used for treating testicular neoplasms.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="metabolism">Metabolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-metabolism-biotransformation">iii)metabolism/biotransformation:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-metabolism-biotransformation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>the biological transformation of a drug into an inactive metabolite, a more soluble compound ,or a more potent metabolite.
The Liver is the main organ of metabolism.
The Kidneys, gut mucosa, lungs and the skin are also involved in drug metabolism.
NB: Delayed drug metabolism results in accumulation of drug in the body and prolonged effect of the drug</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="factors-influencing-metabolism">Factors influencing metabolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factors-influencing-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Physiological factors like starvation, liver diseases, cardiovascular problems, these depress microsomal enzyme systems.</li>
<li>Age people with extreme ages have decreased metabolism</li>
<li>Genetic predisposition genetic differences in the rate of metabolism of some drugs exist.</li>
<li>Prior administration of the particular drugs or other drugs e.g. repeated administration of a particular drug may cause induction or inhibition</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="enzyme-induction-or-inhibition">Enzyme induction or inhibition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#enzyme-induction-or-inhibition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>enzyme induction this is a situation whereby the re is an increase in amount and activity of the liver microsomal enzymes usually due to exposure to certain substances such as drugs and endogenous substances.</li>
<li>A drug may induce its own metabolism
pharmacological Importance of enzyme induction</li>
</ul>
<ol>
<li>Drug interaction may occur.</li>
<li>Disease may result .</li>
<li>Tolerance (metabolic) to the drug.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="enzyme-induction-or-inhibition-conti">Enzyme induction or inhibition Conti.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#enzyme-induction-or-inhibition-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Enzyme inhibition this refers to decrease synthesis and activity of liver microsomal enzymes.it results in reduced metabolism of other drugs/inhibiting drug and endogenous substance.</li>
<li>General enzyme inhibition(beyond liver enzymes )has a greater pharmacological importance utility than enzyme induction.</li>
<li>Examples of drugs that inhibit enzymes include chloramphenicol and cimetidine.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="excretion">Excretion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#excretion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>iv) Excretion: this the process by which drugs and pharmacologically active or inactive metabolites are eliminated from he body primarily through the Kidneys.
Net renal excretion of a drug is as a result of 3 processes</p>
<ol>
<li>filtration (passive glomerular filtration)</li>
<li>re-absorption,</li>
<li>active tubular secretion.
other routes through which drugs are eliminated include
intestines or biliary excretion e.g. neomycin
Pulmonary elimination e.g. volatile liquids (general anaesthetics)
Sweat and saliva elimination e.g. thiazides.
Breast milk elimination e.g. narcotics.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacodynamics-mechanism-of-action">Pharmacodynamics/mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics-mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The study of how drugs act on the body. It is the chemical changes or effects that a drug has on body cell and tissues.</p>
<ul>
<li>Drug action: the cellular process involved in the drug and cell interaction.</li>
<li>Drug effects: the physiology reaction of the body to the drug.</li>
</ul>
<p>The common drug molecules (targets) on which drugs bind to produce therapeutic effects include enzymes, carrier molecules, ion channels, and receptors.</p>
<ul>
<li>The receptor : these are proteins that are found within or on the surface of cells Two terms related to receptors are affinity and efficacy.</li>
<li>Efficacy the tendency of a drug to activate the receptor once bound.</li>
<li>Affinity the tendency of a drug to bind to the receptor.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="harmful-interactions">Harmful interactions-<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#harmful-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>-Oral contraceptives and anti TB drugs - contraceptive failure.
-Tetracycline and antacids - cimetidine renders tetracycline ineffective.
-Anticoagulants warfarin and aspirin - may result to bleeding.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="beneficial-drug-interactions">Beneficial drug interactions-<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beneficial-drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>-Amino glycoside &amp; penicillin's achieve synergic antimicrobial effects -probenecid plus penicillin prolong action of penicillin..
-Morphine poisoning-naloxone is used as an antidote.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="continuation">Continuation.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#continuation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="synergism">Synergism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#synergism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This can either be
summation- this occurs when the effect of two drugs having the same action are additive e.g. beta blockers plus thiazide diuretics have an additive anti hypertensive effects.
Potentiating- this means to make more powerful, occurs when the action of one drug increases the action of another. e.g trimethoprim plus sulfamethoxazole.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antagonism">Antagonism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antagonism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Agonist- drug binds to a receptor there is a response.</li>
<li>Antagonist-drug binds to a receptor-no response, prevents binding of agonist(alpha and beta blockers)</li>
<li>Partial agonist-a drug that is able to both stimulate and block at receptor.</li>
<li>Antagonism- occurs when two or more drugs oppose the action of one another producing opposite pharmacodynamic effects e.g.
Antacids and tetracycline form a complex which is excreted in feaces chemical antagonism.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="administration-of-medications-drugs">Administration of Medications/Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#administration-of-medications-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Administration of medication involves all the activities related to safe drug use which include;-
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Assessing the risk to a client of a new drug order.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Delivering the drug dose to the proper body tissues.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Assessing the client's response to drug therapy.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Treatment of adverse reactions to drugs.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Consulting with the doctor about adjusting the prescribed regime.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Educating the client about proper use of drugs substances.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="principles-of-drug-administration">Principles of Drug Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-drug-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>For a Clinical officer to administer any medication, it is important to avoid errors to adhere to the principles of drug administration.</li>
<li>To provide safe administration of drugs a Clinical officer should practice the rights of drug administration... they are;-
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Right patient.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Right drug.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Right dose.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Right time.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Right route.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="principles-of-drug-administration-conti">Principles of Drug Administration Conti.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-drug-administration-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Five additional right are essential in Clinical practice; These includes;-
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> The right assessment e.g. patients ability to swallow, allergies, contraindication, new signs and symptoms that may indicate adverse effects of administration, heart, liver or kidney disorders etc.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> The right documentation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> The clients right to information of name, purpose, action and potential side effects.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> The right evaluation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> The clients right to refuse medication regardless of the consequences.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="principles-of-drug-administration-conti">Principles of Drug Administration Conti.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-drug-administration-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="right-client-or-patient">- Right client or patient:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#right-client-or-patient" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> You should make sure that the right client receives the right drug.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> You should only give drugs to the person for whom they are prescribed or recommended for.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> If the patient is wearing an identification bracelet, check the clients name on the identification bracelet with the name, hospital number on the medication card in your hand.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Alternatively if the patient is conscious and sane simply call out the patients name.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="principles-of-drug-administration-conti">Principles of Drug Administration Conti.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-drug-administration-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="right-drug">Right drug<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#right-drug" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>You must check and double check the package label of the drug.</li>
<li>The right drug label should be read at list three times;
--Before preparing or measuring the actual prescribed does.
-Before replacing the drug on the shelf just before administering the drug to the client.</li>
<li>You must prepare the medication you give yourself and DO NOT giver drugs prepared by someone else.
A Mentally alert person will notice a change in medication or mention problems that have arisen from the medication.</li>
</ul>
<p>Ensure that you take the following precaution when administering medicine.</p>
<ul>
<li>All doses are best prepared from the original container.</li>
<li>Medicines should not be prepared in the dark</li>
<li>You should caution clients about the use of non-labelled pillboxes</li>
<li>Do not mix supplies of several tablets or capsules in a single container</li>
<li>make sure you check medication label before removing from the shelf before pouring or measuring and when returning to the shelf.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="the-right-dose">The right dose:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-right-dose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>To obtain the right dose you must carefully measure the medicine. When pouring solid drugs such as capsules and tablets use proper technique to avoid contaminating the drugs. you should pour the medication in the container cap, and transfer the number of units required from the cap to the medication cup</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="right-route">Right route:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#right-route" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>The right route must be used for drug delivery.</li>
<li>Most drugs are given orally or by topical application .</li>
<li>Ensure the patient understands how the drug is to be taken.</li>
<li>sub lingual or chewable tablets should NOT BE swallowed whole.</li>
<li>Crush oral drugs if swallowing is difficult or if they are to be taken in liquid form.</li>
<li>Demonstrate to the patient the procedures for application of topical drugs.</li>
<li>Always check the doctors orders ,the cardex and the treatment sheet to verify the medication route.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="right-time">Right time:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#right-time" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>For example;</li>
</ul>
<p>The hourly interval between doses
The relationship of dose to the clients activity ,such as before or after meals, on rising or retiring, every 4 hours, hour, 12 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medication-in-children">Medication in children<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-in-children" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Take great care when administering drugs in children;</p>
<ul>
<li>There is high risk of errors due to changes in weight and age.</li>
<li>Most drugs have not been tested in children.</li>
<li>Many drugs are marked in dosage forms and concentration suitable for adults. Therefore this requires dilution, calculation preparation and administration of very small doses.</li>
<li>Children have limited sites for IV (intravenous)administration ,several drugs may be given through the same site.</li>
<li>This increases the need for small volumes of fluid and flushing between sites.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medication-errors">Medication errors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-errors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Wrong client
Wrong route
Wrong medication or IV fluids
Wrong dose or IV rate
Omission of dose
Incorrect discontinuation of treatment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-storage">Drug storage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-storage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>Many factors can change your medication including heat, .air , light, and moisture. This will infective or even harmful.</p>
</li>
<li>
<p>Drugs require careful storage and handling to maintain their safety and potency.</p>
</li>
<li>
<p>Every medication has its owner recommended storage condition from room temperature, refrigeration and freezing thus check the specific storage condition.</p>
</li>
<li>
<p>They must be kept in special spaces secured from access by unauthorized persons.</p>
</li>
<li>
<p>Storage areas should be kept clean, cool, and dry with no direct sun light.</p>
</li>
<li>
<p>Drugs should not be placed on the floor.</p>
</li>
<li>
<p>Sterile substances should be protected from contamination.</p>
</li>
<li>
<p>Drugs are best kept in their original containers. original containers protect their content.</p>
</li>
<li>
<p>Do not transfer sterile substances from container to container as it increases the probability of contamination. Protect the label from soiling to ensure it remains legible.</p>
</li>
<li>
<p>Drugs should only be labeled in pharmacy.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-drugs">Classification of drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Classification systems enable us to readily identify the similarities and differences among a large number of medications within or outside a classification.
Drugs can be classified according to;</p>
<ol>
<li>
<p>Body systems as follows;
-Respiratory system medications
-Cardiovascular system
-Nervous system
-GIT medications.</p>
</li>
<li>
<p>Their functions or usage e.g.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Antidepressant
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Diuretics
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Analgesics
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Antibiotics</p>
</li>
<li>
<p>Their chemical make up
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Estrogens
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Opioids</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antibiotics-agents">Antibiotics Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antibiotics-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Antibiotics are among the most commonly used and misused of all drugs.</li>
<li>The inevitable consequence of their widespread use has been the emergence of antibiotic-resistance pathogens.</li>
<li>There different groups of antibacterial agents based on molecular structure and members of each group have a comparable pharmacokinetic and pharmacodynamics.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-antibiotics">Classification of Antibiotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-antibiotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Beta- lactam antibiotics
tetracycline
Aminoglycoside
Macrolides
Quinolones
Azoles
Antimycobacterial
Sulphonemides
lincosamides
Unclassified antibiotics like chloramphenicol, spectinomycin and vancomycin</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="beta-lactam-antibiotics">Beta-lactam Antibiotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beta-lactam-antibiotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>All beta -lactam compounds ,so named because of their unique four membered lactam ring as a basic chemical structure.
They are sub divided into the Following;-</p>
<ul>
<li>Penicillins</li>
<li>Cephalosporins</li>
<li>Others like;-carbapenems and monobactams</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="penicillins">Penicillins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#penicillins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-penicillins">Classification of penicillins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-penicillins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Narrow spectrum e.g. benzyl penicillin(Xpen), phenoxy methyl penicillin, penethicillin etc.</li>
<li>Antistaphylococcal penicillin also called beta-lactamase resistant penicillin, or penicillinase resistant penicillin's e.g. nafcillin, cloxacillin, flucloxacillin, methicillin etc.</li>
<li>Broad spectrum penicillin e.g. ampicillin, amoxicillin, bacampicillin etc</li>
<li>Antipseudomonal (extended spectrum penicillin) e.g. carbecillin, carfecillin, ticarcillin, temocillin etc.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>All beta lactam anti biotics inhibit bacteria cell wall synthesis. this is by inactivating enzymes located in the bacteria cell membrane .</li>
<li>They are bactericidal agents acting against multiplying bacteria (diving cells) as resting bacteria do not make new cell walls.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-bacterial-resistance">Mechanism of bacterial resistance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-bacterial-resistance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>General mechanism of bacteria resistance to antibiotics including beta -lactams are;
Decreased penetration to the target cells
Alteration of the target site
Inactivation of the antibiotics by a bacterial enzyme e.g. beta lactamase.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Benzylpenicillin is destroyed by gastric acid hence it is parenterally administered.</li>
<li>Phenoxymethylpenicillin can be orally given.</li>
<li>Metabolism is in the liver.</li>
<li>Half life less than 2hours.</li>
<li>Poor lipid solubility hence they don't cross the BBB.</li>
<li>Distribution in body fluids and tissues with a few exception. they are polar hence extracellular concentrations exceed he intracellular.</li>
<li>Elimination in the kidneys by glomerular filtration and tubular secretion.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="benzyl-penicillin-g">Benzyl penicillin G<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#benzyl-penicillin-g" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*Penicillin G is gastric acid unstable is used where high plasma concentration era required.
*Maximum plasma concentration is reached after 15 minute of administration
*Half life 0.5 hours hence reasonably spaced doses have to be large to maintain a therapeutic concentration high doses can be maintained by use of probenecid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="indication-for-penicillin-g">Indication for penicillin G<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication-for-penicillin-g" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is generally active against gram positive and gram negative cocci, hence indicated for treatment of the following conditions;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Otitis media
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Gonococcus infection
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Throat infections
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Streptococcal endocarditis
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Meningococcal meningitis
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Pneumonia meningitis
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> actinomycosis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cloxacillin">Cloxacillin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cloxacillin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Half live is 30 minutes</li>
</ul>
<p>Indication for infections due to penicillinase (enzyme against penicillin) producing staphylococci especially skin infections and soft tissue infections e.g. cellulitis, otitis externa, impetigo</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dosage">Dosage;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Adults by oral 500 mg every 6 hours at least 30 minutes before meals because food decreases absorption.
IM 500mg every 4-6 hours.
IV injection or infusion 500 mg every 4-6 hours .
The dose may be increased in severe Conditions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ampicillin">Ampicillin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ampicillin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Is gastric stable, it is moderately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> absorbed orally as food interferes with absorption..
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> The drug is concentrated in the bile and it undergoes enteral hepatic recycling.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Excretion is through the kidneys <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>3</mn></mrow><annotation encoding="application/x-tex">1 / 3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/3</span></span></span></span></span> of the administered drug appears unchanged in urine.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Almost all staphylococcus aureus, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of E.coli, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of haemophilus influenza are now resistant.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clioxallin">Clioxallin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clioxallin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Urinary tract infections.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Sinusitis .
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Chronic bronchitis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Invasive salmonellosis gonorrhea
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Boils and septic wounds</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-effects">Side effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Diarrhea is quiet common, nausea
Macular rashes resembling measles/rubella - discontinue treatment</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dosage">Dosage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Adults oral 0.25 to 1 g 6 hourly at least 30 minutes before food.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Different dose are used in treating different condition.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Gonorrhea 2-3g is administered as a single dose with probenecid.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> UTI :500mg every 8 hours IM/IV/infusion.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Children under age 10 years give half the adult dose.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="amoxicillin">Amoxicillin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#amoxicillin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>This is a broad spectrum penicillin.</li>
<li>A derivative of ampicillin and differs by only one hydroxyl (OH) group.</li>
<li>Have similar anti bacteria spectrum as ampicillin.</li>
<li>when given orally absorption is better than ampicillin.</li>
<li>Absorption is not affected by food in the stomach.</li>
<li>Half life is 1 hour’</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indication">Indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> UTI, otitis media, sinusitis, chronic bronchitis, inversive salmonellosis and gonorrhea.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dosage">Dosage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Adult dose orally 250 mgs 8 hourly which can be doubled in severe infections.</li>
<li>Children up to 10 years of age get 125 mg 8 hourly this is doubled in severe infections.
*IM/IV adults 500 mg 8 hourly.
*IM/IV children get 50-100mg/kg daily in divided doses.</li>
</ul>
<p>Side effects
Diarrhea is less frequent with the use of amoxicillin than ampicillin</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="co-amoxiclav">Co- amoxiclav<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#co-amoxiclav" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Amoxicillin ( 250 mg or 500 mg )can be combined with clavulanic acid ( 125 mg ) to make co- amoxiclav.
Clavulanic acid itself has no significant anti bacteria activity but binds to beta-lactamase and there by competitively inhibits its activity hence protecting the penicillin. This potentiate the action of penicillin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indication">Indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Active against beta-lactamase producing bacteria that are resistant to amoxicillin which include; staphylococcus aureus, 50% of E-coli, 15% of H. influenzae strains and klebsiella spp,</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effect-of-penicillin-s">Adverse Effect of Penicillin's<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effect-of-penicillin-s" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*1gE -Mediated allergic reactions.</p>
<ul>
<li>serum sickness.
*Dermatological reactions e.g. eryema multiforme ,steven johsons syndrome and exfoliative dermatitis.</li>
<li>Neurologic reactions.</li>
<li>Gastrointestinal reactions.</li>
<li>Hepatobiliary reaction.</li>
<li>Renal reactions.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions">Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Instruct clients that penicillin V, amoxicillin, and amoxicillinclavulanate may be taken with meals. All others should be taken with a full glass of water 1 hours before meals or 2 hours after.</li>
<li>Instruct clients to report any signs of an allergic response such as skin rash, itching, and/or hives.</li>
<li>IM injection should be done cautiously to avoid injection into a nerve or an artery.</li>
<li>Advise clients to complete the entire course of therapy regardless of presence of absence of symptoms.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cephalosporins">Cephalosporins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cephalosporins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cephalosporins are the most frequently prescribed class of antibiotics.
They are structurally and pharmacologically related to the penicillins. they have a wider spectrum of activity than penicillins hence they are more expensive.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanisms-of-action">Mechanisms of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanisms-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> They are bactericidal, interfere with the bacterial cell wall synthesis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-cephalosporins">Classification of cephalosporins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-cephalosporins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> They are grouped in "generations" based on their spectrum of antimicrobial activity.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> The first cephalosporins were designated first generation while later, more extended generation cephalosporins.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Each newer generation of cephalosporins has a significantly greater gram negative antimicrobial properties than the preceding generation, in most cases with decreased activity against gram positive organism.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> The newer agents have a much longer half life resulting in the decreased of dosing frequency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="first-generation-cephalosporins">First Generation Cephalosporins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#first-generation-cephalosporins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These are generally active against gram positive bacteria. They have moderate activity against gram negative bacterial. Examples;Used for upper and lower respiratory tract infnxs.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cephalexin.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cephaloridine
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cephalothin
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cephapirin
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cefazolin
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cephradine
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cefadroxil.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="second-generation-cephalosporin">Second Generation Cephalosporin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#second-generation-cephalosporin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They have a greater gram-negative spectrum eg H.influenza n. gonorrhea, E.coli, shigella.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Also some gram-positive organism e.g. clostridium, staphylococcus, streptococcus and pneumococcus.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> they are more resistant to beta lactamase.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indications-of-cephalosporins">Indications of Cephalosporins;-<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications-of-cephalosporins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Upper and lower respiratory tract infection ie tonsolitis, pharyngitis etc
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Sinusitis
Acute bacterial Otitis media
Impetigo</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="third-generation-cephalosporins">Third generation cephalosporins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#third-generation-cephalosporins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They are especially better than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mtext>nd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">2^{\text {nd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">nd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation cephalosporin against gram negative bacteri
Uses;- Meningitis, lung infections, otitis media, peritonitis, bones and joint infections, UTI, Soft tisue infxns, some heart conditions which bacterial, gonorrhea and syphilis, neutrophenia and lyme dse.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Cefriaxone
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Cefperazone
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Cefotaxime
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Ceftazidine
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Cefodizime</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="71b12cea">Ceftriaxone (Rocephin) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> gen <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>T&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {T }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">T&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span><span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#71b12cea" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Half life 4hours hence requires to be administered Twice a daily.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indications">Indications;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Septicemia, Pneumonia, UTI, RTI, soft tissue infections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindication">Contraindication;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Penicillin sensitivity
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Administer with caution in renal impairment.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Do not administer to infants below 6 weeks.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Cephalosporin hypersensitivity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="fourth-generation-cephalosporin">Fourth generation cephalosporin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fourth-generation-cephalosporin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs has excellent activity on gram positive and gram negative bacteria such as methicillin susceptable staphylococci, penicillin restistant pneumococco and varidins group streptococci.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="examples-includes">Examples includes;-<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#examples-includes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Cefepime
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Cefditoren and cefpirome.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetic-of-cephalosporins">Pharmacokinetic of cephalosporins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetic-of-cephalosporins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Usually given parenterally, though few may be given orally e.g.
cephalexin
cephradine
cefadroxil</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="distribution-wide-distribution-because-of-lipid-solubility">Distribution- Wide distribution because of lipid solubility.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#distribution-wide-distribution-because-of-lipid-solubility" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Metabolism- in the liver with half life of 1-4 hours.
Excretion- excreted unchanged in urine especially tubular secretion.</p>
<ul>
<li>Dosage should be reduced for patients with renal impairment.</li>
<li>Active excretion in the kidneys can be blocked by probenecid.</li>
</ul>
<p>Additional Indication; Septicemia, Pneumonia, Meningitis, Biliary tract infection, Peritonitis, Urinary tract infection, sinusitis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="unwanted-effects-of-most-cephalosporins">Unwanted effects of most cephalosporins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#unwanted-effects-of-most-cephalosporins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypersensitivity is the most common
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of the patients sensitive to penicillin are sensitive to cephalosporin.
Hemorrhage due to interference with blood clotting factors.
Use of cephalosporin for more than two weeks causes thrombocytopenia, neutropenia, interstitial nephritis and abnormal liver function tests.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cephalosporin with alcohol- disulfiram like effects.
Patient should avoid alcohol when taking these class of drug.
Cephalosporin with high frusemide and torsemide are likely to cause nephrotoxicity.
Cephalosporin with aminoglycoside - nephrotoxicity.
Cephalosporin with oral anticoagulant like warfarin may cause bleed because both interfere with clotting factors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-of-cephalosporins-in-general">Precautions of Cephalosporins in general;-<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-of-cephalosporins-in-general" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Instruct clients to complete the prescribed course of therapy, even though symptoms may resolve before the full course of antimicrobial treatment is completed.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Advise clients to take oral cephalosporins with food.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Instruct clients to store oral cephalosporin suspensions in a refrigerator.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="tetracyclines">Tetracyclines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tetracyclines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>First isolated in 1948, isolated from Streptomyces fungi.</li>
</ul>
<p>Naturally occurring;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Tetracycline
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Chlortetracycline
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Oxytetracycline
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Demeclocycline</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="semi-synthetic">Semi-synthetic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#semi-synthetic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Doxycycline, lymecycline, meclocycline, methacyline, minocycline, rolitetracycline etc.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Tetracyclines are partially absorbed in the alimentary tract EXCEPT minocycline and doxycycline which have a good absorption.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Absorption is increased in absence of food
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> antacids and milk decrease absorption as they contain metals like magnesium, calcium, aluminum ,iron which chelate with them.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Distribution is narrow but they cross the placenta barrier.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Metabolism is in the liver
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Excretion in urine via glomerular filtration unchanged.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacodynamics">Pharmacodynamics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Tetracyclines are broad spectrum bacteriostatic.
They inhibit protein synthesis by binding to the 30s sub unit of the bacterial ribosomes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indication">Indication;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Psittacosis, pneumonia, brucellosis, shigellosis, rickettsia diseases e.g. Q fever, typhus, cholera, borrelia ( lame disease, relapsing fever)acne ,amoebic dysentery, spirochetes, protozoa, bacillary dysentery and chlamydia infections</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="aminoglycosides">Aminoglycosides<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aminoglycosides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="examples">Examples;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#examples" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Gentamycin, kanamycin, amikacin, tobramycin, streptomycin, neomycin,
They are always used in combination of beta lactam antibiotic because of their synergism effect.
Pharmacokinetics; they are water soluble hence hey not absorbed through the gut .
They are given IM/IV route
Distribution; narrowly distributed hence do not cross the blood brain barrier.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacodynamics-mechanism-of-action">Pharmacodynamics/Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics-mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>They are bactericidal- they act by binding to the 30s ribosomal sub unit and they inhibit bacterial protein synthesis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-interaction">Drug interaction;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Synergic effect when give with beta lactam antibiotic .
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Bone marrow depression when give with bone marrow depressing agents.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Muscle weakness or paralysis when given with neural muscular blocking agent.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Ototoxicity when given with ototoxic agent.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects-unwanted-effects">Side effects /unwanted effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects-unwanted-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Have serious un wanted effects and that are dose dependent</li>
</ul>
<p>These are; nausea, vomiting, diarrhea, lethargy, hypersensitivity and headache.
Others are ,nephrotoxicity, ,ototoxicity, bone marrow depression, neuromuscular blockade, palpitation, numbness, tingling sensation, depression and disorientation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Patients with hearing deficit because thy damage the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>8</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">8^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> cranial nerve(vestibular cochlear/auditory nerve)</li>
<li>Myasthenia gravis since they cause neural muscular blockade.</li>
<li>Patients with severe renal disease as they are nephrotoxic</li>
<li>Hypersensitivity</li>
<li>Neonates, geriantrics, infant, botulism and patients with packinsonism</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="gentamycin">Gentamycin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gentamycin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> This is the most active aminoglycoside.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Half life 2-3 hours and reaches peak plasma concentration within 30 minute.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="route-of-administration-im-iv">Route of administration;- IM/IV.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#route-of-administration-im-iv" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indication">- Indication;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Gram negative and gram positive; septicemia, meningitis, endocarditis, UTI, neonatal sepsis and acute pyelonephritis among other infections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications">Contraindications;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Like other aminoglycoside.
Children below 2wks <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">7.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">7.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> body weight every 12 hrly. (od)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="gentamycin-cont">Gentamycin Cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gentamycin-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Aminoglycoside can replace penicillin in penicillin sensitive patients</li>
<li>Gentamycin combine with penicillin have a synergic antibiotic effect expands the spectrum of antibiotics activity and prevent emergence of resistance..</li>
<li>Neomycin and kanamycin can be used for hepatic coma to reduce normal flora and therefore ammonia gas formation.</li>
<li>Amikacin has broadest antibacterial spectrum because it is stable to 8 of the 9 classified aminoglycoside inactivating enzymes whereas gentamycin is inactivated by five of them.</li>
<li>Amikacin is indicated for serious gram negative infections resistant to gentamycin.</li>
<li>Neomycin and framycetin are too toxic for systemic use hence used topically for treatment of aer, nose and skin infections,</li>
</ul>
<p>These are broad spectrum antibiotic though some like nalidixic acid and cinoxacin have a narrow antibacterial spectrum.
Most popular quinolones are fluoroquinolones Which include;-</p>
<ul>
<li>Norfloxacin</li>
<li>Ciprofloxacin</li>
<li>Moxifloxacoin</li>
<li>Ofloxacin</li>
<li>Levofloxacin</li>
<li>Acrofloxacin
*Pefloxacin</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacodynamics-mode-of-action">Pharmacodynamics/Mode of Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics-mode-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>They are act by inhibiting bacterial DNA gyrase the enzyme that maintains the Helical twist/structure of the DNA.</li>
<li>They are bactericidal but some are bacteriostatic.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Quinolones are absorbed in the gut though aluminum and magnesium antacid interfere with the absorption.
Distribution wide distribution such that they cross the placenta and are distributed in breast milk.
They are concentrated in the lungs, kidneys, prostate, and phagocytes.
They don't cross the BBB except ofloxacin and pefloxacin.
Metabolism they under go hepatic metabolism with a variable half life
Norfloxacin and ciprofloxacin half life of 2-3 hours, 5 hour ofloxacin, perfloxacin10 hour.
Excretion/elimination via renal and biliary.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects-of-quinolones">Adverse effects of Quinolones<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects-of-quinolones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>GIT effects like nausea, vomiting, and diarrhea
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> CNS effects like dizziness, headache, confusion and convulsions.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Allergic reactions in form of skin rashes,
They are reported to cause arthropathy in immature animals hence not recommended for children and adolescence unless the benefit out ways the risk.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Photosensitivity
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Bone marrow suppression.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-of-quinolones">Contraindications of Quinolones<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-of-quinolones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> History of epilepsy or seizures.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Glucose-7-phosphatedehydrogenase deficiency.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Myasthenia gravis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Pregnancy and breast feeding.
Indications; quinolones are basically indicated for UTI ciprofloxacin has a broader spectrum of antibacterial activity.
These are often caused by gram negative organisms like E.coli, proteus spp. Therefore infections like complicated UTI, inversive otitis externa, salmonella typhi infection, gonorrhea, bacteria prostatitis and cervicitis.
They are also indicated for anthrax which has been used as a biological warfare.
So the soldiers can take quinolones just before they go to war just in case they are at risk of exposure to anthrax.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These antibiotics are enzyme (cytochrome p-450) inhibitor hence interact with other drugs at metabolism e.g. theophylline, warfarin, and caffeine.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> NSAIDs and quinolones causes an increase in the risk of convulsion.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> NSAIDs tends to potentiate the effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ciprofloxacin">Ciprofloxacin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ciprofloxacin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Half life is 3hrs</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indications">Indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is mostly effective against gram negative bacteria e.g. salmonella, shigella, Campylobacter, pseudomonas, enterobacteria,chlamydia and some mycobacteria, UTIs and genital urinary tract infections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dosage">Dosage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Oral 250-750mg bd depending with what is being treated.</li>
<li>IV infusion (adult) 500 mg bd daily.....</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cationic compounds (aluminum-magnesium antacids, iron salts, sucralfate, milk and dairy products) decrease absorption of ciprofloxacin;
Administer cationic compounds 6 hrs . before or 2 hrs after ciprofloxacin
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Plasma levels of theophylline can be the increased with concurrent use of ciprofloxacin;
Monitor levels and adjust dosage accordingly.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Plasma levels of warfarin can be increased with concurrent use of ciprofloxacin;
Monitor prothrombin time and INR, and adjust the dosage of warfarin accordingly.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="quinolones">Quinolones<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quinolones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ciprofloxacin is available in oral and intravenous forms.
Decrease doses of ciprofloxacin in clients with renal dysfunction.
Intravenous ciprofloxacin should be administered slowly over 60 min.
For inhalation anthrax infection, ciprofloxacin is administered every 12 hrs for 60 days.
Instruct clients to complete the prescribed course of antimicrobial therapy, even though symptoms may resolve before the full course is completed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="macrolides">MACROLIDES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#macrolides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These broad spectrum antimicrobials including;
Erythromycin
Azithromycin( brand name is Zithromax)
Spiramycin
Clarithromycin (Klacid) en Telithromycin (ketec)
Pharmacodynamics; they inhibit protein synthesis by irreversibly binding to ribosomal 50s sub unit of the sensitive microorganism hence they are bacteriostatic.
But sometimes can be bactericidal if the dose is high.
Example azithromycin is bactericidal against streptococcus pyogenes, streptococcus pneumonia and hemophilus influenza</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They can be administered orally though erythromycin is unstable in acidic environment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="distribution">Distribution;-<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#distribution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Is good except that the drugs do not cross the BBB</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="metabolism">Metabolism;-<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tiz in the liver and have variable half life.
e.g. clarithromycin has 4.5 hours, azithromycin less than 3.5 hours and erythromycin has 1.4 to 2 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses-indication">Therapeutic Uses/indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses-indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Used to treat infections in clients with a penicillin allergy, such as for prophylaxis against rheumatic fever and bacterial endocarditis.
Used for clients with Legionnaires' disease, whooping cough (pertussis), and acute diphtheria (eliminates the carrier state of diphtheria) .
Used for chlamydia infections (urethritis and cervicitis; pneumonia caused by Mycoplasma pneumoniae; respiratory tract infections caused by Streptococcus pneumoniae and Neisseria gonorrhea.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="gastrointestinal-discomfort">Gastrointestinal discomfort<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gastrointestinal-discomfort" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>(nausea, vomiting, epigastric pain) Administer erythromycin with meals.</li>
<li>Observe for GI symptoms and notify the provider.</li>
</ul>
<p>Hepatotoxicity (abdominal pain, lethargy, jaundice) . Instruct clients to notify the provider because the medication should be discontinued.
Prolonged QT interval causing dysrhythmias and possible sudden cardiac death</p>
<ul>
<li>Use in clients with prolonged QT intervals is not recommended.</li>
<li>Avoid concurrent use with medications that affect hepatic drug metabolizing enzymes.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>pre-existing liver disease</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="erythromycin">Erythromycin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#erythromycin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Erythromycin is the most commonly used macrolide.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetic">Pharmacokinetic;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Erythromycin is inactivated by gastric enzymes hence it is administered as protected enteric coated tablets.
It is hydrolyzed in the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> phase metabolism to release the active erythromycin.
It is dissolved and absorbed in the small intestines where it undergoes enetro hepatic recirculation.</p>
<ul>
<li>Distribution;- is very good as it is well distributed in the spleen, liver, placenta, breast milk and inflamed meninges.</li>
<li>Excretion;- 90% in feaces and small amounts in urine.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dosage-and-route-of-administration">Dosage and Route of Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosage-and-route-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Orally adults and children above 8years 250-500mg 6 hourly.</li>
<li>Maximum dose is 4 g in severe infections.</li>
<li>Children up to 2years 125mg 6hourly.</li>
<li>IV infusion 25-50/kg body wt. daily as continuous infusion.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Macrolides are enzyme inhibitor and they interfere with the metabolism of drugs like warfarin, carbamazepine, theophylline, corticosteroids, oral contraceptives, digoxin, and cyloserine and sodium valproate</p>
<ul>
<li>Food tends to decrease the absorption of macrolide, hence should be given one hour before food or 2-3 hours after meals.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="azithromycin">Azithromycin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#azithromycin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Azithromycin is derived from erythromycin by adding a methylated nitrogen into the lactogen ring.</p>
<ul>
<li>Its specrum of activity and clinical uses are virtually identical to those of clarithromycin.</li>
<li>Azithromycin is active against mycobacteria avium complex and toxoplasma gondii.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sulphonamide">SULPHONAMIDE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sulphonamide" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Are a group of man-made medicines that contain the sulfonamide chemical group. They are called sulfa drugs.</p>
<ul>
<li>Examples</li>
<li>Trimethoprim and Sulfamethoxazole</li>
<li>Sulphadiazine,</li>
<li>Sulfisoxazole,</li>
<li>Sulphadimidine,</li>
<li>Sulfasazine,</li>
<li>Sulfametopyrazine,</li>
<li>Sulphaloxate</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics-of-sulfa-drugs">Pharmacokinetics of sulfa drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics-of-sulfa-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They inhibition of other metabolic processess. They interfere with folic acid synthesis by preventing addition of para-aminobenzoic acid (PABA) int the folic acid molecule through competing for the enzyme dihydropteroate synthesis
they have good absorption except a few of them sulpadiazine and which are poorly absorbed in the gut.
Distribution widely distributed in body tissues and fluid including crossing the BBB.
They are metabolized in the liver withhalf life of 10 hours.
Majority are excreted in urine hence dose should be reduced in renal impairment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-and-adverse-effects">Side and adverse effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-and-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hypersensitivity-including-stevens-johnson-syndrome">- Hypersensitivity including Stevens-Johnson syndrome<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypersensitivity-including-stevens-johnson-syndrome" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Do not administer TMP-SMZ to clients with allergies to: Sulfonamides (sulfa), Thiazide diuretics [hydrochlorothiazide (HCTZ)] , Sulfonylurea-type oral hypoglycemics [tolbutamide (Orinase)], Loop diuretics [furosemide (Lasix)]</li>
<li>Stop TMP-SMZ at the first indication of hypersensitivity, such as rash.</li>
<li>Blood dyscrasias (hemolytic anemia, agranulocytosis, aplastic anemia) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span>
-Draw the client's baseline and periodic CBC levels to detect any hematologic disorders.</li>
<li>Observe for any bleeding episodes, sore throat, or pallor. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> If the above symptoms occur, instruct clients to notify the provider.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="crystalluria">- Crystalluria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#crystalluria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Maintain adequate oral fluid intake.</li>
<li>Instruct client to drink 2 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">3 \mathrm{~L} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span><span class="mord">/</span></span></span></span></span> day.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="kernicterus-jaundice-increased-bilirubin-levels">- Kernicterus (jaundice, increased bilirubin levels)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#kernicterus-jaundice-increased-bilirubin-levels" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Avoid administering TMP-SMZ to women who are pregnant near term, breastfeeding mothers, and infants younger than 2 months.</li>
<li>Monitor the client's liver function. Photosensitivity</li>
<li>Avoid prolonged exposure to sunlight, use sunscreen, and wear appropriate</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cotrimoxazole-serpin">Cotrimoxazole (serpin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cotrimoxazole-serpin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This has replaced use of sulphonamide due to resistance.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dosage-for-children">Dosage for children<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosage-for-children" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It's a bd drug</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indications">Indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Pneumocystic carinii pneumonia</li>
<li>Toxoplasmosis</li>
<li>UTI</li>
<li>Chronic bronchitis</li>
<li>Others sulphonamides are used for topical application for prophylaxis of burns, leg ulcers, pressure sores because of their wide anti bacteria spectrum</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Sulfonamides can increase the effects of warfarin (Coumadin), phenytoin (Dilantin), sulfonylurea oral hypoglycemic, and tolbutamide (Orinase) by inhibiting hepatic metabolism.</li>
<li>dosages of these medications may be required during therapy.</li>
</ul>
<p>Precautions; Instruct patient not to take the drugs on an empty stomach plus to use a full glass of water.</p>
<ul>
<li>Instruct clients to complete the prescribed course of antimicrobial therapy, even though symptoms may resolve before the full course is completed.
Depending on therapeutic intent, effectiveness may be evidenced by:
Improvement of infection symptoms, such as improvement of urinary tract symptoms (decreased frequency, burning, and pain during urination) and negative urine cultures.......</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="azoles">AZOLES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#azoles" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Azoles are synthetic antifungals with broad-spectrum fungistatic activity against yeasts and fungi, including candidal species. By blocking fungal cytochrome P450-dependent enzymes, azoles disrupt the synthesis of ergosterol, which is the principal sterol in fungal cell membranes.</li>
<li>Are 5 membered heterocyclic compounds containing a nitrogen atom and at least one other non carbon atom as part of the ring.</li>
<li>Classified into two groups: those with two nitrogens in the azole ring (the imidazoles; examples include clotrimazole, econazole, ketoconazole, miconazole, and tioconazole) and those with three nitrogens in the azole ring (the triazoles; examples include fluconazole, itraconazole, posaconazole.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="azoles-cont">AZOLES cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#azoles-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Names of azoles maintain the prefix upon reduction (e.g., pyrazoline, pyrazolidine). The numbering of ring atoms in azoles starts with the heteroatom that is not part of a double bond, and then proceeds towards the other heteroatom.
Imidazole and other five-membered aromatic heterocyclic systems with two nitrogens are extremely common in nature and form the core of many biomolecules, such as histidine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="azoles-cont">AZOLES cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#azoles-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="compound-classes">Compound classes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#compound-classes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Nitrogen only
Imidazole
Pyrazole
1,2,3Triazole
1,2,4Triazole
Tetrazole
Pentazole</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="azoles-cont">AZOLES cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#azoles-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>N,O compounds</li>
<li>Oxazole</li>
<li>Isoxazole</li>
<li>1,2,3-oxadiazole (unstable)</li>
<li>Oxadiazole (1,2,4-Oxadiazole)</li>
<li>Furazan (1,2,5-oxadiazole)</li>
<li>1,3,4-oxadiazole</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="azoles-cont">AZOLES cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#azoles-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="n-s-compounds">N,S compounds<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#n-s-compounds" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Thiazole</li>
<li>Isothiazole</li>
<li>Thiadiazole
(1,2,3-Thiadiazole)</li>
<li>1,2,4-thiadiazole</li>
<li>1,2,5-thiadiazole</li>
<li>1,3,4-thiadiazole</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="azoles-mechanism-of-action">Azoles mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#azoles-mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>The generally accepted mode of action of azoles is the inhibition of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mi>α</mi></mrow><annotation encoding="application/x-tex">14 \alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">14</span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-lanosterol demethylase, a key enzyme in ergosterol biosynthesis, resulting in depletion of ergosterol and accumulation of toxic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mi>α</mi><mo>−</mo></mrow><annotation encoding="application/x-tex">14 \alpha-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">14</span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="mord">−</span></span></span></span></span> methylated sterols in membranes of susceptible yeast species.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classes-of-antifungal-drugs">Classes of antifungal drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classes-of-antifungal-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th style="text-align: left;">Class</th><th style="text-align: left;">Mechanism of action Drugs</th></tr></thead><tbody><tr><td style="text-align: left;"></td><td style="text-align: left;">What are the classes of antifungal drugs?</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">Tables</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="azole">Azole<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#azole" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Echinocandin
Impairs
impairs <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mn>1</mn><mo separator="true">,</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">\beta 1,3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">3</span></span></span></span></span>
glucan synthesis
Caspofungin</p>
<p>Nucleoside
Impairs pyrimidine metabolism</p>
<p>Flucytosine</p>
<p>.</p>
<p>.</p>
<p>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="azoles">AZOLES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#azoles" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Are 5 membered heterocyclic compounds containing a nitrogen atom and at least one other non carbon atom as part of the ring.</li>
<li>This includes several classes of drugs e.g. metronidazole and tinidazole which have both anti bacteria and anti protozoal activity.</li>
<li>Others are fluconazole, itraconazole econazole, ketoconazole, and miconazole which are anti fungal drugs .( to be covered under anti fungal drugs)</li>
<li>others are mebendazole, thiabendazole, which are anti helminths (to be covered under ant-helminths).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="metronidazole">Metronidazole<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#metronidazole" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> It is very effective against anaerobic bacterial and protozoa.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacodynamics-moa">Pharmacodynamics/MOA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics-moa" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> metronidazole is converted into an active form and bind to the bacterial DNA and prevents nucleic acid formation which consequently interferes with bacterial replication hence its bacteriostatic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetics">Pharmacokinetics;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>well absorbed after oral and rectal administration
Distribution;- is wide.
Metabolism;- is in the liver.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Excretion;- in urine partly unchanged and partly as metabolite.
Half life is 8 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="indications">Indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> used for treatment of sepsis caused by orgasms like Bacteroides
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> and anaerobic cocci.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Intra-abdominal infections
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Septicemia, wounds, pelvic infection
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Osteomyelitis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> pelvic infections
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Infections of the brain and lungs.</p>
<p>Indications cont...
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Used in prevention of post operative infection especially after bowel, antibiotic related colitis, eg pseudomembranous colitis , amoebiasis EH
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> other indications include giardiasis, acute ulcers, gingivitis, and dental infections. and anaerobic vaginosis
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Treatment of protozoal infections (intestinal amoebiasis, giardiasis, trichomoniasis) and obligate anaerobic bacteria (Bacteroides fragilis, antibiotic-induced Clostridium difficile, Gardnerella vaginalis)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Treatment of H. pylori in clients who have peptic ulcer disease in combination with tetracycline and bismuth salicylate.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dosage-and-route-of-administration">Dosage and route of administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosage-and-route-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Established anaerobe are usually treated for 7 days.
The dose per oral is then 4 oomgs 8 hourly for 7 days.
By infusion 500 mg 8 hourly.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="for-surgical-prophylaxis">For surgical prophylaxis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#for-surgical-prophylaxis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Per oral 400 mg 8 hourly started 24 hours before surgery then continued postoperatively by IV infusion for 5-7days.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects">Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Gastrointestinal discomfort (nausea, vomiting, dry mouth, and metallic taste) Advise clients to observe for symptoms and to notify the provider.
Dark urine Advise clients that this is a harmless effect of metronidazole.
CNS symptoms (numbness of extremities, ataxia, and seizures)
Advise clients to notify the provider if symptoms occur.
Stop metronidazole.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Use cautiously in clients with renal dysfunction to prevent accumulation of toxic levels with prolonged use.</li>
<li>Avoid use during the first trimester of pregnancy and use with caution during the rest of pregnancy because metronidazole can pass through the placenta.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="interactions">Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Alcohol causes a disulfiram-like reaction/ Advise clients to avoid alcohol consumption.</li>
<li>Metronidazole inhibits inactivation of warfarin.</li>
<li>Monitor prothrombin time and INR, and adjust warfarin dosage accordingly.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions">Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Administer by oral or IV route.</li>
<li>Instruct clients to complete the prescribed course of antimicrobial therapy, even though symptoms may resolve before the full course is completed.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nursing-evaluation-of-medication-effectiveness">Nursing Evaluation of Medication Effectiveness<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nursing-evaluation-of-medication-effectiveness" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Depending on therapeutic intent, effectiveness may be evidenced by: Improvement of symptoms (resolution of bloody mucoid diarrhea, formed stools, negative stool results for ameba and Giardia, , decrease or absence of watery vaginal/ urethral discharge, negative blood cultures for anaerobic organisms in the CNS, blood, bones and joints, and soft tissues).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chloramphenicol">Chloramphenicol<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chloramphenicol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is soluble in water and poorly soluble in alcohol
Chloramphenicol succinate which is used for parenteral administration is highly water soluble.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>The usual dosage of chloramphenicol is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg} / \mathrm{kg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span>.</li>
<li>After oral administration crystalline chloramphenicol is rapidly and completely absorbed.</li>
<li>A 1g oral dose produces blood levels between 10and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{mcg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span></li>
<li>Chloramphenicol palmitate is a pro drug that is hydrolyzed in the intestine to yield free chloramphenicol.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacodynamic">Pharmacodynamic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>chloramphenicol potent inhibitor of microbial protein synthesis.
It binds to the 50s sub unit of the bacteria ribosome
It is bacteriostatic, broad spectrum against both aerobic and anaerobic gram positive and gram negative bacterial.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="indications">Indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>It is rarely used due to it potential toxicity and bacterial resistance.</li>
<li>Used to treat; serious rickettsia infections such as typhus and rocky mountain spotted fever.</li>
<li>Alternative for beta lactam antibiotics for treatment of meningococcal meningitis and pneumococcal meningitis</li>
<li>Topical eye infections.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>GIT disturbance nausea, vomiting and diarrhea.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> This rare in children.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Oral and vaginal candidiasis may occur due to alteration of the normal flora.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="born-marrow-disturbance">Born marrow disturbance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#born-marrow-disturbance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Suppression of the born marrow
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Aplastic anemia it is irreversible and fatal</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="toxicity-for-new-born-infants">Toxicity for new born infants:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#toxicity-for-new-born-infants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> New born infants lack glucuronic acid for the conjugation and detoxification of chloramphenicol.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Therefore drugs may accumulate resulting in gray baby syndrome with vomiting flaccidity, hypothermia, gray colour, shock and collapse</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-fungal-drugs">ANTI-FUNGAL DRUGS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-fungal-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Fungi are saprophytic organism as they lack chlorophyll which is present in plants.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Many fungi are commensals in the bodies of healthy people but pose a problem when immune system is compromised.</p>
<p>Fungal infections has increased due to the following reasons
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Increase use of broad spectrum antibiotics which decrease non pathogenic bacterial that compete with the fungi.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Increases number of people with immunosuppression, use of cancer chemotherapy, and immunosuppressants, diabetes mellitus or have burns.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Inversive procedures may introduce fungi into systemic circulation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Antifungals are the treatment of choice for systemic fungal infection (Candidiasis, Aspergillosis, Cryptococcosis, Mucormycosis) and non opportunistic mycoses, (Blastomycosis, Histoplasmosis, Coccidioidomycosis)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="resistant-is-usually-due">Resistant is usually due;-<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#resistant-is-usually-due" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Decrease in membrane ergosterol content
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Change in membrane structure</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-anti-fungal-drugs">Classification of anti fungal drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-anti-fungal-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Topical anti-fungal
Polyenes anti-fungal agents e.g. nystatin
Benzoic acid</li>
<li>Systemic anti fungal
Polyenes anti-fungal agents e.g. amphotericin B
Fluorinated pyramids e.g. only flu cytosine
Azoles ;imidazole and triazoles
-Imidazole's include clotrimazole and econazole, sulconazole, fenticonazole, ketoconazole, and miconazole
-triazole include fluconazole, itraconazole and voriconazoles among others</li>
<li>Miscellaneous; terbinafine and Griseofulvin</li>
</ol>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Polyenes anti-fungal agents; nystatin and amphotericin B are the only ones in clinical use.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> MOA; they act by binding to the ergostel in fungal cell walls forming pores or channels which increase permeability and allow leakage of fungal cellular molecules e.g. potassium and magnesium</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Antifungals are the treatment of choice for systemic fungal infection (Candidiasis, Aspergillosis, Cryptococcosis, Mucormycosis) and nonopportunistic mycoses, (Blastomycosis, Histoplasmosis, Coccidioidomycosis).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Some antifungals treat superficial fungal infections:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> dermatophytic infections (tinea Pedis [ringworm of the foot], tinea cruris [ringworm of the groin]); candida infections of the skin and mucous membranes; and fungal infections of the nails (Onychomycosis).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="amphotericin-b">Amphotericin B<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#amphotericin-b" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Amphotericin B has been available for use since 1950s</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="moa-pharmacodynamics">MOA/PHARMACODYNAMICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#moa-pharmacodynamics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Amphotericin B deoxycholate is an antifungal agent that acts on fungal cell membranes to cause cell death.</li>
<li>Depending on concentration, these agents can be fungi static (slows growth on the fungus) or fungicidal (destroys the fungus).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetics">PHARMACOKINETICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>administered intravenously</li>
<li>wide distribution though poor penetration to the CNS</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> bound to plasma, half life of 24 and 15 days</li>
<li>excretion predominantly via the biliary route(slow excretion over a period of days)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Antifungals are the treatment of choice for systemic fungal infection (Candidiasis, Aspergillosis, Cryptococcosis, Mucormycosis) and nonopportunistic mycoses, (Blastomycosis, Histoplasmosis, Coccidioidomycosis).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Infusion reactions (fever, chills, rigors, and headache) 1 to 3 hr . after initiation</p>
<ul>
<li>Pretreat with diphenhydramine (Benadryl) and acetaminophen.</li>
<li>Meperidine (Demerol), Dantrolene, or hydrocortisone may be given for rigors.</li>
</ul>
<p>Thrombophlebitis Observe infusion sites for signs of erythema, swelling, and pain.</p>
<ul>
<li>Rotate injection sites.</li>
<li>Administer in a large vein and administer heparin before infusing amphotericin B</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nephrotoxicity">Nephrotoxicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nephrotoxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Obtain baseline kidney function (BUN and creatinine) and do weekly kidney function test, Monitor I&amp;O.</li>
<li>Infuse 1 L of saline on the day of amphotericin B infusion.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hypokalemia">Hypokalemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypokalemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Monitor electrolyte levels, especially potassium.</li>
<li>Administer potassium supplements accordingly.</li>
</ul>
<p>Bone marrow suppression <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> Obtain baseline CBC and hematocrit, and monitor weekly.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ketoconazole">Ketoconazole<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ketoconazole" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hepatotoxicity (anorexia, nausea, vomiting, jaundice, dark urine, and clay-colored stools)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Obtain baseline liver function studies and monitor liver function monthly.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> If symptoms occur, notify provider and discontinue medication.
Effects on sex hormones:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> In males, gynecomastia (enlargement of breast), Impotence, erectile dysfunction
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> In females, irregular menstrual flow
Advise clients to observe for these symptoms and to notify the health provider.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Antifungals are contraindicated in clients with renal dysfunction because of the risk for nephrotoxicity.
Interactions Medication/Food Interactions Nursing Interventions/Client Education</li>
<li>Aminoglycosides (gentamicin, streptomycin, cyclosporine) have additive nephrotoxic risk when used concurrently with antifungal medications.
Avoid use of these antimicrobials when clients are taking amphotericin B due to additive nephrotoxicity risk.</li>
<li>Antifungal effects of Flucytosine (Ancobon) are potentiated with concurrent use of amphotericin B.
Potentiating the effects of flucytosine allows for a reduction in amphotericin B dosages.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nursing-administration">Nursing Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nursing-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Amphotericin B is highly toxic and should be reserved for severe lifethreatening fungal infections</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="systemic-infection-for-mucocutaneous-infections">Systemic infection for mucocutaneous infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#systemic-infection-for-mucocutaneous-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="griseofulvin">Griseofulvin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#griseofulvin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Griseofulvin is a very insoluble fungistatic drug derived from a species of penicillium.</li>
<li>It is only used in the systemic treatment of dermatophytosis.</li>
<li>It is administered in a microcrystalline at a dose of 1 g per day.</li>
<li>Absorption is improved when it is given with fatty foods.</li>
<li>Nail infections may require therapy for months to allow regrowth of the new protected nail and is often followed by relapse.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="topical-anti-fungal">Topical anti fungal<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#topical-anti-fungal" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nystatin">Nystatin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nystatin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Nystatin is a polyene macrolide much like amphotericin B.
it is too toxic for parenteral administration and is only used topically
nystatin is currently available in creams, ointments, suppositories and other forms for application to skin and mucous membrane.
nystatin is active against most candida species and is most commonly used for suppression of local candida infections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-mycobacterial-agents-anti-tuberculosis">Anti mycobacterial agents (anti-tuberculosis)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-mycobacterial-agents-anti-tuberculosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The main mycobacterial infection are the tuberculosis and leprosy. The treatment of tuberculosis assumes the principle of combination therapy for two main reasons,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> To prevent emergency of resistance (tubercle bacilli develops resistant very fast when monotherapy is used).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> To reduce the rate of spread by reducing bacterial population rapidly.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> For this reason the available tablets contain multiple drugs in a fixed dose combination (FDC).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-tb-conti">Anti-TB conti'<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-tb-conti" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Anti TB are divided into two first line and second line
I. First line; this is not a universal principle but depend on local scientific evidence.
The drugs include isoniazid, ethambutol, pyrazinamide and streptomycin.
ii Second line drugs include capreomycin, cycloserine, clarithromycin and ciprofloxacin</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-tb-cont">Anti TB cont.'<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-tb-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>First initial phase: takes two months and three drugs are used concomitantly.</li>
<li>These includes Isoniazid (H), Rifampicin (R) Pyrazinamide (Z) plus (Ethambutol or streptomycin) if resistant organism are suspected. This combination reduces bacterial population rapidly.</li>
<li>Continuation phase takes four months and two drugs are used these are isoniazid and rifampicin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="isoniazid">ISONIAZID<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#isoniazid" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>This medication is highly specific for mycobacteria. Isoniazid inhibits growth of mycobacteria by preventing synthesis of mycolic acid in the cell wall.</li>
<li>Therapeutic Uses; Indicated for active and latent tuberculosis</li>
<li>Latent: INH only -6 to 9 months</li>
<li>Active: Multiple medication therapy including INH, for a minimum of 6 months</li>
<li>The initial phase (induction phase); focuses on eradicating the active tubercle bacilli, which will result in non infectious sputum.</li>
<li>The second phase (continuation phase) works toward eliminating any other pathogens in the body.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="isoniazid-cont">Isoniazid cont.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#isoniazid-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Length of treatment varies and may be as short as 6 months for medication-sensitive tuberculosis ( 2 months for the initial phase and 4 months for the continuation phase) or as long as 24 months for medication-resistant infections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects">Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic skin eruptions are the commonest side effects</li>
<li>Others are fever, GIT disturbance</li>
<li>Peripheral neuropathy (tingling, numbness, burning, and pain resulting from deficiency of pyridoxine, vitamin B6 ).
Instruct clients to observe for symptoms and to notify the provider if symptoms occur.
Administer 50 to 200 mg of vitamin B6 daily.</li>
<li>Hepatotoxicity (anorexia, malaise, fatigue, nausea, and yellowish discoloration of skin and eyes).
Instruct clients to avoid consumption of alcohol.
Medication may need to be discontinued if liver function test results are elevated.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>INH is contraindicated for clients with liver disease.
INH inhibits metabolism of phenytoin, leading to buildup of medication and toxicity.
Ataxia and incoordination may indicate toxicity.
Monitor the client's levels of phenytoin.
Dosage of phenytoin may need to be adjusted based on phenytoin levels.
Concurrent use of alcohol, rifampin, and pyrazinamide increases the risk for hepatotoxicity.
Instruct clients to avoid alcohol consumption.
Monitor liver function.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="700415af">Interactions cont. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>P&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {P }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8413em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8413em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">P&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span><span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#700415af" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Induce liver enzymes,hence affect the metabolism of warfarin, glucocorticoids, narcotics, oral anti diabetes, dapsone and estrogens and oral contraceptives.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Advice clients on oral contraceptives to change method of family planning or use a back up method.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="rifampicin">Rifampicin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rifampicin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> This is one of the most active anti TB .it is also active against gram positive and gram negative bacteria.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Mechanism of action: Rifampin is bactericidal as a result of inhibition of protein synthesis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Indications:
Rifampin is a broad-spectrum antibiotic effective for gram-positive and gram-negative bacteria,
M. tuberculosis, and M. Leprae.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Given orally
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Has a wide distribution
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> It causes orange tinge coloration to saliva ,sputum, tears, sweat and urine.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> It is excreted in urine and under goes enterohepatic recycling.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Metabolism is in the liver and the metabolites has anti bacterial activity but poorly absorbed from the gut.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Half life is one to five hours but reduces during treatment since it induces microsomal enzymes, hence its own metabolism.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/adverse effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-discoloration-of-body-fluids">i) Discoloration of body fluids.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-discoloration-of-body-fluids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Inform clients of expected orange color of urine, saliva, sweat, and tears.
ii)Hepatotoxicity (jaundice, anorexia, and fatigue)</li>
<li>Monitor the client's liver function.</li>
<li>Inform clients regarding symptoms of anorexia, fatigue, and malaise, and instruct them to notify the provider if symptoms occur.</li>
<li>Avoid alcohol.
iii) Mild gastrointestinal discomfort associated (anorexia, nausea, and abdominal discomfort.</li>
<li>Abdominal discomfort is mild and usually does not require intervention</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Use cautiously in clients with liver dysfunction.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="interactions">Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Rifampin accelerates metabolism of warfarin (Coumadin), oral contraceptives, protease inhibitors, and NNRTIs (medications for HIV), resulting in diminished effectiveness.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Increased dosages of HIV medications may be necessary.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Monitor PT (prothrombin time) and INR (international normalized ratio)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Clients may need to use alternative form of birth control.
Concurrent use with INH and pyrazinamide increases risk of hepatotoxicity.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Instruct clients to avoid alcohol consumption. Monitor liver function.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="attention">Attention<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#attention" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Depending on therapeutic intent, effectiveness may be evidenced by:</p>
<ul>
<li>Improvement of tuberculosis symptoms such as clear breath sounds, no night sweats, increased appetite, no afternoon rises of temperature</li>
<li>3 negative sputum cultures for tuberculosis, usually taking 3 to 6 months to achieve.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ethambutol">Ethambutol<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ethambutol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacodynamics">Pharmacodynamics;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Mechanism of action through inhibiting inhibition of bacterial growth through suppression of RNA synthesis. Resistance emergence occurs rapidly if used on its own.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetic">Pharmacokinetic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Good absorption from GIT.</li>
<li>Metabolism is in the liver.</li>
<li>Excretion in urine.</li>
<li>It can reach therapeutic concentrated with CSF for tuberculosis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These are common.</p>
<ul>
<li>Optic neuritis dose related especially if renal function decreases. this leads to visual disturbances, red/ green color blindness followed by decreased visual acuity.
Monitor color vision in long treatments</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Patients with known optic neuritis</li>
</ul>
<p>Patients who are unable to appreciate and report visual side effects or changes in vision e.g.</p>
<ul>
<li>young children and unconscious patients</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pyrazinamide">Pyrazinamide<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pyrazinamide" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>It is often inactive in neutral PH.</li>
</ul>
<p>Pharmacodynamics.</p>
<ul>
<li>its mechanism of action is unknown but it is tuberculostatic at acidic PH.</li>
<li>it is very effective against intracellular organism in macrophages since after phagocytosis, in which PH is low.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetic">Pharmacokinetic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>it has good gut absorption .</li>
<li>it is widely distributed in that it crosses the BBB</li>
<li>excreted in the kidneys</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dapsone">Dapsone<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dapsone" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacodynamics">Pharmacodynamics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>DAPSONE is chemically related to sulphonemides and it acts by inhibiting the enzyme dihydrofolate reluctance hence inhibits folate synthesis.</li>
<li>Its action is antagonized by PABA. resistance to this drug</li>
<li>Has increased, hence it 's combined with other drugs during treatment.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetic">Pharmacokinetic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Good oral absorption.</li>
<li>It under goes enteral hepatic recycling.</li>
<li>It has a half life of 24 to 48 hours</li>
<li>it is excreted in feces</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Hemolysis of white blood cells .
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Anorexia , nausea and vomiting.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Fever and allergic dermatitis,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> neuropathy
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Leprareation where there is exacerbation of lepromatous lesions can occur and a syndrome resembling infectious mononucleosis which can be fatal.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiviral-agents">Antiviral agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiviral-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Viruses present a more difficulty problem of chemotherapy than do higher organisms, e.g. bacteria, for they are intracellular parasites that use the metabolism of the host cells.</li>
<li>Antiviral agents are most active when virus are replicating.</li>
<li>The earlier the treatment is given the better.</li>
<li>Apart from primary infections ,viral illness is often the consequences of reactivation of latent virus in the body.</li>
<li>Patients whose immune system is compromised may suffer particular severe illness.</li>
<li>Viruses are capable of developing resistance.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiviral-and-antiretroviral-cont">Antiviral and antiretroviral cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiviral-and-antiretroviral-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>Drug</th><th>viruses</th><th>Chemical type</th><th>target</th></tr></thead><tbody><tr><td>Non nucleotide reverse</td><td></td><td></td><td></td></tr><tr><td>transcriptase inhibitor.</td><td></td><td></td><td></td></tr><tr><td>(NNRTIs);Nevirapine,</td><td></td><td></td><td></td></tr><tr><td>Delavirdine.</td><td>HIV Virus</td><td>Non nucleotide analogue</td><td>Reverse transcriptase</td></tr><tr><td>protease inhibitors;</td><td></td><td></td><td></td></tr><tr><td>Saquinavir, Ritonavir,</td><td></td><td></td><td></td></tr><tr><td>Indinavir, Nelfinavir.</td><td>HIV virus</td><td>Peptide analogue</td><td>HIV protease</td></tr><tr><td>Ribavirin</td><td>Broad spectrum: HCV, HSV,</td><td></td><td></td></tr><tr><td>Measles, Lasa fever, SARS</td><td>Triazole carboxamide</td><td>RNA mutagen</td><td></td></tr><tr><td>Amantadine/Rimantadine</td><td>Influenza A strains</td><td>Tricyclic amine</td><td>Matrix</td></tr><tr><td>protein/hemagglutinin</td><td></td><td></td><td></td></tr><tr><td>Zanamivir, oseltamivir</td><td></td><td></td><td></td></tr><tr><td>phosphate</td><td>Influenza strains A and B</td><td>Neuraminic acid mimetic</td><td>Neuraminidase inhibitor</td></tr><tr><td>Pleconaril</td><td>picornaviruses</td><td>Small cyclic</td><td>Blocks attachment and</td></tr><tr><td>coating</td><td></td><td></td><td></td></tr><tr><td>Interferons</td><td>Hepatitis B and C virus</td><td>protein</td><td>Cell defense</td></tr></tbody></table>
<table><thead><tr><th>Drug(</th><th>Viruses</th><th>chemical</th><th>Target</th></tr></thead><tbody><tr><td>vidarabine</td><td>herpesvirus</td><td>Nucleoside analogue</td><td>Virus polymerase</td></tr><tr><td>acyclovir</td><td>Herpes simplex (HSV)</td><td>Nucleoside analogue</td><td>Virus polymerase</td></tr><tr><td>Ganciclovir and valganciclovir</td><td>Cytomegalovirus (CMV)</td><td>nucleoside analogue</td><td>Virus polymerase</td></tr><tr><td>Nucleoside reverse transcriptase inhibitor (NRTI) zidovudine( AZT) didanosine (ddI), zalcitabine (ddC), stavudine (D4T), lamivudine (3TC)</td><td>Retroviruses (HIV)</td><td>Nucleoside analogue</td><td>Reverse transcriptase</td></tr><tr><td>Non nucleotide reverse transcriptase inhibitor (NNRTI) nevirapine and delavirdine</td><td>HIV virus</td><td>Non nucleotide analogue</td><td>Reverse transcriptase</td></tr><tr><td>Protease inhibitors saquinavir, Ritonavir, indinavir, nelfinavir</td><td>HIV virus</td><td>Peptide analogue</td><td>HIV protease</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acyclovir">Acyclovir<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acyclovir" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Acyclovir prevents the reproduction of viral DNA and thus interrupts cell replication.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Acyclovir is used to treat herpes simplex and varicella-zoster viruses Ganciclovir is used for treatment and prevention of cytomegalovirus (CMV).</li>
<li>Prevention therapy using ganciclovir is given for clients who have HIV/AIDS, organ transplants, and other immunocompromised states.</li>
<li>Interferon alfa-2b and lamivudine are used to treat hepatitis.</li>
<li>Oseltamivir is used to treat influenza A and B.</li>
<li>Ribavirin is used to treat respiratory syncytial virus (RSV) and influenza.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acyclovir Phlebitis and inflammation at the site of infusion
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Rotate IV injection sites.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Monitor IV sites for swelling and redness.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nephrotoxicity">Nephrotoxicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nephrotoxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Administer acyclovir infusion slowly over 1 hr .
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Ensure adequate hydration during infusion and 2 hr . after to minimize nephrotoxicity by administering IV fluids and increasing oral fluid intake as prescribed.
Mild discomfort associated with oral therapy (nausea, headache, diarrhea)</p>
<ul>
<li>Observe for symptoms and notify the provider.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects-cont">Side/Adverse Effects cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ganciclovir">Ganciclovir<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ganciclovir" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="granulocytopenia-and-thrombocytopenia">Granulocytopenia and thrombocytopenia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#granulocytopenia-and-thrombocytopenia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Obtain baseline CBC and platelet count.</li>
<li>Administer granulocyte colony-stimulating factors.</li>
<li>Monitor WBC, absolute neutrophil, and platelet counts.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Acyclovir should be used cautiously in clients with renal impairment or dehydration, and clients taking nephrotoxic medications.</li>
<li>Ganciclovir is Pregnancy Risk Category C;</li>
<li>contraindicated in clients with a neutrophil count below 500/mm3 or platelet counts less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo separator="true">,</mo><mn>000</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mn>3</mn></mrow><annotation encoding="application/x-tex">25,000 / \mathrm{mm} 3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000/</span><span class="mord"><span class="mord mathrm">mm</span></span><span class="mord">3</span></span></span></span></span>, and should be used cautiously in clients with pre-existing low white and platelet counts.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="acyclovir">Acyclovir<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acyclovir" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Probenecid may decrease elimination of acyclovir.
Monitor for medication toxicity.
Concurrent use of zidovudine may cause drowsiness.
Use with caution</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ganciclovir">Ganciclovir<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ganciclovir" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cytotoxic medications may cause increased toxicity.</li>
<li>Use together with caution.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions">Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="acyclovir">Acyclovir:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acyclovir" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>For topical administration, advise clients to put on rubber gloves to avoid transfer of virus to other areas of the body.
Administer IV infusion slowly over 1 hr or longer.
Inform clients to expect symptom relief but not cure.
Instruct clients to wash affected area with soap and water 3 to 4 times/day and to keep the lesions dry after washing.
Advise clients to refrain from sexual contact while lesions are present.
Clients with healed herpetic lesions should continue to use condoms to prevent transmission of the virus.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions">Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ganciclovir">Ganciclovir<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ganciclovir" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Administer IV infusion slowly, with an infusion pump, over at least 1 hr .
Administer oral medication with food.
Administer intraocular for CMV retinitis.
Instruct clients to complete the prescribed course of antimicrobial therapy, even though symptoms may resolve before the full course is completed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiretroviral-drugs">Antiretroviral drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiretroviral-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Antiretroviral therapy goal is to delay disease progression and to prolong survival by suppressing the replication of the virus.</li>
<li>Two types of antiretroviral combination are recommended for initial HIV therapy;</li>
</ul>
<ol>
<li>First line ; 1 NNRTI plus 2NRTI.</li>
<li>Second line; 1PI plus 2 NRTI.</li>
<li>protease inhibitors are preserved for second line</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="five-goals-of-art">Five goals of ART<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#five-goals-of-art" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>To reduce amount of HIV virus in the body.</li>
<li>Support and restore the immune system.</li>
<li>Improve the quality of life.</li>
<li>Reduce HIV related illness and deaths.</li>
<li>Reduce general risk of transmission.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action-of-arvs">Mechanism of action of ARVs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-arvs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Block reverse transcriptase to disrupt copying of HIV genetic cord(NRTIs, NNRTIs).</li>
<li>Block protease enzyme, preventing maturation of new virions.(PIs).</li>
<li>Prevent fusion of HIV with cell membranes (fusion inhibitors).</li>
<li>Block CCR5 co receptor (CCR5 antagonist)</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hiv-life-cycle-targets-for-antivirals">HIV life cycle: Targets for antivirals<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hiv-life-cycle-targets-for-antivirals" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><img src="data:image/jpeg;base64,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" alt="img-1.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="zidovudine-retrovir">ZIDOVUDINE (RETROVIR)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#zidovudine-retrovir" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-medications">Other Medications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-medications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Didanosine (Videx)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Stavudine (Zerit)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Lamivudine (Epivir)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Abacavir (Ziagen)
Combination Medications:
Abacavir, lamivudine zidovudine (Trizivir)
Abacavir, lamivudine (Epzicom)
Lamivudine, zidovudine (Combivir)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Reduces HIV symptoms by inhibiting DNA synthesis and thus viral replication.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Used to treat HIV infection
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Route of Administration: Oral, IV</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="suppressed-bone-marrow-resulting-in-anemia-agranulocytosis-neutropenia-and-thrombocytopenia">Suppressed bone marrow resulting in anemia, agranulocytosis (neutropenia) and thrombocytopenia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#suppressed-bone-marrow-resulting-in-anemia-agranulocytosis-neutropenia-and-thrombocytopenia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Monitor CBC and platelets. Advise clients that transfusions may be needed.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lactic-acidosis">Lactic acidosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lactic-acidosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Monitor for symptoms of lactic acidosis, such as hyperventilation, nausea, and abdominal pain. Pregnancy increases the risk of lactic acidosis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nausea-vomiting-diarrhea">Nausea, vomiting, diarrhea<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nausea-vomiting-diarrhea" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Clients may take the medication with food to reduce gastric irritation. Monitor fluids and electrolytes.
Hepatomegaly/fatty liver so Monitor liver enzymes</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions">Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Probenecid, valproic acid, and methadone may increase zidovudine.</p>
<ul>
<li>Reduce dosage</li>
<li>Monitor for medication toxicity.</li>
</ul>
<p>Ganciclovir or medications that decrease bone marrow production may further suppress bone marrow.</p>
<ul>
<li>Use together with caution.</li>
</ul>
<p>Rifampin and ritonavir may reduce zidovudine levels.</p>
<ul>
<li>Adjust dosage if needed.</li>
</ul>
<p>Phenytoin may alter both medication levels.</p>
<ul>
<li>Monitor medication levels.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="non-nucleoside-reverse-transcriptase-inhibitors-nnrti-s">Non-nucleoside reverse transcriptase inhibitors (NNRTI s)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#non-nucleoside-reverse-transcriptase-inhibitors-nnrti-s" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Select medication: delavirdine (Rescriptor), efavirenz (Sustiva)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Other Medications: nevirapine (Viramune), etravirine (Intelence)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>NNRTIs act directly on reverse transcriptase to stop HIV reprication</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Primary HIV-1 infection
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Often used in combination with other antiretroviral agents to prevent medication resistance</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="route-of-administration">Route of administration:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#route-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Oral
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Monitor for rash.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects">Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="rash-which-may-become-serious-and-lead-to-steven-s-johnson-syndrome">Rash, which may become serious and lead to Steven's-Johnson syndrome<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rash-which-may-become-serious-and-lead-to-steven-s-johnson-syndrome" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Monitor for rash.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Treat with diphenhydramine (Benadryl), if prescribed.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Notify the provider for fever or blistering.
Flu-like symptoms, headache, fatigue
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Monitor for adverse reactions.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Encourage rest and adequate oral fluid intake</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>NNRTIs are Pregnancy Risk Category C.
These medications are contraindicated in clients with medication hypersensitivity.
Use with caution in clients who have liver disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions">Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Antacids may decrease absorption of delavirdine.</p>
<ul>
<li>Allow 1 hr . between medications.</li>
</ul>
<p>NNRTIs may increase effects of amphetamines, antihistamines, calcium channel blockers, ergot alkaloids, quinidine, warfarin, and others.</p>
<ul>
<li>Monitor for medication toxicity.</li>
</ul>
<p>Rifampin and phenytoin may cause decrease in levels of delavirdine.</p>
<ul>
<li>Do not use together.</li>
</ul>
<p>Didanosine may reduce both medications' absorption.
Allow 1 hour between medications.
NNRTIs hypotension and changes in vision.</p>
<ul>
<li>may cause increase in sildenafil level.</li>
<li>Monitor for Use together with caution.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="protease-inhibitors">Protease inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#protease-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Members of this group are;
ritonavir (Norvir)
Saquinavir (Invirase)
Indinavir (Crixivan)
Amprenavir (Agenerase)
Nelfinavir (Viracept)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism Of Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Protease inhibitors act against HIV-1 and HIV-2 to alter and inactivate the virus by inhibiting enzymes needed for HIV replication.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indication">Indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Used to treat HIV infections
Should be used with another antiretroviral medication to reduce medication resistance
Route of administration: Oral</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects">Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Diabetes mellitus/hyperglycemia ; Monitor serum glucose,</li>
</ul>
<p>Adjust diet and administer anti-diabetic medications as prescribed. Advise clients to monitor for increased thirst and urine output.</p>
<ul>
<li>hypersensitivity reaction;</li>
</ul>
<p>Monitor for rash.
Notify the provider if rash develops.</p>
<ul>
<li>Nausea and vomiting; Take medication with food to reduce GI effects and increase absorption.</li>
<li>Elevated serum lipids</li>
</ul>
<p>Monitor for hyperlipidemia.
Adjust diet.</p>
<ul>
<li>Thrombocytopenia, leukopenia</li>
</ul>
<p>Monitor CBC. Monitor for signs of infection (fever, sore throat). Monitor for bleeding, blood in stool and bruising</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions">Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Ritonavir may cause these medications to accumulate to toxic levels: Bupropion, carbamazepine, diazepam, lidocaine, prednisone clozapine, lovastatin, simvastatin, alprazolam, and ergotamine.
Avoid concurrent use.</li>
<li>Ritonavir may increase medication levels of sildenafil, tadalafil, and vardenafil.
Use with caution. Dosages of these medications may need to be reduced.</li>
<li>Ritonavir decreases levels of ethynyl estradiol in oral contraceptives. Instruct clients to use an alternative form of birth control.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="fusion-inhibitors">Fusion inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fusion-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Enfuvirtide this is the first antiretroviral to target the host cell attachment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action-pharmacodynamics">Mechanism of action/pharmacodynamics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-pharmacodynamics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>It inhibits fusion of the cellular and viral membranes.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetic">Pharmacokinetic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>It is give by S.C. injection half life is 4 hours.
adverse effects</li>
<li>Limited to mild injection site reactions</li>
<li>Hypersensitivity and peripheral neuropathy may occur.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bd1a4d85">Standard 1 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> line regime for adults in Kenya<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bd1a4d85" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Stavudine (D4T)/Zidovudine (AZT)+ Lamivudine(3TC)+Nevirapine (NVP)
OR</li>
<li>Stavudine (D4T)/Zidovudine (AZT) +Lamivudine (3TC)+ Efavirenz. Assignment
Find out the standard <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> line and the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mtext>nd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">2^{\text {nd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">nd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> line ART regime in children.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="analgesics-and-nsaids">ANALGESICS and NSAIDS)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#analgesics-and-nsaids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Analgesics may be defined as any member or group of drugs used to achieve analgesia, relief from pain. They relieve pain without causing any loss of consciousness.</li>
<li>Analgesics drug works in various ways on the periphery and the CNS.</li>
<li>NSAIDs are referred to as non narcotic analgesics or non-opioid analgesics.</li>
</ul>
<p>They differ from opioids in the aspects;</p>
<ul>
<li>They are less potent</li>
<li>Fail to produce drowsiness or CNS depression</li>
<li>Non additive in nature</li>
<li>Posses anti inflammatory/antipyretic activities</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nsaids-cont">NSAIDs cont.'<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nsaids-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1st generation NSAIDs (COX-1 and COX-2 inhibitors):
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Aspirin
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Ibuprofen (Motrin, Advil)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Naproxen (Naprosyn)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Indomethacin (Indocin)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Diclofenac (Voltaren)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Ketorolac (Toradol)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Meloxicam (Mobic)
2nd generation NSAIDs (selective COX-2 Inhibitor):
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Celecoxib (Celebrex)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Inhibition of prostaglandin synthase, also known as cox - Inhibition of COX-1 can result in decreased platelet aggregation and kidney damage.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Inhibition of COX-2 results in decreased inflammation, fever, and pain.
Therapeutic Uses /indication ( analgesic, antipyretic, and anti inflammatory)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Inflammation suppression.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Analgesia for mild to moderate pain, such as with osteoarthritis and rheumatoid arthritis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Fever reduction.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Dysmenorrhea.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Inhibition of platelet aggregation, which protects against stroke and myocardial infarction. (aspirin)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> The exception of acetaminophen which is an analgesic and antipyretic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects">Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Gastrointestinal discomfort (dyspepsia, abdominal pain, heartburn, nausea)</li>
<li>Damage to gastric mucosa may lead to GI bleeding and perforation, especially with long-term use. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span></li>
<li>Advise clients to take medication with food or with a full glass of water or milk.</li>
<li>Advise clients to avoid alcohol.</li>
<li>Observe for signs of bleeding (passage of black or dark-colored stools, severe abdominal pain, nausea, vomiting).</li>
<li>Administer a proton pump inhibitor, such as omeprazole (Prilosec), or an H2 receptor antagonist, such as ranitidine (Zantac) to decrease the risk of ulcer formation. Use prophylaxis agents such as misoprostol (Cytotec).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects-cont">Side/adverse effects cont.'<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="renal-dysfunction-decreased-urine-output-weight-gain-from-fluid-retention-increased-bun-and-creatinine-levels">Renal dysfunction (decreased urine output, weight gain from fluid retention, increased BUN and creatinine levels)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#renal-dysfunction-decreased-urine-output-weight-gain-from-fluid-retention-increased-bun-and-creatinine-levels" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Use cautiously with older adults and clients who have heart failure.</li>
<li>Monitor I&amp;O and kidney function (BUN, creatinine).</li>
</ul>
<p>Increased risk of heart attack and stroke (non aspirin NSAIDs)</p>
<ul>
<li>Use the smallest effective dose for clients with known cardiovascular disease.</li>
<li>Salicylism may occur with aspirin. Signs and symptoms include tinnitus, sweating, headache and dizziness, and respiratory alkalosis.</li>
<li>Advise clients to notify the provider and to stop taking aspirin if symptoms occur.</li>
<li>Reyer syndrome is rare, but serious in childhood.</li>
<li>This occurs when aspirin is used for fever reduction in children who have a viral illness, such as chickenpox or influenza</li>
<li>Advise clients to avoid giving aspirin when a child has a viral illness, such as chickenpox or influenza.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects-cont">Adverse effects cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="aspirin-toxicity">Aspirin toxicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aspirin-toxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Aspirin toxicity should be managed as a medical emergency in the hospital.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapy-includes">Therapy includes:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapy-includes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cooling with tepid water.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Correction of dehydration and electrolyte imbalance with IV fluids.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Reversal of acidosis and promotion of salicylate excretion with bicarbonate.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Gastric lavage Activated charcoal may also be given to decrease absorption.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Hemodialysis may be indicated.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-for-aspirin-and-other-1st-generation-nsaids-include">Contraindications for aspirin and other 1st generation NSAIDs include<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-for-aspirin-and-other-1st-generation-nsaids-include" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Pregnancy (Pregnancy Risk Category D)</li>
<li>Peptic ulcer disease</li>
<li>Bleeding disorders such as hemophilia, vitamin K deficiency</li>
<li>Hypersensitivity to aspirin and other NSAIDs</li>
<li>Children with chickenpox or influenza (aspirin)</li>
<li>Use NSAIDs cautiously in older adults, clients who smoke cigarettes, and in clients with H. pylori infection, hypovolemia, asthma, chronic urticaria, and/or a history of alcoholism.</li>
<li>Celecoxib is contraindicated in clients with allergy to sulfonamides.</li>
<li>Ketorolac is contraindicated in clients with advanced renal dysfunction</li>
<li>Use should be no longer than five days because of the risk for kidney damage.</li>
<li>2nd generation NSAIDs should be used cautiously in clients who have known cardiovascular disease.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acetaminophen">Acetaminophen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acetaminophen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism Of Action;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Acetaminophen slows the production of prostaglandins in the central nervous system.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Analgesic (relief of pain) effect</li>
<li>Antipyretic (reduction of fever) effects</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects">Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acute toxicity that results in liver damage with early symptoms of nausea, vomiting, diarrhea, sweating, and abdominal discomfort progressing to, hepatic failure, coma and death</p>
<ul>
<li>Advise clients to take acetaminophen as prescribed and not to exceed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">4 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day.</li>
<li>Administer the antidote, acetylcysteine (Mucomyst).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Use cautiously in clients who consume three or more alcoholic drinks/day and those taking warfarin (interferes with metabolism).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="alcohol-increases-the-risk-of-liver-damage">Alcohol increases the risk of liver damage.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#alcohol-increases-the-risk-of-liver-damage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Advise clients about the potential risk of liver damage with consumption of alcohol.
Acetaminophen slows metabolism of warfarin (Coumadin) leading to increased levels of warfarin.</li>
<li>This places clients at risk for bleeding.</li>
<li>Instruct clients to observe for signs of bleeding (bruising, petechiae, hematuria).</li>
<li>Monitor prothrombin time and INR levels and adjust dosages of warfarin accordingly</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="opioid-analgesics-narcotic-analgesics">Opioid analgesics/narcotic analgesics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#opioid-analgesics-narcotic-analgesics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Opioids are classified as agonists, agonist-antagonists, and antagonist.</li>
</ul>
<p>Opioid Agonists
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> morphine sulfate
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Fentanyl (Sublimaze, Duragesic)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Meperidine (Demerol)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Methadone (Dolophine)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Codeine, oxycodone (OxyContin)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Opioid agonist produce analgesia by binding to specific proteinscoupled receptors that are located in the brain and the spinal cord regions involved in the transmission and modulation of pain</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indication-therapeutic-uses">Indication/Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication-therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Relief of moderate to severe pain (postoperative, myocardial infarction, cancer)
Sedation
Reduction of bowel motility
Codeine: cough suppression</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="route-of-administration">Route of administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#route-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Morphine sulfate - Oral, subcutaneous, IM, rectal, IV, epidural, and intrathecal
Fentanyl (Sublimaze, Duragesic) - IV, IM, transmucosal and transdermal
Meperidine (Demerol) - Oral, subcutaneous IM, and IV
Codeine - Oral, subcutaneous IM, and IV
Methadone (Dolophine) - Oral, subcutaneous, and IM
Oxycodone (OxyContin) - Oral, rectal
Hydromorphone (Dilaudid) - Oral, subcutaneous, IM, IV</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects-morphine-sulphate">Adverse Effects (morphine sulphate)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects-morphine-sulphate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="respiratory-depression">Respiratory depression.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#respiratory-depression" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Monitor the client's vital signs.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Stop opioids if the client's respiratory rate is less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">12 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, and then notify the provider.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Have naloxone (Narcan) and resuscitation equipment available.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Avoid the use of opioids with CNS depressant medications (barbiturates, benzodiazepines, and consumption of alcohol).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="constipation">Constipation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#constipation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Increased fluid intake and physical activity.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Administer a stimulant laxative, such as Bisacodyl (Dulcolax), to counteract decreased bowel motility, or a stool softener, such as docusate sodium (Colace), to prevent constipation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects-cont">Side/ adverse effects cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="orthostatic-hypotension">Orthostatic hypotension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#orthostatic-hypotension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Advise clients to sit or lie down if symptoms of lightheadedness or dizziness occur.
Avoid sudden changes in position by slowly moving clients from a lying to a sitting or standing position.
Provide assistance with ambulation as needed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="urinary-retention">Urinary retention<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#urinary-retention" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Advise clients to void every 4 hr .
Monitor I&amp;O.
Assess the client's bladder for distention by palpating the lower abdomen area every 4 to 6 hr . side and adverse effects</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects-cont">Adverse effects cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cough-suppression">Cough suppression<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cough-suppression" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Advise clients to cough at regular intervals to prevent accumulation of secretions in the airway.
Auscultate the client's lungs for crackles, and instruct clients to increase intake of fluid to liquefy secretions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sedation">Sedation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sedation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Advise clients to avoid hazardous activities such as driving or operating heavy machinery.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="biliary-colic">Biliary colic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#biliary-colic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Avoid giving morphine to clients who have a history of biliary colic. Use meperidine as an alternative.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects-cont">Adverse effects cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="emesis">Emesis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#emesis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Administer an antiemetic such as promethazine (Phenergan).</li>
</ul>
<p>Opioid overdose triad of coma, respiratory depression, and pinpoint pupils</p>
<ul>
<li>Monitor the client's vital signs.</li>
<li>Provide mechanical ventilation.</li>
<li>Administer opioid antagonists, such as naloxone (Narcan) or nalmefene (Revex)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Morphine is contraindicated after biliary tract surgery.
Morphine is contraindicated for premature infants during and after delivery because of respiratory depressant effects.
Meperidine is contraindicated for clients with renal failure because of the accumulation of normeperidine, which can result in seizures and neurotoxicity.
Use cautiously with: Clients who have asthma, emphysema, and/or head injuries; infants, and older adults.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="caution">Caution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#caution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Clients who have asthma, emphysema, and/or head injuries; infants, and older adult clients (risk of respiratory depression).</li>
<li>Clients who are pregnant (risk of physical dependence of the fetus).</li>
<li>Clients in labor (risk of respiratory depression in the newborn and inhibition of labor by decreasing uterine contractions)</li>
<li>Clients who are extremely obese (greater risk for prolonged side effects because of the accumulation of medication that is metabolized at a slower rate)</li>
<li>Clients with inflammatory bowel disease (risk of megacolon or paralytic ileus)</li>
<li>Clients with an enlarged prostate (risk of acute urinary retention)</li>
<li>Clients with hepatic or renal disease</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="opioid-agonist-antagonist">Opioid Agonist-Antagonist<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#opioid-agonist-antagonist" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Butorphanol (Stadol)</li>
<li>Nalbuphine hydrochloride (Nubain)</li>
<li>Buprenorphine hydrochloride (Buprenex)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>These medications act as antagonists on mu receptors and agonists on kappa receptors.
Compared to pure opioid agonists, agonist-antagonists have:</li>
</ul>
<ul>
<li>A low potential for abuse causing little euphoria.</li>
<li>In fact, high doses can cause adverse effects (anxiety, restlessness, mental confusion).</li>
<li>Less respiratory depression.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="indication">Indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Relief of moderate to severe pain
Treatment of opioid dependence (buprenorphine)
Adjunct to balanced anesthesia
Relief of labor pain (butorphanol)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="route-of-administration">Route of administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#route-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Butorphanol - IV, IM, intranasal</li>
<li>Nalbuphine - IV, IM, subcutaneous</li>
<li>Buprenorphine - IV, sublingual, epidural</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Abstinence syndrome (cramping, hypertension, vomiting)
Sedation respiratory depression
Dizziness
Increased intracranial pressure, headache</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Use cautiously in clients who have a history of myocardial infarction, renal or liver disease, respiratory depression, or head injury, and clients who are physically dependent on opioids.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> CNS depressants and alcohol may cause additive effects.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Use together cautiously.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Monitor respirations.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Opioid agonists may antagonize and reduce analgesic effects of the opioid. Do not use concurrently.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="opioid-antagonist">Opioid Antagonist<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#opioid-antagonist" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Naloxone (Narcan) Naltrexone (Re Via, Depade ),</li>
<li>nalmefene (Revex )</li>
</ul>
<p>Mechanism of Action Opioid antagonists interfere with the action of opioids by competing for opioid receptors. Opioid antagonists have no effect in the absence of opioids.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Treatment of opioid overdose Reversal of effects of opioids, such as respiratory depression
Reversal of respiratory depression in an infant</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="route-of-administration">Route of administration:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#route-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Naloxone- IM, IV, subcutaneous
nalmefene - IV, IM, subcutaneous
Naltrexone - Oral</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="opioid-antagonist-cont">Opioid antagonist cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#opioid-antagonist-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Treatment of opioid overdose Reversal of effects of opioids, such as respiratory depression
Reversal of respiratory depression in an infant</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="route-of-administration">Route of administration:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#route-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Naloxone,
Nalmefene - IV, IM, subcutaneous
Naltrexone - Oral</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="opioid-anti-agonist-cont">Opioid anti-agonist cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#opioid-anti-agonist-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tachycardia and tachypnea
Abstinence syndrome (cramping, hypertension, vomiting)
Pulmonary edema</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Opioid antagonists are Pregnancy Risk Category B.
*These medications are contraindicated in clients with opioid dependency.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adjuvants-medication-for-pain">Adjuvants medication for pain<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adjuvants-medication-for-pain" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Tricyclic antidepressants: amitriptyline (Elavil) - oral/IM
Anticonvulsants: carbamazepine (Tegretol) - gabapentin (Neurontin) oral
CNS stimulants: methylphenidate (Ritalin) - oral
Antihistamines: hydroxyzine (Vistaril) - oral/IM
Glucocorticoids: dexamethasone (Decadron) - oral, IV, IM
Bisphosphonates: etidronate (Didronel) - oral</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adjuvants-medication-for-pain-cont">Adjuvants medication for pain cont..<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adjuvants-medication-for-pain-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> NSAIDs: ibuprofen (Motrin) - oral
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Other Medication: Tricyclic antidepressants: imipramine (Tofranil) oral
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Anticonvulsants: phenytoin (Dilantin) - oral, IV, IM
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> CNS stimulants: dextroamphetamine (Dexedrine) - oral
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Glucocorticoids: prednisone (Deltasone) - oral
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Bisphosphonates: pamidronate (Aredia) - IV
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> NSAIDs: ketorolac (Toradol)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Adjuvant medications for pain enhance the effects of opioids</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> These medications are used in combination with opioids and cannot be used as a substitute for opioids.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> NSAIDs are used to treat inflammation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Tricyclic antidepressants are used to treat depression and neuropathic pain such as cramping, aching, burning, darting, and lancinating pain.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses-cont">Therapeutic Uses cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Anticonvulsants are used to relieve neuropathic pain.</li>
<li>CNS stimulants augment analgesia and decrease sedation.</li>
<li>Antihistamines decrease anxiety, prevent insomnia and relieve nausea.</li>
<li>Glucocorticoids decrease pain from intracranial pressure and spinal cord compression.</li>
<li>Bisphosphonates manage hypercalcemia and bone pain</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-helminthic">ANTI HELMINTHIC<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-helminthic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Benzimidazole (BZAs)</li>
</ul>
<p>These are broad spectrum anthelmintic agents.
Thiabendazole., Mebendazole and Albendazole have been used extensively for human helminth infections.</p>
<ul>
<li>Other drugs are ;pyrantel pamoate, ivermectin, praziquental, piperazine citrate, benzdiazepines and diethylcarbamazine.</li>
</ul>
<p>Indication/uses;
Thiabendazole is active against a wide range of nematodes that infect the GI tract but it clinical use has declined due to its toxicity.
Mebendazole is used for the treatment of intestinal roundworm infections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anthelminthic-cont">Anthelminthic cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anthelminthic-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Albendazole is used primarily against a variety of intestinal and tissue nematodes but also against Larva forms of certain cestodes (cysticercosis, hydatidosis)</li>
<li>Used with ivermectin or diethylcarbamazine for control of helminthes.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anthelminthics-mechanism-of-action">Anthelminthics mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anthelminthics-mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>The BZAs inhibit microtubule polymerization by binding to btubulin.</li>
<li>Mebendazole and Albendazole are highly effective in treating the major infections (ascariasis, enterobiasis, trichuriasis, and hookworm)'
-These drugs are active against both larva and adult stages of the nematodes, and they are ovicidal for ascaris and trichuris .
-Immobilization and death of susceptible GI parasites occur slowly and their clearance from the GI tract may not be complete until several days after treatment.
Albendazole is more effective than mebendazole for strongyloidiasis, cystic hydatid disease caused By Echinococcus Granulosus And Neurocysticercosis</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anthelminthic-mechanism-of-cont">Anthelminthic mechanism of cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anthelminthic-mechanism-of-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The choice of drug depends on specific helminths involved
Example cestodes infestations e.g. echinococcus granulosus the drugs used are thiabendazole, Albendazole, piperazine citrate, pyrantel pamoate, ivermectin and diethylcarbamazine (hetrazan).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="absorption-fate-and-excretion">Absorption, fate, and excretion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#absorption-fate-and-excretion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Thiabendazole is absorbed rapidly after oal ingestion and reaches peak plasma concentration after 1 hour. Most of the drug is excreted in urine.
Mebendazole is rapidly metabolized resulting to low systemic bioavailability.
Albendazole is variably absorbed after oral administration, a fatty meal enhances absorption. It is well distributed into various tissues including hydatid cysts. It excreted in urine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-protozoa-and-antimalaria">ANTI PROTOZOA AND ANTIMALARIA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-protozoa-and-antimalaria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> The common protozoa infection include;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Amoebiasis ,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Trypanosomiasis,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Giardiasis,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Malaria,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cutaneous and visceral leishmaniasis
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Chagas disease,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> toxoplasmosis and
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> trichomoniasis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimalarial">Antimalarial<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimalarial" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Examples include; quinine, Artesunate,chloroquine, mefloquine, proguanil, pyrimethamine/sulfadoxine, tetracycline, doxycycline &amp; minocycline, primaquine, and also artemether-Lumefantrine (coartem)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> The first line treatment of uncomplicated malaria in Kenya is Artemether-Lumefantrine.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> The second line treatment for uncomplicated malaria in Kenya is dihydroartemisinic-piperaquine (DHA-PPQ)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> This is available in a fixed dose combination with adult tablets containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>320</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mathrm{mg} / 320 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/320</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of DHA-PPQ
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Pediatric tablets containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>160</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / 160 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/160</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of DHA-PPQ</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dosage-artemether-lumefantrine">Dosage; Artemether Lumefantrine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosage-artemether-lumefantrine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>|  WEGHT IN KG | AGE IN
YEARS | NUMBER OF TABLETS PER DOSE |  |  |  |  |   |
| --- | --- | --- | --- | --- | --- | --- | --- |
|   |  | day 1 |  | day 2 |  | day 3 |   |
|   |  | <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> dose | 8 hours | 24 hours | 36 hours | 48 hours | 60 hours  |
|  5-14 | 5/12- 3 years | 1 | 1 | 1 | 1 | 1 | 1  |
|  15-24 | 3-7 years | 2 | 2 | 2 | 2 | 2 | 2  |
|  25-34 | 8-11 years | 3 | 3 | 3 | 3 | 3 | 3  |
|  Above 34 | Above 12 years | 4 | 4 | 4 | 4 | 4 | 4  |</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-malaria-cont">Anti-malaria cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-malaria-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Other anti-malarial drugs for uncomplicated malaria are;
Amodiaquine plus artesunate
Mefloquine plus artesunate
Halofantrine (halfan) .this drug can cause arrhythmias, and is contraindicated in patients with heart disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="quinine">Quinine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quinine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Quinine is an alkaloid derived from cinchona tree.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indication">Indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Reserved for severe and complicated malaria.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacodynamics-mechanism-of-action">Pharmacodynamics/mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics-mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> It binds to plasmodium DNA to prevent protein synthesis but its exact mode of action remains uncertain.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> It is used to treat plasmodium falciparum in areas of multiple drug resistant.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Quinine is well absorbed in the gut but absorption is delayed by antacids. It can be given via slow IV Infusion.
Metabolism occurs in the liver, the excretion is in the kidneys.
It is used for the treat of chloroquine resistant P . falciparum often With Combination Of Pyrimethamine/ Sulfadoxine</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Has a low therapeutic widow and it produces effects in the skeletal muscles and can cause; GI irritation, renal damage, hemolytic anemia (rarely)associated with "black water fever" in previously sensitized patients.
Black water fever has a fatality rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> due to intravascular coagulation and renal failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects-cont">Side effects cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Hypotension
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Hypoglycemia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cinchonism</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dosage">Dosage;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Loading dose IV Quinine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> body wt. in 500 mls of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> dextrose (MAX 1200MG) for 4 hours then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> body wt. as intravenous infusion in 500 mls of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> dextrose to run for 4 hrs every 8 hourly ( maximum 600 mgs )
After 3 IV doses of quinine, one should try to change into oral treatment and treatment should continue for 7 days.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dosage-cont">Dosage cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosage-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>For children loading dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> body wt. in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi><mi mathvariant="normal">s</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{mls} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm">mls</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> of isotonic fluid to run over 4 hours and maintenance dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> body wtin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi><mi mathvariant="normal">s</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mls} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">mls</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> of isotonic fluids to run over 4 hours every 12 hourly un til the patient can take orally.
Oral quinine is given <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> body wt 8 hourly to complete a total of (parenteral + oral ) 7 days.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prevention-of-malaria">Prevention of malaria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prevention-of-malaria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Chemoprophylaxis; mefloquine or atovaquone-proguanil or doxycycline.
Intermittent presumptive treatment (IPT) in recommended for pregnant women in areas of high malaria transmission.
Current recommended IPT medication is sulphadoxine 500 mg ,pyrimethamine 25 mg given as a dose of 3 tablets.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="amoebicidal-drugs">Amoebicidal drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#amoebicidal-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Metronidazole was covered under azoles antibiotics.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sedatives-hypnotics">SEDATIVES-HYPNOTICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sedatives-hypnotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Also known as anti anxiety drugs
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Sedative hypnotics refers to drugs that depress the CNS activity, relieve anxiety and induce sleep.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Effective Sedatives (anxiolytic ) drug should reduce anxiety and exert a calm effect.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Hypnotics drug should produce drowsiness and encourage the onset and maintenance of a state of sleep.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> All sedative hypnotics cross the placenta barrier and may contribute to the depression neonatal vital function.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Sedative-hypnotics are detectable in breast milk and may exert depressant effects in the nursing infant.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-sedative-hypnotics">Classification of Sedative Hypnotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-sedative-hypnotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Benzodiazepines; clonazepam, diazepam, midazolam, lorazepam, triazolam, flurazepam, alprazolam, chlordiazepoxide.</li>
<li>Barbiturates; phenobarbital, metharbital, thiopental sodium</li>
<li>Newer generation; zopiclodine, zolpidem.</li>
<li>Miscellaneous; chloral hydrate</li>
<li>B-adrenoreceptor antagonist; Flumezanil</li>
<li>The most commonly used are benzodiazepines and barbiturates medications.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-actions">Pharmacological actions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Useful predominantly as anticonvulsants, muscle relaxant and in status epilepticus.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Abrupt withdrawal causes precipitation of epileptiform seizures.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> They potentiate analgesics .
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Wide margin of safety
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Give rise to drug dependency (abuse liability)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Obliterate moments of sequential events</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacodynamics-of-benzodiazepines-barbiturates-new-hypnotics">Pharmacodynamics of benzodiazepines, barbiturates &amp;new hypnotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics-of-benzodiazepines-barbiturates-new-hypnotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Molecular pharmacology of GABA (gamma aminobutyric acid) receptor (GABA is an inhibitory neurotransmitter)
The benzodiazepine, barbiturates, zolpidem, zaleplon and other drugs bind to molecular component of GABA, a receptor in neuronal membrane in the CNS. improving the symptoms of sleep disturbance, tremors and muscle tension.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="organ-level">Organ level<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#organ-level" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Effects
Sedation; exert calming effects with reduction of anxiety at relatively low doses.
Hypnosis; all sedative hypnotics induce sleep if high enough doses are given.
Muscle relaxation
Effects on respiratory and cardiovascular functions especially on patients with pulmonary disease
Anticonvulsant effects e.g. phenobarbitone
anesthesia, e.g. barbiturates thiopental
Tolerance ; psychological &amp; physiological Dependence</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-indications">Clinical Indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Insomnia
Sedation and amnesia before and during medical surgical procedures.
Treatment of epilepsy and seizure state.
as a component of balanced anesthesia.
For control of ethanol and other sedative hypnotic withdrawal states.
For muscle relaxation in specific neural muscular disorders</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="direct-toxic-action">Direct toxic action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#direct-toxic-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Relatively low doses may lead to Drowsiness, impaired judgement, diminished motor skills. sometimes with impact on driving, working and personal relationship.
Criminals use BZDs in cases of "date rape" is based on their dose dependent amnestic effects.
At higher dose toxicity may present as lethargy or state of exhaustion or as gross symptoms equivalent to those of ethanol intoxication.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="benzodiazepines-common-indications">Benzodiazepines Common Indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#benzodiazepines-common-indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Most commonly used sedatives hypnotics.</li>
</ul>
<p>MOA exert their action as the other CNS depressants.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification">Classification<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Short acting e.g. midazolam, triazolam, half life five hours.
Intermediate e.g. lorazepam, oxazepam, clonazepam. Half life five to 24 hours.
Long acting e.g. diazepam, chlordiazepoxide, prazepam. Half life 24 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects-of-benzodiazepines">Side Effects of Benzodiazepines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects-of-benzodiazepines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Daytime drowsiness, ataxia, rebound insomnia on withdrawal</li>
<li>The elderly develop blurred vision, tremors , constipation, and anterograde amnesia.</li>
<li>Respiratory depression which may worsen in COPD</li>
<li>Decrease BP and heart rate.</li>
<li>Paradoxical effects in the first 2 weeks of therapy such as hostility, aggression, excitement, antisocial behavior</li>
<li>cross tolerance with other sedative/hypnotics agents e.g. alcohol/ barbiturates.</li>
<li>withdrawal symptoms may develop any time after stopping E.G. anxiety, insomnia, GIT disturbance, tinnitus, perceptual disturbance, lack of appetite and perspiration. treat with flumazenil</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In pregnancy, shock, acute alcohol intoxication and neonatal withdrawal symptoms, in the elderly and during lactation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Alcohol plus benzodiazepines cause severe CNS depression.</li>
<li>Cimetidine, disulfiram and oral contraceptives cause increase benzodiazepines effects.</li>
<li>Ranitidine and theophylline decrease benzodiazepine effects.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="barbiturates">Barbiturates<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#barbiturates" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Include;-
Mephobarbital (mebaral)
Pentobarbital (Nembutal)
Phenobarbital (luminal, solfoton)
Amobarbital
Thiopental sodium.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-effects">Pharmacological Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cns">CNS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cns" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Depression of CNS
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Sedative hypnotic
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Anticonvulsant
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> General anesthetic (sodium thiopental)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Enhance analgesic effect of morphine</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-application">Therapeutic Application<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-application" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Sedatives
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Hypnotic
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Anticonvulsant
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> pre anesthetic medicament
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Potentiate analgesic activity
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> anti epileptic; phenobarbitone, metharbital
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> general anesthesia ;thiopental sodium</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reaction">Adverse Reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Acute drug dependence
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Drug tolerance
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Withdrawal symptoms
Contraindication</p>
<ul>
<li>Renal damage</li>
<li>Hepatic ailments</li>
<li>Pulmonary insufficient</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anticonvulsant-seizure-anti-epileptic-medication">Anticonvulsant/seizure /anti epileptic medication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anticonvulsant-seizure-anti-epileptic-medication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Barbiturates: Phenobarbital (Luminal), Primidone (Mysoline) amobarbital, metharbital.
Hydantoins: phenytoin (Dilantin)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Benzodiazepines: Diazepam (Valium), Lorazepam (Ativan)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Carboxamide: Carbamazepine (Tegretol, carbatrol), oxcarbazepine (Trileptal)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Phenyltriazine: Lamotrigine (lamictal)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Pyrrolidines: levetiracetam (Keppra)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Succinimides: ethosuximide (zorontin)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Miscellaneous: acetazolamide (Diamox), primidone(mysoline), valproic acid(depakene, Depakote), zonisamide (zonegran)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Unfortunately the mechanism of seizure activity is not well understood.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> AEDs control seizure disorders by various mechanisms, which include:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Slowing the entrance of sodium and calcium back into the neuron and, thus extending the time it takes for the nerve to return to its active state.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Suppressing neuronal firing, which decreases seizure activity and prevents propagation of seizure activity into other areas of the brain.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Decreasing seizure activity by enhancing the inhibitory effects of gamma butyric acid (GABA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phenobarbital">Phenobarbital<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phenobarbital" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Phenobarbital is used for partial seizures and generalized tonic clonic seizures.</li>
<li>This medication is not effective against absence seizures.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phenytoin">Phenytoin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phenytoin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>phenytoin effective against all major forms of epilepsy except absence seizures.</li>
<li>Use IV route for status epilepticus.</li>
</ul>
<p>Phenytoin is an ant dysrhythmic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="carbamazepine">Carbamazepine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#carbamazepine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Carbamazepine is used for the treatment of partial (simple and complex) seizures, tonic-clonic seizures, bipolar disorder, and trigeminal and glossopharyngeal neuralgias.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-use-cont">Therapeutic use Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-use-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ethosuximide is only indicated for absence seizures.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="valproic-acid">Valproic Acid<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#valproic-acid" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Valproic acid is used for partial, generalized, and absence seizures; bipolar disorder; and migraine headaches.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="gabapentin">Gabapentin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gabapentin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Gabapentin is used as a single agent for control of partial seizures.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> This medication is also used for neuropathic pain and the prevention of migraine headaches.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="diazepam">Diazepam<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diazepam" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Diazepam is used in status epilepticus.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-drug-reaction-of-anti-epileptics-anticonvulsant-medication">Adverse drug reaction of anti epileptics/ anticonvulsant medication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-drug-reaction-of-anti-epileptics-anticonvulsant-medication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Almost all cause undesired effects
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> All cross the placenta barrier;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Cleft lip, cardiac malformation; phenobarbitone, phenytoin.
Spina bifida; folate deficiency induced by sodium valproate, phenytoin, phenobarbital</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="phenytoin">Phenytoin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phenytoin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> This is the oldest non sedative anti seizure drug introduced in 1938.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It blocks sodium channels and inhibit the generation of rapidly repetitive action potentials.</p>
<p>Pharmacokinetics
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> oral ,IM, IV.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="metabolism">Metabolism;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Is in the liver.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects-of-phenytoin">Side /Adverse Effects of Phenytoin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects-of-phenytoin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CNS effects (nystagmus, sedation, ataxia, double vision, cognitive impairment)
Monitor for symptoms and notify the provider if symptoms occur.
Gingival hyperplasia (softening and overgrowth of gum tissue, tenderness, and bleeding gums)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Advise clients to maintain good oral hygiene (dental flossing, massaging gums).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Skin rash <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> Stop medication if rash develops.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Teratogenic (cleft palate, heart defects)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Avoid use in pregnancy..</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects-of-phenytoin">Side /adverse Effects of Phenytoin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects-of-phenytoin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cardiovascular effects (dysrhythmias, hypotension)
Administer at slow IV rate and in dilute solution to prevent adverse CV effects.
Endocrine and other effects (coarsening of facial features, hirsutism, and interference with vitamin D metabolism)
Instruct clients to report changes.
Encourage clients to consume adequate amounts of calcium and vitamin D.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="psychothepeutic-agents">PSYCHOTHEPEUTIC AGENTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#psychothepeutic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These are Antipsychotics, Antidepressants and Mood Stabilizers ANTIDEPRESSANTS
Depression is a mood (affective) disorder and is a widespread problem, ranking high among causes of disability.
Clients starting antidepressant medication therapy for depression need to be advised that symptom relief can take 1 to 3 weeks and possibly 2 to 3 months for full benefits to be achieved. Encourage continued adherence.
Clients with major depression may require hospitalization with close observation and suicide precautions until the antidepressant medications reach their peak effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antidepressants-cont">Antidepressants Cont.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antidepressants-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Antidepressant mediations are classified into four main groups:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Tricyclic antidepressants
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Selective serotonin reuptake inhibitors (SSRIs)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Monoamine oxidase inhibitors (MAOIs)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Atypical antidepressant
a)Tricyclic antidepressant;</p>
<p>Amitriptyline (Elavil), Imipramine (Tofranil), Doxepin (Sinequan), Nortriptyline (Aventyl), Amoxapine (Asendin),
Trimipramine (Surmontil)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action-of-antidepressants">Mechanism of Action of Antidepressants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-antidepressants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Tricyclic antidepressant medications block reuptake of norepinephrine and serotonin in the synaptic space, thereby intensifying the effects of these neurotransmitters.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Depression
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Chronic pain
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Childhood Enuresis
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Obsessive compulsive disorders (clomipramine)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects-of-antidepressants">Side Effects of Antidepressants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects-of-antidepressants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Sedation
Anticholinergic Effects
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Dry mouth
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Blurred vision
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Photophobia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Urinary hesitancy or retention
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Constipation
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Seizures and impotence</p>
<ul>
<li>older patients; dizziness, postural hypotension, constipation, delayed micturition, edema, muscle tremors.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="tricyclic-overdose">Tricyclic Overdose<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tricyclic-overdose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Lethal 70 to 80 percent die before reaching the hospital
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> CNS and cardiovascular systems are affected.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> death results from seizures and dysrhythmias
No specific antidote
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Decrease drug absorption with activated charcoal
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Speed elimination by alkalinizing urine
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Manage seizures and dysrhythmias
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Basic life support</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Antipsychotics and steroids may inhibit TCAs
Aspirin may displace TCAs from binding site
TCAs and alcohol potentiate the effects of each other hence death due to severe respiratory distress.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="monoamine-oxidase-inhibitors-maoi-s">Monoamine Oxidase Inhibitors (MAOI s)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#monoamine-oxidase-inhibitors-maoi-s" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Phenelzine (Nardil)
Isocarboxazid (Marplan)
Tranylcypromine (Parnate)
Selegiline (Emsam) - transdermal MAOI
Mechanism of action
MAOIs inhibit the MAO enzyme system in the CNS.
Amines ( Norepinephrine, Dopamine And Serotonin) resulting in higher levels in the brain to transmit impulses.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-use">Therapeutic use<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Highly effective considered second line treatment for depression not responsive to cyclics.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Atypical depression
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Bulimia nervosa
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Obsessive compulsive disorders (OCD)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-effects">Side effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Few side effects most common; orthostatic hypotension.
Tachycardia, dizziness, insomnia, anorexia, blurred vision, palpitation, drowsiness, headache, nausea, impotence</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="maois-overdose">MAOIs overdose<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#maois-overdose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Symptoms appear 12 hours after ingestion.
these are; tachycardia, circulatory collapse, seizure, coma.
Treatment;
gastric lavage
Urine acidification
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> hemodialysis</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="maois-hypertensive-crisis-and-tyramine">Maois Hypertensive Crisis And Tyramine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#maois-hypertensive-crisis-and-tyramine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ingestion of food/drinks with amino acid tyramine leads to hypertensive crisis, which may lead to cerebral hemorrhage, stroke, coma, or death
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Avoid foods that contain tyramine;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Aged mature cheese
Smoked/pickled or aged meat, fish, poultry(herring ,sausages, corned beef, salami, pepperoni).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Red wine(chianti, sherry, vermouth)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Italian broad beans (fava).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> MAOIs are Pregnancy Risk Category C.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> These medications are contraindicated in clients taking SSRIs and in those with pheochromocytoma, heart failure, cardiovascular and cerebral vascular disease, and severe renal insufficiency.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Use cautiously in clients with diabetes and seizure disorders or those taking TCAs.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Transdermal selegiline is contraindicated for clients taking carbamazepine (Tegretol) or oxcarbazepine (Trileptal), which may increase blood levels of the MAOI.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="selective-serotonin-reuptake-inhibitors-ssris">Selective Serotonin Reuptake Inhibitors (SSRIs)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#selective-serotonin-reuptake-inhibitors-ssris" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Fluoxetine (Prozac)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Citalopram (Celexa)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Escitalopram oxalate (Lexapro)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Paroxetine (Paxil)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Sertraline (Zoloft)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacodynamics">Pharmacodynamics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> SSRI inhibit the reuptake of only serotonin at the part of the amine pump that is specifically for reuptake of serotonin.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> This explains why these drugs have lesser unwanted effects compared to TCAs.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> the drug of choice for Depression.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Major depression
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Obsessive compulsive disorders (OCD)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Bulimia nervosa
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Premenstrual dysphoric disorders
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Panic disorders
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Posttraumatic disorder (PTSD)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>SSRIs are well absorbed orally</li>
<li>Wide distribution and half life of fifteen to 24 hour but fluoxetine has a half life of 24 to ninety six hours.</li>
<li>They achieve effects within 2 to 4 weeks.</li>
<li>Paroxetine and fluoxetine are not used with TCAs since they inhibit TCA hepatic metabolism</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="unwanted-effects">- Unwanted effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#unwanted-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This include nausea and vomiting, diarrhea, agitation, anorgasmia priapism.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>MAOIs, TCAs, and St. John's wort increase the risk of serotonin syndrome.</li>
<li>Fluoxetine can displace warfarin (Coumadin) from bound protein and result in increased warfarin levels.</li>
<li>Fluoxetine can increase the levels of tricyclic antidepressants and lithium.</li>
<li>Fluoxetine suppresses platelet aggregation and thus increases the risk of bleeding when used concurrently with NSAIDs and anticoagulants.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="second-generation-antidepressants">Second Generation Antidepressants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#second-generation-antidepressants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="newer">Newer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#newer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Fewer side effects than tricyclic but not superior in overall efficacy or onset of action.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="examples-are">Examples are<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#examples-are" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Trazodone,
Bupropion
Duloxetine</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>selective inhibition of serotonin uptake
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Advantage over tricyclic and MAOIs little or no effect on cardiovascular system.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Depression, bipolar affective disorders, obesity, eating disorders, obsessive compulsive disorders, panic attacks, myoclonus, treatment for various substance abuse problems (bupropion is used for smoking cessation treatment)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CNS; headache, dizziness, nervousness, insomnia, fatigue and tremors.
GI; nausea, diarrheal, constipation, dry mouth, sweating, sexual dysfunction .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antipsychotic-tranquilizers-neuroleptics">ANTIPSYCHOTIC/ TRANQUILIZERS/NEUROLEPTICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antipsychotic-tranquilizers-neuroleptics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Classification of neuroleptic is based on chemical structure or severity of resulting unwanted effects.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Based on unwanted effect;
Conventional (typical, first generation)
Examples;
Chlorpromazine, haloperidol, and fluphenazine
Newer (atypical, second generation)
Example; clozapine, loxapine, asenapine, olanzapine, quetiapine, paliperidone, risperidone, sertindole.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a4b572ad">Classification cont. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7519em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span><span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a4b572ad" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>The distinction between typical and atypical neuroleptic is not clear but rest on ; receptor profile, incidence of extrapyramidal effects which are less in the atypical group, efficacy in treatment and efficacy in negative symptoms.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-according-to-chemical-structures">Classification according to chemical structures;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-according-to-chemical-structures" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Phenothiazines; chlorpromazine 100 to 1500 mg , trifluoperazine, fluphenazine 1 to 10 mg</p>
<p>Butyrophenones; haloperidol 2 to 20mg
Dibenzodiazepine; clozapine 25 to 900mg
Thienobenzodiazepines; olanzapine
Thioxanthene's; flupentixol 6 to 18mg
Benzisoxazole; risperidone 1to 12mg</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacodynamics">Pharmacodynamics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacodynamics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> They act by blocking the dopamine receptor.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indication">Indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Treatment of acute and chronic psychosis
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Schizophrenia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Bipolar disorders (primarily the manic phase)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Tourette's syndrome
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Delusional and schizoaffective disorders
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Dementia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Prevention of nausea/vomiting through blocking of dopamine in the chemoreceptor trigger zone of the medulla
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> hiccups</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects-typical-antipsychotic">Side Effects Typical Antipsychotic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects-typical-antipsychotic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Extrapyramidal effects (dystonia, parkinsonism, tardative dyskinesia)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Anticholinergic effects; (dry mouth, blurred vision, urinary retention, constipation and impotence)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Cardiovascular effects; tachycardia, arrhythmias, postural hypotention
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Galactorrhea,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> gynecomastia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effect-atypical-antipsychotics">Side Effect Atypical Antipsychotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effect-atypical-antipsychotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Clozopine; weight gain, agranulocytosis
Risperidone; insomnia anxiety, agitation
Olanzapine; weight gain, dizziness, sedation, anticholinergic effect</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mood-stabilizers">Mood Stabilizers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mood-stabilizers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lithium-carbonate">lithium carbonate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lithium-carbonate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Lithium produces neurochemical changes in the brain, including serotonin receptor blockade.
There is evidence that the use of lithium can show a decrease in neuronal atrophy and/or an increase in neuronal growth.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Lithium is used in the treatment of bipolar disorders. Lithium controls episodes of acute mania, helps prevent the return of mania or depression, and decreases the incidence of suicide.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Other uses:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Alcoholism
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Bulimia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Schizophrenia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Absorption :rate and extent vary with dose form. absorption is complete within hours of oral use.
Distribution :wide distribution in the body, concentration in thyroid gland, bone and brain tissue exceed serum levels.
Metabolism :not metabolized
Excretion : excreted unchanged in urine. Half lif18 hours (adolescence)to 3 hour (elderly).
Dosage adults : 300 mg to six hundred mg up to q.i.d increasing to achieve optimal dosage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reaction">Adverse reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Gastrointestinal distress (nausea, diarrhea, abdominal pain).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Fine hand tremors that can interfere with purposeful motor skills and can be exacerbated by factors such as stress and caffeine.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Polyuria, mild thirst.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Weight gain
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Renal toxicity
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Goiter and hypothyroidism with long-term treatment Brady dysrhythmia, hypotension, and electrolyte imbalances .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Lithium is Pregnancy Risk Category D. This medication is teratogenic, especially during the first trimester.
Discourage clients from breastfeeding if lithium therapy is necessary.
Use cautiously in clients with renal dysfunction, heart disease, sodium depletion, and dehydration</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Sodium is excreted with the use of diuretics. Reduced serum sodium decreases lithium excretion, which can lead to toxicity.
Concurrent use of NSAIDs (ibuprofen [Motrin] and celecoxib [Celebrex]) will increase renal reabsorption of lithium, leading to toxicity.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Avoid use of NSAIDs.
Use aspirin as a mild analgesic.
Anticholinergics (antihistamines, tricyclic antidepressants) can induce urinary retention and polyuria, leading to abdominal discomfort
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Advise clients to avoid medications with anticholinergic effects. rt.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precaution-during-administration">Precaution during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precaution-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Monitor plasma lithium levels while undergoing treatment. At initiation of treatment, monitor levels every 2 to 3 days and then every 1 to 3 months. Lithium blood levels should be obtained in the morning, usually 12 hr . after the last dose.
During initial treatment of a manic episode, levels should be between 0.8 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">1.4 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.4</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>.
Maintenance level range is between 0.4 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">1.0 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>.
Plasma levels <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">&gt;1.5 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> can result in toxicity.
Care for clients who have a toxic plasma lithium level in an inpatient setting and provide supportive measures. Hemodialysis may be indicated.
Advise clients that effects begin within 7 to 14 days.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precaution-during-administration-cont">Precaution during Administration cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precaution-during-administration-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Advise clients to take lithium as prescribed. Lithium must be administered in 2 to 3 doses daily due to a short half life. Taking lithium with food will help decrease GI distress.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Encourage clients to adhere to laboratory appointments needed to monitor lithium effectiveness and adverse effects. Emphasize the high risk of toxicity due to the narrow therapeutic range.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Provide nutritional counseling. Stress the importance of adequate fluid and sodium intake.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Instruct clients to monitor for signs of toxicity and when to contact the provider. Clients should stop taking medication and seek medical attention if experiencing diarrhea, vomiting, or excessive sweating.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-mood-stabilizing-drugs">Other mood stabilizing drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-mood-stabilizing-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Carbamazepine (Tegretol)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Valproic acid (Depakote)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Lamotrigine (Lamictal) Purpose</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>AEDs help treat and manage bipolar disorders by various mechanisms, which include:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Slowing the entrance of sodium and calcium back into the neuron and, thus extending the time it takes for the nerve to return to its active state.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Potentiating the inhibitory effects of gamma butyric acid (GABA)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Inhibiting glutamic acid (glutamate) which in turn suppresses CNS excitation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Treatment of manic and depressive episodes, prevention of relapse of mania and depressive episodes.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Especially useful for clients with mixed mania and rapid cycling bipolar disorders.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cns-stimulants">CNS STIMULANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cns-stimulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>MEDICATION</th><th>SHORT ACTING</th><th>INTERMEDIATE ACTING</th><th>LONG ACTING</th></tr></thead><tbody><tr><td>Methylphenidate</td><td>Ritalin, Methylin</td><td>Ritalin SR, Methylin ER</td><td>ethylin ER Ritalin LA, Concerta,</td></tr><tr><td>Daytrana (transdermal)</td><td></td><td></td><td></td></tr><tr><td>Dexmethylphenidate</td><td>Focalin</td><td></td><td></td></tr><tr><td>Dextroamphetamine</td><td>Dexedrine</td><td></td><td>Dexedrine Spansule</td></tr><tr><td>Amphetamine mixture</td><td>Adderall</td><td></td><td>Adderall-XR</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cns-stimulants-cont">CNS Stimulants Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cns-stimulants-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action :<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These medications raise the levels of norepinephrine, serotonin, and dopamine into the CNS.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>ADHD ( Attention Deficit Hyperactivity Disorder)</li>
<li>Conduct disorder</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> CNS stimulation (insomnia, restlessness)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Weight loss
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Cardiovascular effects (dysrhythmias, chest pain, high blood pressure) - These medications may increase the risk of sudden death in clients with heart abnormalities.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Development of psychotic symptoms such as hallucinations, paranoia Withdrawal reaction.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hypersensitivity skin reaction to transdermal methylphenidate (hives, papules)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These medications are contraindicated in clients who have a history of drug abuse, cardiovascular disorders, severe anxiety, and psychosis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Concurrent use of MAOI s may cause hypertensive crisis.
Concurrent use of caffeine may increase CNS stimulant effects.
Methylphenidate inhibits metabolism of phenytoin (Dilantin), warfarin (Coumadin), and phenobarbital, leading to increased serum levels.
OTC cold and decongestant medications with sympathomimetic action can increase CNS stimulant effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="muscle-relaxant-neuromuscular-blocking-agents">MUSCLE RELAXANT/ NEUROMUSCULAR BLOCKING AGENTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#muscle-relaxant-neuromuscular-blocking-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Neuromuscular blocking agents have various uses including assisting with:</li>
<li>sedation during general anesthesia,</li>
<li>control of seizures during electroconvulsive therapy,</li>
<li>suppression of gag reflex during endotracheal intubation.</li>
<li>Medications include succinylcholine (Anectine) and vecuronium (Norcuron)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-parkinson-s-drugs">Anti -Parkinson's drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-parkinson-s-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="neuromuscular-agents-cont">Neuromuscular Agents Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#neuromuscular-agents-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Muscle relaxants and antispasmodic agents can affect both the central and peripheral nervous systems.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> These agents are used with spasticity related to muscle injury, cerebral palsy, spinal cord injury, and multiple sclerosis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Agents include diazepam (Valium), baclofen (Lioresal), and dantrolene (Dantrium).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Bethanechol (Urecholine), a muscarinic agonist, is used for urinary retention.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Oxybutynin (Ditropan), a muscarinic antagonist, is used for neurogenic bladder</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="muscle-relaxant-neuromuscular-blocking-agents-cont">Muscle relaxant/ Neuromuscular Blocking Agents cont.'<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#muscle-relaxant-neuromuscular-blocking-agents-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Depolarizing neuromuscular blocker: succinylcholine (Anectine)
Nondepolarizing neuromuscular blockers: pancuronium (Pavulon)
Other Medications:
Nondepolarizing neuromuscular blockers: atracurium (Tracrium), Vecuronium (Norcuron)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Neuromuscular blocking agents block acetylcholine (ACh) at the neuromuscular junction, resulting in muscle relaxation and hypotension. They do not cross the blood-brain barrier, so complete paralysis can be achieved without loss of consciousness or decreased pain sensation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="neuromuscular-agents-cont">Neuromuscular Agents Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#neuromuscular-agents-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Neuromuscular blocking agents are used as adjuncts to general anesthesia to promote muscle relaxation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> These agents are used to control spontaneous respiratory movements in clients receiving mechanical ventilation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> These agents are used as seizure control during electroconvulsive therapy.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Neuromuscular blocking agents are used during endotracheal intubation and endoscopy</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Respiratory arrest from paralyzed respiratory muscles
Hypotension
Low pseudo cholinesterase activity can lead to prolonged apnea
Signs of malignant hyperthermia include muscle rigidity accompanied by increased temperature, reaching levels as high as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>43</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">43^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">4</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">C</mi><mrow><mo fence="true">(</mo><msup><mn>109.4</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">F</mi><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{C}\left(109.4^{\circ} \mathrm{F}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">C</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord">109.</span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">F</span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>.
After 12 to 24 hr . postoperative, clients may experience muscle pain in the upper body and back.
Hyperkalemia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>General anesthetics are often used concurrently in surgery.</p>
<ul>
<li>Dosage of tubocurarine should be reduced to prevent extreme neuromuscular blockade.
Aminoglycosides and tetracyclines can increase the effects of neuromuscular blockade.</li>
<li>Take complete medication history of clients who are to receive neuromuscular blockade.
Neostigmine and other cholinesterase inhibitors increase the effects of depolarizing neuromuscular blockers, such as succinylcholine.</li>
<li>Monitor clients during neuromuscular blockade reversal after surgery</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="local-anaesthetics">LOCAL ANAESTHETICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#local-anaesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>local anesthetic bind reversibly to a specific receptor site within the pore of the sodium channels in nerves and block ion movement when applied locally to nerve tissues in appropriate concentration.
Local anesthetic can act on any part of the nervous system, on every type of nerve fibers, reversibly blocking the action potentials responsible for nerve conduction.
Thus a local anesthetic in contact with a nerve trunk can cause both sensory and motor paralysis in the area innervated.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Local anesthetic block conduction by decreasing or preventing the large transient increase in the permeability of excitable membranes.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> This action is due to direct interaction with voltage gated sodium channels.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> As the anesthetic action progressively develops in the nerve ,the threshold for electrical excitability increase. The rate of rise of the action potential also declines, impulse conduction slows, and nerve conduction eventually fails.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="local-anesthetics">Local anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#local-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>Drug</th><th>Duration of action</th></tr></thead><tbody><tr><td>lidocaine</td><td>medium</td></tr><tr><td>Bupivacaine (Marcaine),levobupivacaine (chirocaine)</td><td>long</td></tr><tr><td>Ropivacaine (naropin)</td><td>long</td></tr><tr><td>Mepivacaine (carbocaine, isocaine)</td><td>medium</td></tr><tr><td>articaine</td><td>medium</td></tr><tr><td>Cocaine</td><td>medium</td></tr><tr><td>benzocaine</td><td>surface use only</td></tr><tr><td>Tetracaine (pontocaine)</td><td>long</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="neuromuscular-agents">Neuromuscular agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#neuromuscular-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The action of non depolarizing muscle relaxant is antagonized, once muscle paralysis is no longer desired with an acetylcholinesterase inhibitor such as neostigmine or edrophonium.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="skeletal-muscle-relaxants">Skeletal Muscle Relaxants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#skeletal-muscle-relaxants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="succinylcholine">Succinylcholine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#succinylcholine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Succinylcholine mimics ACh by binding with cholinergic receptors at the neuromuscular junction. This agent fills the cholinergic receptors, preventing ACh from binding with them, and causes sustained depolarization of the muscle, resulting in muscle paralysis.
Reversal agent: Pseudo cholinesterase enzyme</li>
<li>Pancuronium, atracurium, vecuronium</li>
<li>These agents block ACh from binding with cholinergic receptors at the motor end plate. Muscle paralysis occurs because of inhibited nerve depolarization and skeletal muscle contraction.</li>
<li>Reversal agent: Neostigmine (Prostigmin)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="general-anesthetics">General Anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>General anesthetics depress the CNS sufficiently to permit surgery and other noxious or unpleasant procedures.
Gas have a low therapeutic indices and are require great care in administration.
The consideration of patients age, associated medical condition and medication use is important.
The physiological state induced by general anesthesia include; analgesia, amnesia, loss of consciousness, inhibition of sensory and autonomic reflexes, and skeletal muscle relaxation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-parenteral-anesthetics">a)Parenteral anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-parenteral-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetic-principle">Pharmacokinetic principle<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetic-principle" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>After a single intravenous bolus these drugs preferentially partition into the highly perfused and lipophilic tissues of the brain and the spinal cord where they produce anesthesia within a single circulation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Blood levels falls rapidly, resulting in drug redistribution out of the cns back into the blood.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> The anesthetics then perfuse into less perfused tissues such as muscle and viscera, and at a slower rate into the poorly perfused but very hydrophobic adipose tissue.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="parenteral-anesthetics">Parenteral Anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#parenteral-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*Thiopental and Propofol are the two most commonly used parenteral agents.
*thiopental has a long established track record of safety.
*Propofol is advantageous for procedures where rapid return to a preoperative mental status is desirable.
*Etomidate usually is reserved for patients at risk for hypotension and /myocardial ischemia
*Ketamine is best suited for patients with asthma, children undergoing short ,painful procedures</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-characteristics-of-parenteral-anesthetics-iv">Pharmacological characteristics of parenteral anesthetics (IV)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-characteristics-of-parenteral-anesthetics-iv" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>DRUG</th><th>INDUCTION AND RECOVERY</th><th>COMMENTS</th></tr></thead><tbody><tr><td>etomidate</td><td>Rapid onset and moderate fast recovery</td><td>Provides cardiovascular stability, causes decreased steroidal genesis and involuntary muscle movement</td></tr><tr><td>ketamine</td><td>Moderate onset and recovery</td><td>Causes cardiovascular stimulation, increase cerebral blood flow and emergence reaction that impair recovery</td></tr><tr><td>midazolam</td><td>Slow onset and recovery; flumazenil reversal available</td><td>Provides cardiovascular stability and marked amnesia, used in balanced anesthesia and conscious sedation.</td></tr><tr><td>Propofol</td><td>Rapid onset and recovery</td><td>Used in induction and maintenance can cause hypotension ,has useful antiemetic action.</td></tr><tr><td>thiopental</td><td>Rapid onset and recovery (bolus dose) slow recovery following infusion.</td><td>Standard induction agent, causes cardiovascular depression, avoid in porphyria's</td></tr><tr><td>fentanyl</td><td>Slow onset and recovery.</td><td></td></tr><tr><td>Naloxone reversal available</td><td>opioid used in balanced anesthesia and conscious sedation produces marked analgesia</td><td></td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="inhalation-anesthetics">Inhalation Anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inhalation-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They have a low safety margin.
The selection of inhalation anesthetic is often marching a patient pathophysiology with drug side effects.
The inhalation anesthetics also vary widely in their physical properties, which govern the pharmacokinetics of the inhalation agents
They produce a rapid induction of anesthesia and a rapid recovery following discontinuation.
Examples are: nitrous oxide, halothane, desflurane, sevoflurane, enflurane, and methoxyflurane.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effect-of-anesthetics">Side effect of Anesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effect-of-anesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hemodynamic effect e.g. decrease in systemic arteria BP.
respiratory effects; elimination of both ventilatory drive and reflex that maintain airway patency, gag reflex is lost, no cough stimulus, lower esophageal sphincter tone is reduced.
Hypothermia, nausea and vomiting.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-emergence-postoperative-effects">Other Emergence Postoperative effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-emergence-postoperative-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypotension and tachycardia,myocardial ischemia,post anesthesia shivering, (give small dose of meperidine 12 mg lowers the shivering triggers temperature.
Airway obstruction
Respiratory suppression
Hypoxemia may occur
Negative pressure pulmonary edema may occur due to strong inspiratory efforts against a closed glottispain control can be complicated
These emergence phenomena can be greatly reduced when opioids are employed as part of the intraoperative regimen</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cvs-diuretics">CVS: DIURETICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cvs-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diuretics are drugs that increase the rate of urine flow; clinically useful diuretics also increase the rate of excretion of sodium and accompanying anion chloride.
Most clinical application of diuretics aim to reduce extracellular fluid volume by decreasing total sodium chloride volume.
diuretics alter excretion of sodium and also may modify handling of other cations(potassium, hydrogen and magnesium) anions (chloride, bicarbonate, hydrogen phosphate ), and uric acid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-pharmacology-of-diuretics">Clinical Pharmacology of Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-pharmacology-of-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*Edematous state :in heart failure, kidney disease and in renal failure.
*Non edematous state : in hypertension, nephrolithiasis hypercalcemia.</p>
<p>Classification of diuretics
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Loop Diuretics : furosemide</p>
<blockquote>
<p>Thiazide Diuretics: hydrochlorothiazide
Potassium Sparing diuretics: spironolactone
Osmotic Diuretic: mannitol
Carbonic Anhydrase Inhibitors: acetazolamide (DIAMOX)</p>
</blockquote>
<p>Hormones Acting on the Nephron / Diuretics and Their Site of Action</p>
<p><img src="data:image/jpeg;base64,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" alt="img-2.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-high-ceiling-loop-diuretics">a)High Ceiling Loop Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-high-ceiling-loop-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="furosemide-lasix">Furosemide (Lasix)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#furosemide-lasix" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Other Medications:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Ethacrynic acid (Edecrin)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Bumetanide (Bumex)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Torsemide (Demadex)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> High ceiling loop diuretics work in the ascending limb of loop of Henle to:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Block reabsorption of sodium and chloride and to prevent reabsorption of water, Cause extensive diuresis even with severe renal impairment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses-of-furosemide-lasix">Therapeutic Uses of Furosemide (Lasix)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses-of-furosemide-lasix" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>High ceiling loop diuretics are used when there is an emergent need for rapid mobilization of fluid such as:
*Pulmonary edema caused by heart failure</li>
<li>Conditions not responsive to other diuretics such as edema caused by liver, cardiac, or kidney disease; hypertension</li>
<li>These medications may also be used to treat hypercalcemia related to kidney stone formation.</li>
<li>Route of administration: Oral, IV, IM.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Dehydration, hyponatremia, hypochloremia.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hypotension
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Ototoxicity (transient with furosemide and irreversible with ethacrynic acid)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hypokalemia ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">K</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{K}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">K</span><span class="mord">+</span></span></span></span></span> less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">3.5 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.5</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Other adverse effects (hyperglycemia, hyperuricemia, and decrease in calcium and magnesium levels)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Contraindications/Precautions ;Pregnancy Risk Category C , Avoid using these medications during pregnancy unless absolutely required. Use cautiously in clients who have diabetes and/or gout</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug Interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Digoxin (Lanoxin) toxicity can occur in the presence of hypokalemia.</li>
<li>Concurrent use of antihypertensive can have additive hypotensive effect.</li>
<li>Hyponatremia can lead to decrease in lithium carbonate excretion, which may lead to toxicity.</li>
<li>NSAIDs reduce diuretic effect.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Obtain the client's baseline data to include orthostatic blood pressure, weight, electrolytes, and location and extent of edema.</li>
<li>Weigh clients at the same time each day; usually upon awakening.</li>
<li>Monitor the client's blood pressure and I&amp;O.</li>
<li>Avoid administering the medication late in the day to prevent nocturia. Usual dosing time is 0800 and 1400.</li>
<li>Administer furosemide orally, IV bolus dose, or continuous IV infusion. Infuse IV doses at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> or slower to avoid abrupt hypotension and hypovolemia.
*If potassium level drops below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">3.5 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.5</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>, clients should be placed on a potassium supplement.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-cont">Precautions During Administration Cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>If the medication is used for hypertension, teach clients to self-monitor blood pressure and weight by keeping a log.</li>
<li>Advise clients to get up slowly to minimize postural hypotension. If faintness or dizziness occurs, instruct clients to sit or lie down.</li>
<li>Teach clients to report significant weight loss, lightheadedness, dizziness, GI distress, and/ or general weakness to the provider.</li>
<li>Encourage clients to consume foods high in potassium, such as avocados and strawberries.</li>
<li>Instruct clients with diabetes to monitor for elevated blood glucose levels.</li>
<li>Instruct clients to observe for signs of low magnesium levels such as muscle twitching and tremors.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b-thiazide-diuretics">b)Thiazide Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-thiazide-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Hydrochlorothiazide (Hydrodiuril)
Other Medications:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Chlorothiazide (Diuril)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Methyclothiazide (Enduron)
Thiazide-type diuretics:
indapamide (Lozide, Lozol)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> chlorthalidone (Hygroton)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> metolazone (Zaroxolyn)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Thiazide diuretics work in the early distal convoluted tubule to:</li>
<li>Block the reabsorption of sodium and chloride, and prevent the reabsorption of water at this site</li>
<li>Promote diuresis when renal function is not impaired</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Thiazide diuretics are often the medication of first choice for essential hypertension.
These medications may be used for edema of mild-to-moderate heart failure and liver and kidney disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Dehydration
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hypokalemia (K+ less than 3.5 mEq/L)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hyperglycemia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Digoxin (Lanoxin) toxicity can occur in the presence of hypokalemia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Antihypertensive have additive hypotensive effects. Monitor the client's blood pressure.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hyponatremia can lead to decrease in lithium (Eskalith) excretion, which may lead to toxicity.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> NSAIDs reduce diuretic effect</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Chlorothiazide may be administered orally and IV, all others can only be given orally.</li>
<li>Obtain the client's baseline data to include orthostatic blood pressure, weight, electrolytes, and location and extent of edema.</li>
<li>Monitor the client's potassium levels</li>
<li>Instruct clients to take the medication first thing in the morning; if twice-a-day dosing is prescribed, be sure the second dose is taken by 1400 to prevent nocturia.</li>
<li>Encourage clients to consume foods high in potassium and maintain adequate fluid intake ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>500</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">1,500 \mathrm{~mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">500</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mL</span></span></span></span></span></span> per day, unless contraindicated).</li>
<li>If GI upset occurs, clients should take the medication with or after meals.</li>
<li>Alternate-day dosing can decrease electrolyte imbalance</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="c-potassium-sparing-diuretics">c)Potassium-Sparing Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-potassium-sparing-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Spironolactone (Aldactone)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-medications">Other Medications:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-medications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>t\Triamterene (Dyrenium), amiloride (Midamor)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Potassium-sparing diuretics block the action of aldosterone (sodium and water retention), which results in potassium retention and the secretion of sodium and water.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Potassium-sparing diuretics are combined with other diuretics for potassium-sparing effects.
*Potassium-sparing diuretics are used for heart failure.
*In primary hyperaldosteronism, potassium-sparing diuretics block actions of aldosterone.</li>
</ul>
<p>Route of administration: Oral</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-adverse-effects">Side/Adverse Effects;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hyperkalemia (K+ greater than 5.0 mEq/L)
*Endocrine effects (impotence in male clients; irregularities of menstrual cycle in female clients).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precaution">Contraindications/Precaution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precaution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Do not administer to clients who have hyperkalemia.</li>
<li>Potassium-sparing diuretics are contraindicated in clients who have severe renal failure and anuria.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interaction">Medication/Food Interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Concurrent use of ACE inhibitors increases the risk of hyperkalemia
Concurrent use of potassium supplements increases the risk of hyperkalemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Obtain the client's baseline data.</li>
<li>Monitor the client's potassium levels regularly.</li>
<li>Can only be given orally.</li>
<li>Teach clients to avoid salt substitutes that contain potassium.</li>
<li>Teach clients to self-monitor blood pressure.</li>
<li>Instruct clients to keep a log of blood pressure and weight.</li>
<li>Warn clients that triamterene may turn urine a bluish color.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="d-osmotic-diuretics">d)Osmotic Diuretics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-osmotic-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Mannitol (Osmitrol)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Osmotic diuretics reduce intracranial pressure and intraocular pressure by raising serum osmolality and drawing fluid back into the vascular and extravascular space.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Osmotic diuretics prevent renal failure in specific situations, such as hypovolemic shock and severe hypotension.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> These medications decrease intracranial pressure (ICP) caused by cerebral edema.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> These medications decrease intraocular pressure (IOP).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Osmotic diuretics promote sodium retention and water excretion in clients with hyponatremia and fluid volume excess</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Renal failure
Heart failure, pulmonary edema
Fluid and electrolyte imbalances
Contraindications/Precautions
Use extreme caution in clients with heart failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Furosemide contributes to therapeutic effect by promoting renal excretion of fluid drawn into vasculature by osmotic diuretics.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Administer mannitol by continuous IV infusion.
To prevent administering microscopic crystals, use a filter needle when drawing from the vial and a filter in the IV tubing.
Monitor daily weight, I &amp; 0, and serum electrolytes.
Monitor for signs of dehydration, acute renal failure, and edema.
Use of furosemide may help prevent rebound fluid retention; this contributes to therapeutic effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="carbonic-anhydrase-inhibitors">Carbonic Anhydrase Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#carbonic-anhydrase-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Blockade of carbonic anhydrase activity induces a sodium bicarbonate diuresis, which reduces body bicarbonate levels.
These drugs include;
Acetazolamide (DIAMOX)
Dichlorphenamide (DARANIDE)
Methazolamide (GLAUCTABS)
Acetazolamide administration causes a reduction in aqueous humour and CSF fluid production</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acetazolamide-cont">Acetazolamide cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acetazolamide-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>The proximal tubule is the major site of action of carbonic anhydrase inhibitors.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> the collecting duct is the secondary site of action .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-application">Clinical application<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-application" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Glaucoma; because acetazolamide decreases the rate of aqueous humor production, a decline in IOP occurs.
The major indication of carbonate anhydrase inhibitor is open angle glaucoma.
It may also be given in secondary glaucoma
Preoperatively in acute angle glaucoma.
Treatment of epilepsy.
Altitude sickness familial periodic paralysis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="toxicity">Toxicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#toxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hyper chloremic acidosis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Renal potassium loss.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Hepatic cirrhosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antihypertensives">Antihypertensives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antihypertensives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cardiovascular-pharmacology">Cardiovascular pharmacology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-pharmacology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Antihypertensive drugs potential drug targets;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> CNS: decrease sympathetic tone
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Heart: decrease cardiac out put
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Veins: dilate; decrease preload
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> arterioles: dilate; decrease preload
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Kidneys: increase diuresis; inhibit renin angiotensin aldosterone</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-anti-hypertensives-diuretics">Classification of Anti Hypertensives Diuretics:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-anti-hypertensives-diuretics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Thiazide and related agents (hydrochlorothiazide, chlorthalidone)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Loop diuretics (furosemide, bumetanide,, torsemide, ethacrynic)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Potassium sparing diuretics (amiloride, triamterene, spironolactone)
Angiotensin-converting enzyme (ACE) inhibitors ( captopril, enalapril, lisinopril, quinapril, Ramipril, benazepril)</p>
<p>Angiotensin II receptor blockers (ARBS)
(losartan, candesartan, Irbesartan, valsartan, telmisartan, eprosartan)
Calcium channel blockers (CCB)
(verapamil, diltiazem, nifedipine, felodipine, nicardipine, isradipine, amlodipine),</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-antihypertensive-cont">Classification of Antihypertensive Cont..<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-antihypertensive-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vasodilators">Vasodilators<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vasodilators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Arterial ( hydralazine, minoxidil, diazoxide fenoldopam)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Arterial and venous (nitroprusside)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sympatholytic-drugs">Sympatholytic drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sympatholytic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Alpha adrenergic blockers; (prazosin, terazosin, doxazosin, phentolamine, phenoxybenzamine)
Beta adrenergic blockers; (metoprolol, atenolol, etc )
Mixed adrenergic; ( labetalol, carvedilol)
Centrally acting alpha2 agonists (methyldopa, clonidine, guanabenz)
Adrenergic neuron blocking agents;( guanethidine, reserpine)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angiotensin-converting-enzyme-ace-inhibitors">Angiotensin-Converting Enzyme (ACE) Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-converting-enzyme-ace-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="captopril-capoten">Captopril (Capoten)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#captopril-capoten" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span>Other Medications: Enalapril (Vasotec), Enalaprilat (Vasotec IV), Fosinopril (Monopril), Lisinopril (Prinivil), Ramipril (Altace)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>ACEIs prevents conversion of angiotensin I to angiotensin II which is a potent vasoconstrictor. this causes vasodilation, reduces peripheral resistance, and decreases secretion of aldosterone (thereby resulting in decrease sodium and water retention and extracellular volume).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="merits-of-aceis">Merits of ACEIs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#merits-of-aceis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>Safe for asthmatics, diabetics</p>
</li>
<li>
<p>Absence of rebound hypertension upon abrupt withdrawal.</p>
</li>
<li>
<p>Total absence of postural hypotension.</p>
</li>
<li>
<p>maintains renal blood flow.
*devoid of electrolyte imbalance.</p>
</li>
<li>
<p>Hypertension</p>
</li>
<li>
<p>Heart failure</p>
</li>
<li>
<p>Myocardial infarction (To decrease mortality and to decrease risk of heart failure and left ventricular dysfunction)</p>
</li>
<li>
<p>Diabetic and nondiabetic nephropathy</p>
</li>
<li>
<p>For clients at high risk for a cardiovascular event, Ramipril can be used to prevent MI, stroke, or death.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cough related to inhibition of kinase II (alternative name for ACE) which results in increase in bradykinin
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> First-dose orthostatic hypotension.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Hyperkalemia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Rash and dysgeusia (altered taste), primarily with captopril
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Angioedema.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Neutropenia (rare but serious complication of captopril)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These medications are Pregnancy Risk Category D during the second and third trimester, related to fetal injury.
renal stenosis when present bilaterally or in a single remaining kidney.
history of angioedema following use of ACE inhibitor.
Use cautiously in clients with renal impairment and
collagen vascular disease because they are at greater risk for developing neutropenia. Closely monitor these clients for signs of infection.
hypotension</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diuretics can contribute to first-dose hypotension
Antihypertensive medications may have an additive hypotensive effect.
Potassium supplements and potassium-sparing diuretics increase the risk of hyperkalemia.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> ACE inhibitors can increase levels of lithium carbonate (Eskalith)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Use of NSAIDs may decrease the antihypertensive effect of ACE inhibitors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Administer ACE inhibitors orally except enalapril, which is the only ACE inhibitor for IV use.</li>
<li>Advise clients that the medication may be prescribed as a single formulation or in combination with hydrochlorothiazide.</li>
<li>Advise clients that blood pressure has to be monitored after the first dose for at least 2 hr . to detect hypotension.</li>
<li>Instruct clients that captopril should be taken at least 1 hr . before meals. All other ACE inhibitors can be taken with or without food.
*Advise clients to notify the provider if cough, rash, dysgeusia (lack of taste), and/or signs of infection occur</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angiotensin-ii-receptor-blockers-arbs">Angiotensin II Receptor Blockers (ARBs)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-ii-receptor-blockers-arbs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="losartan-cozaar">Losartan (Cozaar)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#losartan-cozaar" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Other Medications: Valsartan (Diovan), Irbesartan (Avapro), Candesartan (Atacand), Olmesartan (Benicar)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These medications block the action of angiotensin II in the body.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="this-results-in">This results in:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#this-results-in" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Vasodilation (mostly arteriole)</li>
<li>Excretion of sodium and water, and retention of potassium (through effects on the kidney)</li>
</ul>
<p>*Hypertension,
*Heart failure and prevention of mortality following MI,</p>
<ul>
<li>Stroke prevention ,</li>
<li>Delay progression of diabetic nephropathy</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="complications">Complications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The major difference between ARBs and ACE inhibitors is that cough and hyperkalemia are not side effects of ARBs</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="angioedema">* Angioedema<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angioedema" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hypersensitivity</li>
<li>Pregnancy</li>
<li>renal stenosis when present bilaterally or in a single remaining kidney</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="considerations">Considerations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>monitor BP, HR, Weight, Edema, Blood Urea Nitrogen, Serum Creatinine.</li>
<li>can be used in patients intolerant to aceis (due to cough)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="calcium-channel-blockers">CALCIUM CHANNEL BLOCKERS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calcium-channel-blockers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Nifedipine (Adalat, Procardia)</li>
<li>Verapamil (Calan)</li>
<li>Amlodipine (Norvasc)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="other-medications">Other Medications:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-medications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Amlodipine (Norvasc)</li>
<li>Felodipine (Plendil)</li>
<li>Nicardipine (Cardene, Cleviprex)</li>
<li>Diltiazem (Cardizem)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action-of-ccb">Mechanism of action of CCB<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-ccb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Inhibits calcium influx in the smooth muscles and the myocardium.</li>
<li>Blocking of calcium channels in blood vessels leads to vasodilation of peripheral arterioles and arteries/arterioles of the heart, slows down heart conduction and reduction of blood pressure.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nifedipine-adalat">NIFEDIPINE (ADALAT)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nifedipine-adalat" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>give rise to coronary vasodilation.</li>
<li>Enhances coronary blood flow.</li>
<li>Reduces total periphery resistance, reduces systolic and diastolic pressure</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-use">Therapeutic use<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Chronic angina</li>
<li>Congestive heart failure</li>
<li>Acute myocardial infarction</li>
<li>Peripheral vascular disorders</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-drug-reaction">Adverse drug reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-drug-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Palpitation, nausea, vomiting, flushing, headache, edema.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="amlodipine">Amlodipine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#amlodipine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Serves as a long acting calcium channel blocker.</li>
</ul>
<p>Therapeutic use</p>
<ul>
<li>Treatment of essential hypertension.</li>
<li>Angina pectoris</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-drug-reaction">Adverse drug reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-drug-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Palpitation,epixtasis,cough,nocturia,musclecramps,breathless,importen ce, conjunctivitis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="verapamil">Verapamil<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#verapamil" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Enhances coronary blood flow rate,vasodilation.</li>
<li>Exerts anti arrhythmic action.</li>
<li>Reduces peripheral resistance.</li>
</ul>
<p>Therapeutic uses</p>
<ul>
<li>Supraventricular tachycardia.</li>
<li>Acute coronary spasms</li>
<li>Angina pectoris</li>
<li>Hypertension with myocardial infarction</li>
</ul>
<ul>
<li>Dizziness, vertigo, constipation, hypotension, nausea, pedal edema</li>
</ul>
<p>Advantages of calcium channel blockers
Exhibits rapid onset and longer duration of action hence administered once a day.
Do not exhibit cardiac depression.
Do not cause adverse effects on the fetus.
Cause no sedation.
Recommended for patients having angina and asthma.
Do not cause male impotence.
Mostly indicated for the elderly, pregnant and asthmatic.
safe with history of renal impairment.
Do not exhibit action on electrolyte balance.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="considerations">Considerations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Monitor BP, HR, rhythm,</li>
<li>Control calcium supplement.</li>
<li>Inform patient not to stop drug abruptly.</li>
<li>Patient to report signs of adverse effects such as irregular heart beat, shortness of breath, oedema in the hands and feet, dizziness, constipation, nausea and hypotension.</li>
<li>Discontinue in breast feeding because they are excreted in breast milk and have potential for adverse effects in neonates.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="direct-acting-vasodilators">DIRECT ACTING VASODILATORS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#direct-acting-vasodilators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hydralazine">HYDRALAZINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hydralazine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Hydralazine (APRESOLINE) causes direct relaxation of the arterio smooth muscle secondary to a fall in the intracellular calcium. this is associated with powerful stimulation of the sympathetic nervous system, due to baroreceptor mediated reflexes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="toxicity-and-precaution">Toxicity and Precaution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#toxicity-and-precaution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These includes; headache, nausea, flushing, hypotension, palpitation, tachycardia, dizziness and angina pectoris.</li>
<li>Myocardial ischemia (increased oxygen demand)</li>
<li>Immunological reactions, drug induced lupus syndrome. this occurs after six months of treatment with hydralazine.</li>
<li>symptoms include, arthralgia, arthritis and fever.</li>
<li>The treatment can result in an illness that resembles serum sickness, hemolytic anaemia, vasculitis, and glomerulonephritis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Due to adverse effect profile, hydralazine is no longer a first line drug in the treatment of hypertension.</li>
<li>Used in patients with CCF(in combination with nitrates for patients who cannot tolerate ACE inhibitors.</li>
<li>Treatment of hypertension emergencies in pregnancy.
*(especially preeclampsia).</li>
<li>The usual dose is twenty five to 100 mgs twice a day</li>
<li>He maximum recommended dose of hydralazine is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">200 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Parenteral administration in coronary artery disease.
Elderly patients</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="alpha-adrenergic-blockers-sympatholytics">ALPHA ADRENERGIC BLOCKERS (SYMPATHOLYTICS)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#alpha-adrenergic-blockers-sympatholytics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Medication: prazosin (Minipress)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> doxazosin mesylate (Cardura)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> It inhibits Alpha adrenergic receptor causing Venous and arterial dilation leading to reduction in total peripheral vascular resistance.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Smooth muscle relaxation of the prostatic capsule and bladder neck</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Primary hypertension.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Doxazosin mesylate (Cardura) may be used to decrease symptoms of benign prostatic hypertrophy (BPH), which include urgency, frequency, and dysuria.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="first-dose-orthostatic-hypotension">First-dose orthostatic hypotension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#first-dose-orthostatic-hypotension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Start treatment with low dosage of medication.
First dose may be given at night.
Monitor blood pressure for 2 hr . after the initiation of treatment.
Instruct clients to avoid activities requiring mental alertness for the first 12 to 24 hr .
Instruct clients to change positions slowly and to lie down if feeling dizzy, lightheaded, or faint</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Pregnancy
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> clients with hypersensitivity to medication
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Antihypertensive medications may have an additive hypotensive effect
Instruct clients to observe for signs of hypotension (dizziness, lightheadedness, faintness).
Instruct clients to lie down if these symptoms occur, and to change positions slowly.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> NSAIDs and clonidine may decrease the antihypertensive effects of prazosin.
Advise clients to avoid OTC NSAIDs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions-during-administration">Contraindications/Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Obtain baseline blood pressure and heart rate.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Instruct clients that the medication can be taken with food.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Recommend that clients take the initial dose at bedtime to decrease "first-dose" hypotensive effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="centrally-acting-alpha2-agonists-clonidine-catapres">CENTRALLY ACTING ALPHA2 AGONISTS Clonidine (Catapres)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#centrally-acting-alpha2-agonists-clonidine-catapres" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>guanfacine HCl (Tenex),</li>
<li>methyldopa (Aldomet)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>These medications act within the CNS to decrease sympathetic outflow resulting in decreased stimulation of the adrenergic receptors (both alpha and beta receptors) of the heart and peripheral vascular system.</li>
<li>Decrease in sympathetic outflow to the myocardium results in bradycardia and decreased cardiac output (CO).</li>
<li>Decrease in sympathetic outflow to the peripheral vasculature results in vasodilation, which leads to decreased blood pressure.</li>
</ul>
<p>Primary hypertension (administered alone, with a diuretic, or with another antihypertensive agent)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Severe cancer pain (administered parenterally by epidural infusion)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="investigational-use">Investigational use<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#investigational-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Migraine headache
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Flushing from menopause
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Management of ADHD and Tourette's syndrome
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Management of withdrawal symptoms from alcohol, tobacco, and opioids</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Drowsiness and sedation
*Dry mouth</li>
<li>Rebound hypertension</li>
</ul>
<p>Contraindication
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Clonidine is Pregnancy Risk Category C.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Avoid use during lactation.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> This medication is contraindicated for clients taking anticoagulant medications
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Avoid use of transdermal patch on affected skin in scleroderma and systemic lupus erythematosus (SLE).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Use cautiously in clients with cerebrovascular disease, recent MI, diabetes mellitus, major depressive disorder, or chronic renal failure</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects-cont">Side/Adverse Effects cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Antihypertensive medications may have an additive hypotensive effect.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Concurrent use of prazosin (Minipress), MAOI s, and tricyclic antidepressants can counteract the antihypertensive effect of clonidine.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Additive CNS depression can occur with concurrent use of other CNS depressants, such as alcohol.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Administer medication by oral, epidural, and transdermal routes.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Medication is usually administered twice a day in divided doses. Take larger dose at bedtime to decrease the occurrence of daytime sleepiness.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Transdermal patches are applied every seven days. Advise clients to apply patch on hairless, intact skin on torso or upper arm.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="methyldopa-aldomet">Methyldopa (ALDOMET)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#methyldopa-aldomet" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Acts through its metabolites (amethylnorepinephrine)which stimulates central alpha adrenergic receptors, thus increasing total peripheral resistance.</li>
<li>It does not affect glomerular filtration, cardiac output or heart rate.</li>
</ul>
<p>Therapeutic effects
Moderate to severe hypertension
Adverse effects
GIT upsets, sedation, depression, nasal stuffiness, myocarditis edema, orthostatic hypotension, diarrhea, dry mouth, erectile dysfunction, eosinophilia, hemolytic anemia, fever.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Hypersensitivity, activity liver disease, those who developed liver cirrhosis with previous treatment of methyldopa.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="caution">Caution;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#caution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Patients taking diuretics and antihypertensive.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Those taking levodopa because of potential for additive antihypertensive effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="consideration">Consideration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#consideration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> patient to avoid hazardous task.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Lower dose in impaired renal disease.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Monitor liver functions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="caution-cont">Caution cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#caution-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Monitor HB, RBCs for signs of anemia.</li>
<li>Monitor weight, fluid input and out put.</li>
<li>Signs of drug induced depression,</li>
<li>Take BP in different patients position during dose adjustments, warn of signs and symptoms of adverse effects and toxicity</li>
<li>Tolerance may develop 2to 3 weeks after start of treatment.</li>
<li>Urine may darken on exposure to air(as drug is broken down to its metabolites)</li>
<li>Dose increase should be made with the evening dose to minimize the effects of drowsiness.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="beta-adrenergic-blockers-sympatholytics">BETA ADRENERGIC BLOCKERS (SYMPATHOLYTICS)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beta-adrenergic-blockers-sympatholytics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cardioselective: Beta1</p>
<ul>
<li>Metoprolol (Lopressor)</li>
<li>Atenolol (Tenormin)</li>
<li>Metoprolol succinate (Toprol XL)</li>
<li>Esmolol HCL (Brevibloc)</li>
</ul>
<p>Nonselective: (Beta1 and Beta2)</p>
<ul>
<li>Propranolol (Inderal)</li>
<li>Nadolol (Corgard)</li>
<li>Labetalol (Normodyne)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They block beta- adrenergic receptors in the myocardium and in the electrical conduction system of the heart.
*Decreased heart rate
*Decreased myocardial contractility
*Decreased rate of conduction through the AV node</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>hypertension, Angina, arrhythmias, heart failure and myocardial infarction.
Other uses may include: Treatment of hyperthyroidism, migraine headache, pheochromocytoma, and glaucoma</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse">Adverse<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="effects">effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Bradycardia, fatigue, dizziness, nightmares, depression, memory loss, hallucination, impotence, cold extremities, elevated serum cholesterol.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindication">Contraindication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>severe hypotension, bradycardia, congestive heart failure, asthma, diabetics, critically abnormal lipid profile</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="consideration">Consideration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#consideration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Explain the rationale of therapy and importance of taking drugs as prescribed.</li>
<li>Patient should not discontinue drugs abruptly because it can cause MI or angina</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="consideration-cont">Consideration cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#consideration-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Advise clients to avoid sudden changes in position to prevent occurrence of orthostatic hypotension
Administer medications orally, usually once or twice a day.
Administer the following medications by IV route: atenolol, metoprolol, labetalol, propranolol.
Teach clients to self monitor heart rate and blood pressure at home on a daily basis.
Monitor weight &amp; signs of hypovolemic shock especially in diabetic patients.
Glucagon is prescribed to reverse signs of overdose.
Dose are lowered in geriatrics due to delayed metabolism and enhanced side effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medications-for-hypertensive-crisis">Medications for Hypertensive Crisis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medications-for-hypertensive-crisis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nitroprusside sodium (Nitropress)
Other Medications:
Nitroglycerin (Nitrostat IV)
Nicardipine (Cardene)
Clevidipine (Cleviprex)
Enalaprilat (Vasotec IV)
Esmolol HCL (Brevibloc)
Mechanism of Action; Direct vasodilation of arteries and veins resulting in rapid reduction of blood pressure (decreased preload and afterload)
Therapeutic Uses; Hypertensive emergencies</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="excessive-hypotension">Excessive hypotension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#excessive-hypotension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Administer medication slowly because rapid administration will cause blood pressure to go down rapidly.</li>
<li>Monitor the client's blood pressure and ECG.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="interactions">Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nitroprusside should not be administered in the same infusion as any other medication.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Prepare medication by adding to diluent for IV infusion.</li>
<li>Note color of solution. Solution may be light brown in color. Discard solution of any other color.</li>
<li>Protect IV container and tubing from light.</li>
<li>Discard medication after 24 hr .</li>
<li>Monitor vital signs and ECG continuously</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cardiac-glycoside">CARDIAC GLYCOSIDE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiac-glycoside" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="two-main-types">Two main types<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#two-main-types" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cardenolides (digitalis, convallaria, oleandra)
*Bufadienolides (Helleborus, Poison Arrow Frog)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Cardiac glycoside slows down the heart rate and increase the force of contraction</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-action">Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Enhances myocardial contractility and is used in congestive cardiac failure.</li>
<li>Enhances cardiac output, minimizes dilated cardiac size, blood volume and venous pressure.</li>
<li>They modulate autonomic nervous system activity, and this contributes to their efficacy in management of heart failure.</li>
<li>Diuretic effect, reduce oedema.</li>
<li>It is usually given only when diuretics and ACEIs have failed.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="indications">Indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Congestive heart failure, heart failure with atrial fibrillation, or pts who remain symptomatic despite therapy with ACE inhibitors and b Adrenergic receptor antagonists
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Left ventricular failure.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Atrial fibrillation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="digoxin">Digoxin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digoxin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is the most commonly used digitalis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="forms">Forms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#forms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tablets (Lanoxin)
Capsules (lanoxicaps)
Parenteral digoxin is available for intravenous administration and maintenance doses can be given intravenously when oral dosin is impractical.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="digoxin-cont">Digoxin Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digoxin-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="positive-inotropic-effect">Positive inotropic effect<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#positive-inotropic-effect" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> increased force of myocardial contraction Increased force and efficiency of myocardial contraction improves the heart's effectiveness as a pump,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> improving stroke volume and cardiac output.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Increase perfusion of the kidneys which facilitates excretion of fluid by the kidneys</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="negative-chronotropic-effect">Negative chronotropic effect<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#negative-chronotropic-effect" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> decreased heart rate ,
At therapeutic levels, digoxin slows the rate of SA node depolarization and the rate of impulses through the conduction system of the heart.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> A decreased heart rate gives the ventricles more time to fill with blood coming from the atria, which leads to increased SV and increased CO.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="digoxin-cont">Digoxin cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digoxin-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Treatment of heart failure</li>
<li>Dysrhythmias (atrial fibrillation)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-adverse-effects">Side/adverse effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Dysrhythmias (caused by interfering with the electrical conduction in the myocardium)</li>
<li>Cardiotoxicity leading to bradycardia.</li>
<li>GI effects include anorexia (usually the first sign), nausea, vomiting, and abdominal pain.</li>
<li>Teach clients to monitor for these effects and report to the provider if they occur.</li>
<li>CNS effects include fatigue, weakness, vision changes (diplopia, blurred vision, yellow-green or white halos around objects).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="digoxin-cont">Digoxin cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digoxin-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>In Pregnancy</li>
<li>clients with disturbances in ventricular rhythm, including ventricular fibrillation, ventricular tachycardia, and second- and third-degree heart block.</li>
<li>Use cautiously in clients who have hypokalemia, partial AV block, advanced heart failure, and renal insufficiency.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medication-interaction">Medication Interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Thiazide diuretics, such as hydrochlorothiazide (HCTZ), and loop diuretics, such as furosemide (Lasix), may lead to hypokalemia, which increases the risk of developing dysrhythmias</li>
<li>ACE inhibitors and ARBs increase the risk of hyperkalemia, which can lead to decreased therapeutic effects of digoxin.</li>
<li>Sympathomimetic medications such as dopamine (Intropin) complement the inotropic action of digoxin and increase the rate and force of heart muscle contraction.</li>
<li>Quinidine increases the risk of digoxin toxicity when used concurrently.</li>
<li>Verapamil (Calan) increases plasma levels</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-affecting-the-respiratory-system-bronchodilators">DRUGS AFFECTING THE RESPIRATORY SYSTEM (Bronchodilators)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-affecting-the-respiratory-system-bronchodilators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="overview">Overview<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The obstruction occurs either by inflammation or airway hyper-responsiveness leading to bronchoconstriction.</p>
<ul>
<li>Medication management usually addresses both inflammation and bronchoconstriction</li>
<li>These same medications may be used in symptomatic treatment of chronic obstructive pulmonary disease (COPD</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="overview-cont">Overview Cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#overview-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Advise clients to take the medication as prescribed. If a dose is missed, the next dose should NOT be doubled.</li>
<li>Check pulse rate and rhythm before administration of digoxin and record. Notify the provider if heart rate is less than 60/min in an adult, less than 70/min in children, and less than 90/min in infants. Administer digoxin at the same time daily.</li>
<li>Monitor digoxin levels periodically during treatment and maintain therapeutic levels between 0.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.0</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">2.0 \mathrm{ng} / \mathrm{mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">mL</span></span></span></span></span></span> to prevent digoxin toxicity.</li>
<li>Avoid taking OTC medications to prevent adverse and side effects and medication interactions.</li>
<li>Instruct clients to observe symptoms of hypokalemia, such as muscle weakness, and to notify the provider if symptoms occur.</li>
<li>Instruct clients to observe symptoms of digoxin toxicity (anorexia, fatigue, weakness), and to notify the provider if symptoms occur.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-digoxin-toxicity">Management of Digoxin Toxicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-digoxin-toxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Digoxin and potassium-sparing medication should be stopped immediately.</li>
<li>Monitor K+ levels. For levels less than 3.5 mEq/L, administer potassium intravenously or by mouth. Do not give any further <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">K</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{K}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">K</span><span class="mord">+</span></span></span></span></span> if the level is greater than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">5.0 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5.0</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>.</li>
<li>Treat dysrhythmias with phenytoin (Dilantin) or lidocaine.</li>
<li>Treat bradycardia with atropine.</li>
<li>For excessive overdose, activated charcoal, cholestyramine, or Digibind can be used to bind digoxin and prevent absorption.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bronchodilators-cont">Bronchodilators Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bronchodilators-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medications-include">Medications include:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medications-include" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-bronchodilator">Classification of Bronchodilator ;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-bronchodilator" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Beta2-adrenergic agonists short acting; salbutamol,</li>
<li>Beta2-adrenergic agonists long acting; salmeterol and formoterol</li>
<li>Methyl xanthine's e.g. theophylline</li>
<li>Inhaled anticholinergics e.g. tiotropium</li>
<li>Anti-inflammatory agents such as glucocorticoids, mast cell stabilizers, and leukotriene modifiers.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="beta2-adrenergic-agonists">Beta2-Adrenergic Agonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beta2-adrenergic-agonists" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Albuterol (Proventil, Ventolin)</li>
<li>Formoterol (Foradil Aerolizer)</li>
<li>Salmeterol (Serevent)</li>
<li>Terbutaline (Brethine)</li>
<li>Albuterol ( Proventil, Ventolin)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Beta2-adrenergic agonists act by selectively activating the beta2receptors in the bronchial smooth muscle, resulting in bronchodilation. As a result of this: Bronchospasm is relieved, Histamine release is inhibited, Ciliary motility is increased.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>Medication</th><th>Route</th><th>Therapeutic uses</th></tr></thead><tbody><tr><td>Albuterol (Proventil, Ventolin)</td><td>- Inhaled, short-acting Oral, long-acting</td><td>- Prevention of asthma attack (exerciseinduced) - Treatment for ongoing asthma attack - Long-term control of asthma</td></tr><tr><td>Formoterol (Foradil Aerolizer) Salmeterol (Serevent)</td><td>- Inhaled, long-acting</td><td>- Long-term control of asthma</td></tr><tr><td>Terbutaline (Brethine)</td><td>Oral, long-acting</td><td>- Long-term control of asthma</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-effects">Side Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Inhaled agents (short and long acting) have minimal adverse effects.</li>
<li>Oral agents can cause tachycardia and angina because of activation of alpha1 receptors in the heart.</li>
<li>Tremors caused by activation of beta2 receptors in skeletal muscle.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Beta2-adrenergic agonists are Pregnancy Risk Category C.</li>
<li>These agents are contraindicated in clients with tachydysrhythmia.
*Use cautiously in clients who have diabetes, hyperthyroidism, heart disease, hypertension, and angina.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug Interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Use of beta-adrenergic blockers (propranolol) can negate effects of both medications.
*MAOIs and tricyclic antidepressants can increase the risk of tachycardia and angina.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions">Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Instruct clients to follow manufacturer's instructions for use of device: metered-dose inhaler (MDI), dry-powder inhaler(DPI), and nebulizer.
When a client is prescribed an inhaled beta2-agonist and an inhaled glucocorticoid, advise the client to inhale the beta2-agonist before inhaling the glucocorticoid.
The beta2-agonist promotes bronchodilation and enhances absorption of the glucocorticoid.
Advise clients not to exceed prescribed dosages.
Ensure that clients know the appropriate dosage schedule (if the medication is to be taken on a fixed or a when-necessary schedule).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-cont">Precautions Cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Formoterol and salmeterol are both long-acting beta2-agonist inhalers. These inhalers are used every 12 hr . for long-term control and are not to be used to abort an asthma attack. A short-acting beta2agonist should be used if clients need to treat an acute attack.</li>
<li>Advise clients to observe for signs of an impending asthma attack and to keep a log of the frequency and intensity of attacks.</li>
<li>Instruct clients to notify the provider if there is an increase in the frequency and intensity of asthma attacks.</li>
</ul>
<p>Theophylline (Theolair, Theo-24)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Theophylline causes relaxation of bronchial smooth muscle, resulting in bronchodilation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Oral theophylline is used for long-term control of chronic asthma.
Route of administration: oral or IV (emergency use only)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Mild toxicity reaction may include GI distress and restlessness.</p>
<ul>
<li>More severe reactions can occur with higher therapeutic levels and can include dysrhythmias and seizures.</li>
</ul>
<p>Contraindications/Precautions</p>
<ul>
<li>In Pregnancy</li>
<li>Use cautiously in clients who have heart disease, hypertension, liver and renal dysfunction, and diabetes.</li>
<li>Use cautiously in children and older adults.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="inhaled-anticholinergics">INHALED ANTICHOLINERGICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inhaled-anticholinergics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ipratropium (Atrovent)
Tiotropium (Spiriva)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These medications block muscarinic receptors of the bronchi, resulting in bronchodilation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These medications are used to relieve bronchospasm associated with chronic obstructive pulmonary disease (COPD)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> These medications are used for allergen-induced and exerciseinduced asthma.
Route of administration: inhalation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">SIDE/ADVERSE EFFECTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Local anticholinergic effects (dry mouth, hoarseness)
Advise clients to sip fluids and suck on hard candies to control dry mouth.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Inhaled anticholinergics are Pregnancy Risk Category B.</li>
<li>These agents are contraindicated in clients who have an allergy to peanuts because the medication preparations may contain soy lecithin.
*Use cautiously in clients who have narrow-angle glaucoma and benign prostatic hypertrophy (due to anticholinergic effects).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions-interactions">Drug Interactions Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Caffeine increases CNS and cardiac adverse effects of theophylline.</li>
<li>Caffeine can also increase theophylline levels.</li>
<li>Advise clients to avoid consuming caffeinated beverages (coffee, caffeinated colas).</li>
<li>Phenobarbital and phenytoin decrease theophylline levels.</li>
<li>Cimetidine (Tagamet), ciprofloxacin (Cipro), and other fluoroquinolone antibiotics increase theophylline level.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="glucocorticoids">GLUCOCORTICOIDS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glucocorticoids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Inhalation: beclomethasone dipropionate (QVAR)
Oral: prednisone (Deltasone)
Inhalation:
Budesonide (Pulmicort Flexhaler)
Fluticasone propionate and salmeterol (Advair)
Fluticasone propionate (Flovent)
Triamcinolone acetonide (Azmacort)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="systemic">Systemic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#systemic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Oral Prednisolone E 30 to 40mg for initial to 7 days,</li>
<li>IV/IM dexamethasone</li>
<li>IV Hydrocortisone sodium succinate (Solu-Cortef) (</li>
<li>IV Methylprednisolone sodium succinate (Solu-Medrol)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These medications prevent inflammation, suppress airway mucus production, and promote responsiveness of beta2 receptors in the bronchial tree.</li>
<li>The use of glucocorticoids does not provide immediate effects, but rather promotes decreased frequency and severity of exacerbations and acute attacks.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Short-term IV agents are used for status asthmaticus.
*Inhaled agents are used for long-term prophylaxis of asthma.</li>
<li>Short-term oral therapy is used to treat symptoms following an acute asthma attack.</li>
<li>Long-term oral therapy is used to treat chronic asthma.</li>
<li>Replacement therapy is used for primary adrenocortical insufficiency.</li>
<li>Promote lung maturity and decrease respiratory distress in fetuses at risk for preterm birth</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="beclomethasone-dipropionate">Beclomethasone dipropionate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beclomethasone-dipropionate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Difficulty speaking, hoarseness, and candidiasis
Advise clients to use a spacer with MDI.
Advise clients to rinse mouth or gargle with water or salt water after use.
Advise clients to monitor for redness, sores, or white patches and to report to provider if they occur.
Candidiasis may be treated with nystatin oral suspension.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prednisolone-when-used-for-more-than-10-days">Prednisolone When Used for More Than 10 days<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prednisolone-when-used-for-more-than-10-days" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Suppression of adrenal gland function, such as a decrease in the ability of the adrenal cortex to produce glucocorticoids: Can occur with inhaled agents and oral agents</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="taper-the-client-s-dose">Taper the client's dose.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#taper-the-client-s-dose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Bone loss (can occur with inhaled agents and oral agents)</li>
<li>Myopathy as evidenced by muscle weakness</li>
<li>Hyperglycemia and glycosuria</li>
<li>Myopathy as evidenced by muscle weakness a</li>
<li>Peptic ulcer disease</li>
<li>Infection</li>
<li>Disturbances of fluid and electrolytes (fluid retention as evidenced by weight gain, and edema and hypokalemia as evidenced by muscle weakness)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions-of-pdl">Contraindications/Precautions of PDL<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions-of-pdl" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Pregnancy risk category C</li>
<li>Contraindicated in clients who have received a live virus vaccine</li>
<li>Contraindicated in clients with systemic fungal infections</li>
<li>Use cautiously in children, and in clients who have diabetes, hypertension, peptic ulcer disease, and/or renal dysfunction.</li>
<li>Use cautiously in clients taking NSAIDs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Concurrent use of potassium-depleting diuretics increases the risk of hypokalemia.</li>
<li>Concurrent use of NSAIDs increases the risk of GI ulceration. Concurrent use of glucocorticoids and hypoglycemic agents (oral and insulin) will counteract the effects.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration">Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Instruct clients to use glucocorticoid inhalers on a regular, fixed schedule for longterm therapy of asthma.</li>
<li>Glucocorticoids are not to be used to treat an acute attack.</li>
<li>Administer using an MDI device, DPI, or nebulizer.</li>
<li>When a client is prescribed an inhaled beta2-agonist and an inhaled glucocorticoid, advise the client to inhale the beta2-agonist before inhaling the glucocorticoid. The beta2-agonist promotes bronchodilation and enhances absorption of the glucocorticoid.</li>
<li>Oral glucocorticoids are used short-term, 3 to 10 days following an acute asthma attack.</li>
<li>If client is on long-term oral therapy, additional dosages of oral glucocorticoids are required in times of stress (infection, trauma).</li>
<li>Clients who discontinue oral glucocorticoid medications or switch from oral to inhaled agents require additional doses of glucocorticoids during periods of stress.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mastcell-stabilizers-anti-inflatory-drugs">MASTCELL STABILIZERS ANTI INFLATORY DRUGS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mastcell-stabilizers-anti-inflatory-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cromolyn-sodium-intal">(cromolyn sodium (Intal)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cromolyn-sodium-intal" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Others are: nedocromil sodium (Tilade)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Anti-inflammatory action</li>
<li>These medications stabilize mast cells, which inhibits the release of histamine and other inflammatory mediators.</li>
<li>These medications suppress inflammatory cells (eosinophils, macrophages).
Complications Safest of all asthma medications, Safe to use for children</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Management of chronic asthma
*Prophylaxis of exercise-induced asthma</li>
<li>Prevention of allergen-induced attack</li>
<li>Allergic rhinitis by intranasal route</li>
<li>Route of administration: inhalation</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>These agents are Pregnancy Risk Category B.</li>
<li>Fluorocarbons in aerosols make this medication contraindicated for clients who have coronary artery disease, dysrhythmias, and status asthmaticus.</li>
<li>Use cautiously in clients with liver and kidney impairment.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="leukotriene-modifiers">LEUKOTRIENE MODIFIERS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#leukotriene-modifiers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>leukotriene receptor antagonist ;</p>
<ul>
<li>Montelukast (Singulair), Zileuton (Zyflo),Zafirlukast (Accolate)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Leukotriene modifiers prevent the effects of leukotrienes, thereby suppressing inflammation, bronchoconstriction, airway edema, and mucus production.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Leukotriene modifiers are used for long-term therapy of asthma in adults and children 15 years and older and to prevent exercise-induced bronchospasm.</p>
<p>Route of administration: oral</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Use cautiously in clients with liver dysfunction</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Zileuton and zafirlukast inhibit metabolism of warfarin (Coumadin), leading to increased warfarin levels.</li>
<li>Zileuton and Zafirlukast inhibit metabolism of theophylline, leading to increased theophylline levels.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Advise clients to take zileuton as prescribed. Zileuton can be given with or without food.</li>
<li>Advise clients that zafirlukast should not be given with food, and to administer it 1 hr . before or 2 hr . after meals.</li>
<li>Advise clients to take Montelukast once daily at bedtime.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="git-drugs-peptic-ulcer-disease">GIT DRUGS( PEPTIC ULCER DISEASE)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#git-drugs-peptic-ulcer-disease" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acid peptic disease includes:</p>
<ul>
<li>peptic ulcers (gastric ulcer, duodenal ulcer , NSAIDS induced ulcers)</li>
<li>gasro oesophageal reflux disease,</li>
<li>hypersecretory states like Zollinger Ellison Syndrome (ulcerogenic tumour of the islets of Langerhans.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-therapy">Principles of therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The aim of therapy is to;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋆</mo></mrow><annotation encoding="application/x-tex">\star</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4653em;"></span><span class="mord">⋆</span></span></span></span></span> relieve symptoms,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋆</mo></mrow><annotation encoding="application/x-tex">\star</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4653em;"></span><span class="mord">⋆</span></span></span></span></span> induced ulcer healing and cure in the long run
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋆</mo></mrow><annotation encoding="application/x-tex">\star</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4653em;"></span><span class="mord">⋆</span></span></span></span></span> Decreased risk of complications
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋆</mo></mrow><annotation encoding="application/x-tex">\star</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4653em;"></span><span class="mord">⋆</span></span></span></span></span> Stopping reoccurrence .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-agents-used-in-treatment-of-peptic-ulcer">Classification Of Agents Used in Treatment of Peptic Ulcer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-agents-used-in-treatment-of-peptic-ulcer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="inhibition-of-acid-secretion">Inhibition Of Acid Secretion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inhibition-of-acid-secretion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> H2 receptor agonist e.g. cimetidine, ranitidine, famotidine roxatidine.
Proton pump inhibitors e.g. omeprazole, pantoprazole, esomeprazole, lansoprazole.
Anticholinergics e.g. pirenzepine.
Prostaglandin analogue e.g. misoprostol.
Neutralization of gastric acids
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Sodium bicarbonate systemic
Non systemic: magnesium hydroxide, aluminium hydroxide, magnesium trisilicate.</p>
<p>Mucosal protective agents e.g. sucralfate, colloidal bismuth.</p>
<ul>
<li>Anti helicobacter pylori drugs (ANTIBIOTICS) e.g. Clarithromycin, Ampicillin, Metronidazole, Tetracycline, Tinidazole</li>
</ul>
<p>Anti H. pylori drugs</p>
<ul>
<li>Amoxicillin (Amoxil)</li>
<li>Bismuth (Pepto-Bismol)</li>
<li>Clarithromycin (Biaxin)</li>
<li>Metronidazole (Flagyl)</li>
<li>Tetracycline</li>
</ul>
<p>Expected Pharmacological Action</p>
<ul>
<li>Eradication of H. pylori bacteria</li>
<li>Therapy should include: Combination of 2 or 3 antibiotics for 14 days</li>
</ul>
<p>The disease process is only altered by the use of antibiotics. All other medications make an environment that is conducive to healing</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="two-weeks-regimen">Two weeks Regimen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#two-weeks-regimen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Tetracycline 500mg QID and metronidazole 200mg BID and Bismuth sub salylicylate.</li>
<li>Amoxicillin 100mg BID and clarithromycin 500mg BID+ Lansoprazole 30mgs BID.</li>
<li>Clarithromycin 500mg TDS +Omeprazole.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="one-week-regimen">ONE WEEK REGIMEN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#one-week-regimen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Clarithromycin 250mg BID + Metronidazole 400mgs + Omeprazole 20mgs BID.
Amoxicillin 500mg Bid + Clarithromycin 250mg Bid+ Omeprazole 20mg</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="histamine2-receptor-antagonists">Histamine2 -Receptor Antagonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#histamine2-receptor-antagonists" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*Ranitidine hydrochloride (Zantac)
*Cimetidine (Tagamet)</p>
<ul>
<li>Nizatidine (Axid)</li>
<li>Famotidine (Pepcid)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Histamine2-receptor antagonists suppress the secretion of gastric acid by selectively blocking H 2 receptors in parietal cells lining the stomach.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>0Gastric and peptic ulcers,
0 Gastroesophageal reflux disease (GERD),
0 Hypersecretory conditions, such as Zollinger-Ellison syndrome.
0 Histamine2-receptor antagonists are used in conjunction with antibiotics to treat ulcers caused by H. pylori.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cimetidine may block androgen receptors, resulting in decreased libido and impotence.</li>
<li>Cimetidine may cause CNS effects (lethargy, depression, confusion)</li>
<li>Ranitidine, nizatidine, and famotidine have few adverse effects and interactions.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These medications are Pregnancy Risk Category B</li>
<li>Use in older adults can cause antiadrenergic effects (e.g., impotence) and CNS effects (e.g., confusion).</li>
<li>H2-receptor antagonists decrease gastric acidity, which promotes bacterial colonization of the stomach and the respiratory tract. Use cautiously in clients who are at a high risk for pneumonia, such as clients with chronic obstructive pulmonary disease (COPD).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Cimetidine can inhibit medication metabolizing enzymes and thus increase the levels of warfarin, phenytoin (Dilantin), theophylline, and lidocaine.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Concurrent use of antacids can decrease absorption of histamine2 -receptor antagonists.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="proton-pump-inhibitor">Proton Pump Inhibitor<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#proton-pump-inhibitor" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*omeprazole (Prilosec)</p>
<ul>
<li>Pantoprazole (Protonix)</li>
<li>Lansoprazole (Prevacid)
*Rabeprazole sodium (AcipHex)</li>
<li>Esomeprazole (Nexium)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Proton pump inhibitors reduce gastric acid secretion by irreversibly inhibiting the enzyme that produces gastric acid.
*Proton pump inhibitors reduce basal and stimulated acid production.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Gastric and peptic ulcers,</li>
<li>GERD,</li>
<li>h\Hypersecretory conditions such as Zollinger-Ellison syndrome.</li>
</ul>
<p>Complications
Insignificant side effects and adverse effects with short-term treatment
Low incidence of headache, diarrhea, and nausea/vomiting</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These medications are Pregnancy Risk Category C.</li>
<li>Use cautiously with children and women who are breastfeeding.</li>
<li>Contraindicated for clients hypersensitive to medication</li>
<li>These medications increase the risk for pneumonia. Omeprazole decreases gastric acid pH , which promotes bacterial colonization of the stomach and the respiratory tract. Use cautiously in clients at high risk for pneumonia, such as clients with COPD.</li>
<li>Long-term use of proton pump inhibitors increases the risk of gastric cancer and osteoporosis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions">Drug Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>*Digoxin (Lanoxin) levels may be increased when used concurrently with omeprazole.</p>
<ul>
<li>Monitor digoxin levels carefully if prescribed concurrently.
*Absorption of ketoconazole (formerly Nizoral), itraconazole (Sporanox), and atazanavir (Reyataz) is extremely decreased when taken concurrently with proton pump inhibitors.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions During Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Do not crush, chew, or break sustained-release capsules.</li>
<li>Clients may sprinkle the contents of the capsule over food to facilitate swallowing.</li>
<li>Clients should take omeprazole once a day prior to eating in the morning.</li>
<li>Encourage clients to avoid alcohol and irritating medications such as NSAIDs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-cont">Precautions During Administration cont...<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Active ulcers should be treated for 4 to 6 weeks.</li>
<li>Pantoprazole (Protonix) can be administered to clients intravenously. In addition to low incidence of headache and diarrhea, there may be irritation at the injection site leading to thrombophlebitis. Monitor the client's IV site for signs of inflammation (redness, swelling, local pain) and change the IV site if indicated.</li>
<li>Teach clients to notify the provider for any sign of obvious or occult GI bleeding such as coffee-ground emesis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anticholinergics">ANTICHOLINERGICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anticholinergics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="piperazine">Piperazine :<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#piperazine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is a selective M1 receptor blocker
Produces less effects.
Reduces acid secretion by 40 to fifty percent
Has a small therapeutic window</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prostaglandins-analogue">Prostaglandins Analogue<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prostaglandins-analogue" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>They have o cytoprotective role by inhibiting acid secretion by increasing mucus and bicarbonate secretion.</li>
<li>Inhibit gastrin secretion and increase mucosal blood flow.</li>
</ul>
<p>Misoprostol</p>
<ul>
<li>A synthetic pge1 analogue and inhibits acid output.</li>
<li>ulcer heal in 4 to six weeks but relieving pain</li>
</ul>
<p>Therapeutic Use
prevent ulceration and bleeding induced by NSAIDS</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mucosal-protectant">MUCOSAL PROTECTANT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mucosal-protectant" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sucralfate-carafate">Sucralfate (Carafate)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sucralfate-carafate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The acidic environment of the stomach and duodenum changes sucralfate into a thick substance that adheres to an ulcer. This protects the ulcer from further injury that may be caused by acid and pepsin.
This viscous substance can stick to the ulcer for up to 6 hr .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>promotes healing of duodenal and gastric ulcers</li>
<li>Poorly absorbed systemically, not used frequently due to a large doses.</li>
<li>Should not be used with antacids, H2 Antagonist, PPIs as it is dependent on gastric PH.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="colloidal-bismuth-compounds">Colloidal Bismuth Compounds<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#colloidal-bismuth-compounds" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Promote healing of duodenal and gastric ulcers.</li>
<li>Act by binding to an ulcer, denaturing the protein and creating a physical barrier.</li>
<li>Inhibition of pepsin, activation of mucous production, increase of prostaglandins.</li>
<li>It is effective in healing of duodenal and gastric ulcers.</li>
<li>Effective in non ulcer gastritis, caused by H.pylori</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="considerations">Considerations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Take before meals and at bed time for 4 to 8 weeks.</li>
<li>Poor acceptance due to blackening of tongue, dentures and stool inconvenience of dosing used as a regimen of multiple therapy for H.Pylori not used alone.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="laxatives">LAXATIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This are drugs tha promote deafacation
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋄</mo></mrow><annotation encoding="application/x-tex">\diamond</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋄</span></span></span></span></span> laxatives; mild action
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋄</mo></mrow><annotation encoding="application/x-tex">\diamond</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋄</span></span></span></span></span> Purgative; strong action
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋄</mo></mrow><annotation encoding="application/x-tex">\diamond</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋄</span></span></span></span></span> Classification</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bulk-forming-purgatives">Bulk Forming Purgatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bulk-forming-purgatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Magnesium sulphate, magnesium hydroxide, sodium phosphate, lactulose, sodium tartrate, osmotic cathartic.
Vegetable fibres, bran
Hydrophillic colloids, methyl cellulose</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="irritants-and-stimulants">Irritants and stimulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#irritants-and-stimulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Diphenylmethanes; phenolphthalein, Bisacodyl</li>
<li>Anthraquinone derivatives; senna, cascara</li>
<li>Fixed oil; castor oil</li>
<li>Stool softeners; docusate, mineral oil, glycerin suppositories</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action-of-laxatives">Mechanism of action of laxatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Laxatives cause retention of fluid in colonic contents increasing bulk and softness of stool and its transit.</li>
<li>They may decrease absorption of water and electrolyte by acting on intestinal mucosa.</li>
<li>They may enhance intestinal motility reducing absorption of water.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bulk-forming-purgatives">Bulk Forming Purgatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bulk-forming-purgatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="osmotic-or-saline-cathartics">Osmotic or saline cathartics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#osmotic-or-saline-cathartics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> They are poorly absorbed hold water through osmosis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> In addition the ions stimulate secretion and motility.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Main used salts are; magnesium sulphate, sodium sulphate, magnesium hydroxide, sodium potassium tartrate.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Sodium salts contraindicated in congestive heart failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="considerations">Considerations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cause after constipation therefore not used routinely</li>
<li>Preferred for pre-operative care before colonoscopy and in poisoning.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="lactulose">Lactulose<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lactulose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>A synthetic disaccharide containing fructose and galactose absorbed in the GIT.</li>
<li>Produces soft stools within 1-3 days</li>
<li>Side effects; abnominal cramps, flatulence,</li>
<li>Contraindicated in patients requiring galactose free diet.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vegetable-fibres">Vegetable fibres<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vegetable-fibres" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Dietary fibres derived from whole grains, vegetables and fruits. They contains the indigestible portion of cell wall.</li>
<li>Dietary fibre act by binding water and ions in the intestine softens stool and promotes peristables. Also increases faecel mass.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vegetable-fibres">Vegetable fibres<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vegetable-fibres" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indications">Indications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Prevention and treatment of functional constipation.</li>
<li>Used for symptomatic relief of mild diarrhea</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-effects">Adverse effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Flatulance
Intestinal obstruction, oesophageal obstruction may occur.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraidication">Contraidication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraidication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Stenosis
Ulceration</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="irritant-and-stimulant-purgatives">Irritant and stimulant purgatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#irritant-and-stimulant-purgatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>They promote accumulation of water and electrolytes in the lumen.</li>
<li>Enhance intestinal motility</li>
<li>Increased water secretion is through activation of cAMP and synthesis of prostaglandins</li>
<li>Phenolpthalein and bisacodly are widely used.</li>
<li>Castor oil is hydrolysed to glycerol and ricinoleic acid which stimulates peristalsis. Effect in the small intestines causes rapid complete evacuation.</li>
<li>Side effects include; Cramping, dehydration.</li>
<li>Regular use bordestroys mucosa.</li>
<li>Should be avoided in pregnant women, can intiate labour.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="stool-softeners">Stool softeners<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#stool-softeners" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="docusates">Docusates<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#docusates" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Used as an emulsifying, wetting and dispersing agent.</li>
<li>soften stool with 1-3days</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="liquid-paraffin">Liquid paraffin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#liquid-paraffin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>It's a mineral oil.</li>
<li>Pharmacologically inert and acts as lubricants and softens stool.</li>
</ul>
<p>Adverse effects of liquid paraffin</p>
<ul>
<li>Leakage of oil past anal sphincter</li>
<li>Affect absorption of fat soluble vitamins.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="glcerin">Glcerin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glcerin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Used as a suppository, produces effects within 30mins.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="indication-of-laxatives">Indication of laxatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indication-of-laxatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Constipation not responding to non- pharmacological measures: fibre rich diet, regular exercise, regular bowel movements, ( bulk laxatives are the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> choice).</li>
<li>Before and after surgery to produce soft stool in patients with haemorrhoids and fissures.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications">Contraindications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Undiagnosed abnominal pain
Appendicitis
Intestinal obstruction
Should be avoided during later stages of preganancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-diarrhoeal-agents">Anti- Diarrhoeal Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-diarrhoeal-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Diarrhoea is marked by frequent passage of unformed or liquid stools.</li>
</ul>
<p>Treatment of diarrhoea
Fluid and electrolyte replacement
Nutritional management
Drug therapy</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy">Drug Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="anti-diarrhea-drugs-include">Anti-diarrhea drugs include;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-diarrhea-drugs-include" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Antimotility drugs
Antisecretory drugs
Adsorbents
Antibacterial agents</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="atimotility-drugs">Atimotility drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#atimotility-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>E.g loperamide, diphenoxylate</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="loperamide">Loperamide<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#loperamide" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Acts mainly on GIT receptor.</li>
<li>Acts quickly and has a longer duration of action</li>
<li>Decreases GIT motility and is excreted unchanged indicated for non infective diarrhea, mild travellors diarrhea.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-effects">Adverse effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Skin rash , abdominal cramps with excessive use paralytic ileus</li>
<li>Contraindication; below 4years, infective diarrhea, ulcerative colitis</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antisecretory-drugs">Antisecretory drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antisecretory-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="racecadotril">Racecadotril<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#racecadotril" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Enkephalinase inhibitor that increases endogenous enkephalin level and reduce intestinal hyper tension of water and electrolytes.</li>
<li>Used for systematic treatment of diarrhea.</li>
<li>Has no side effects like bloating and after constipation.</li>
<li>Should not be used in pregnancy, lactation and children.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adsorbents">Adsorbents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adsorbents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Include kaolin, pectin, methylcellulose , magnesium aluminium silicate.
They act by absorbing microorganisms and/ toxins by altering normal flora or by protecting the mucosa of the intestines.
Their efficacy is doubtful</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimicrobial-agents">Antimicrobial agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimicrobial-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Cholera; tetracyclines, norfloxacin/ciprofloxacin</li>
<li>Infections with camphylobacter; erythromycin and flouroquinolones</li>
<li>Amoebiasis or giardiasis; metronidazole, diloxanide furoate, ornidazole
*Shigella spcs, ciprofloxacin, norfloxacin or cotrimoxazole.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous">Miscellaneous<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Contain viable lactic acid bacilli.</li>
<li>Improve intestinal microflora</li>
<li>Known as probiotics</li>
<li>Useful in rotavirus diarrhoea and anti biotic induced diarrhoea</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="d-anti-emetics">D.ANTI EMETICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-anti-emetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Vomitting is reflex action that results in forceful evacuation of gatric contents.</li>
<li>Conditions pregnancy, ulcers, motion sickness, chemotherapy.</li>
</ul>
<p>Anti emetics
Applied to suppress or prevent vomiting.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification">Classification<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Anti muscarinic: scopolamine (hyoscine), dicyclomine
H1 antagonist: promethazine, doxylamine,
Prokinetic drugs; metoclopramide, domperidone, cisapride, mosapride.
Neuroleptics; phenothiazines, chlorpromazine
Adjuvant antiemetics; dexamethasone, benzodiazepines</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1-prokinetic-drugs">1. Prokinetic drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-prokinetic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-metroclopramide">a. Metroclopramide<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-metroclopramide" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Effective for all types of vomiting, post- operatively, radiation, chemotherapy.</li>
<li>Less effective in motion sickness.</li>
<li>Blocks dopamine receptors, enters CNS</li>
</ul>
<p>Side effects: extrapyramidal effects, dystonia, dyskinesia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indications">Indications;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Anti emetic</li>
<li>Dyspesia</li>
<li>facilitate lactation</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prokinetic-drugs-cont">Prokinetic drugs Cont....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prokinetic-drugs-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>b, Domperidone</p>
<ul>
<li>Peripheral D2 receptor agonist .</li>
<li>Causes less extra pyramidal effects, doesnot cross the blood brain barrier.</li>
<li>Lower efficacy than metoclopramide</li>
</ul>
<p>Uses; levodopa or bromocriptine induced vomiting.
Side effects; increased prolactin, galactorrhoea, dry mouth, rashes. Headache.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2-anti-muscarinic">2. Anti muscarinic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-anti-muscarinic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="scopolamine-hyoscine">Scopolamine (hyoscine)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#scopolamine-hyoscine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Alkaloid related to atropine</li>
<li>Most effective in prophylaxis of motion sickness</li>
<li>Antimuscarinic action blocks afferent pathways for vomiting reflex.</li>
<li>Has short duration of action</li>
<li>Produces anticholinergic effects; blurred vision, dry mouth, sedation.</li>
<li>Not effective with vomiting of other aetiologies.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="3-neuroleptics">3. Neuroleptics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-neuroleptics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Phenothiazines: chlorpromazine
potent anti emetics in vomiting due to drug toxicity, chemotherapy.
They act by blocking the D2 receptors in the medulla oblongata chemoreceptor trigger zone.
Not effective in motion sickness
Dosage is lower than antipsychotics</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-effects">Side effects;<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Sedation, extrapyramidal effects; dyskinesia, dystonia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="4-h1-antagonist">4. H1 Antagonist<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-h1-antagonist" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Doxylamie useful in motion sickness</li>
<li>Modest effect on chemotherapy</li>
<li>Reduce extra pyramidal effects of D2 receptor antagonist.</li>
<li>Are antagonist therefore avoided in pregnancy.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adjuvant-antiemetics">Adjuvant Antiemetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adjuvant-antiemetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="corticosteroids">Corticosteroids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#corticosteroids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>dexamethasone, methylprednisolone, used to control chemotherapy vomiting.
Act by blocking prostaglandins.
Cause insomnia and hyperglycemia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cannabinoids">Cannabinoids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cannabinoids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>tetrahydrocannabinol</p>
<ul>
<li>active principle of marijuana</li>
<li>Reduce chemotherapy emesis.</li>
<li>For patients intolerant or refractory to others antiemetics</li>
</ul>
<p>Side effects; hallucinations. Disorientation, vertigo, sedation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hematologic-drugs-anti-coagulants">HEMATOLOGIC DRUGS - ANTI COAGULANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hematologic-drugs-anti-coagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Anti coagulant refers to any substance which inhibits normal blood clotting, lowers coagulability of blood.</li>
<li>The anti coagulant interfere with normal coagulation process by interfering with the clotting cascade and thrombin formation.</li>
<li>These agents are used to inhibit clot formation but they do not dissolve existing clots.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-anticoagulants">Classification of Anticoagulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-anticoagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Parenteral anticoagulants:</li>
</ul>
<p>Heparin
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Low molecular weight heparin; enoxaparin, dalteparine, nadroparin, arteparin.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Semisynthetic heparinoid; heparin sulphate, dextran sulphate, ancrod, danaparoid.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> Others; lepirudin, bivalirudin, argatroban</p>
<ul>
<li>Oral anticoagulant; warfarin, acenocoumarin, dicoumarol</li>
<li>Fibrinolytic; streptokinase urokinase, alteplase</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="heparin">HEPARIN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#heparin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>mechanism of action: heparin acts prophylactically to prevent the formation of clots in the vasculate.it activates anti thrombin III which inhibits thrombin and clotting factor IX, X, XI, XII, consequently conversion of fibrinogen to fibrin does not occur and the formation of a fibrin clot is prevented</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Heparin sodium, LMWH, fondaparinux sodium</p>
<ul>
<li>In conditions necessitating prompt anticoagulant activity (evolving stroke, pulmonary embolism, massive deep venous thrombosis)</li>
<li>As an adjunct for clients having open heart surgery or renal dialysis</li>
<li>As low-dose therapy for prophylaxis against postoperative venous thrombosis (for example, hip/knee replacement surgery, abdominal surgery)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="administration">Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These medications cannot be absorbed by the intestinal tract and must be given by subcutaneous injection or IV infusion.</li>
<li>Heparin sodium: Subcutaneously every 12 hr ., continuous or intermittent IV infusion</li>
<li>Enoxaparin, dalteparin sodium, tinzaparin: Subcutaneously every 12 hr . for 2 to 8 days</li>
<li>Fondaparinux sodium: Subcutaneously every 12 hr . for 5 to 9 day.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hemorrhage secondary to heparin overdose</li>
<li>thrombocytopenia,</li>
<li>Hypersensitivity reactions (chills, fever, urticaria)</li>
<li>Administer a small test dose prior to the administration of heparin. Toxicity/overdose</li>
<li>Administer protamine sulfate, which binds with heparin and forms a heparin-protamine complex that has no anticoagulant properties.</li>
<li>Protamine sulfate should be administered slowly intravenously, no faster than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> or 50 mg in 10 min .</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="enoxaparin">Enoxaparin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#enoxaparin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hemorrhage Monitor vital signs <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> Advise clients to observe for signs and symptoms of bleeding, such as increased heart rate, decreased blood pressure, bruising, petechiae, hematomas, black tarry stools. - Monitor platelet count. Instruct client to avoid aspirin.</li>
<li>Neurologic damage from hematoma formed during spinal or epidural anesthesia</li>
<li>Thrombocytopenia, as evidenced by low platelet count , Monitor platelets. Discontinue medication for platelet count less than 100,000/mm3 .</li>
<li>Toxicity/overdose; Administer protamine sulfate</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">- Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Parenteral anticoagulants are contraindicated in clients with low platelet counts (thrombocytopenia) or uncontrollable bleeding.</li>
<li>These medications should not be used during or following surgeries of the eye(s), brain, or spinal cord; lumbar puncture; or regional anesthesia.</li>
<li>clients who have hemophilia, increased capillary permeability, dissecting aneurysm, peptic ulcer disease, severe hypertension, hepatic or renal disease, or threatened abortion</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Anti-platelet agents such as aspirin, NSAIDs, and other anticoagulants may increase risk for bleeding..</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="oral-anti-coagulants">ORAL ANTI COAGULANTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oral-anti-coagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These are the most commonly used oral anti coagulants;</li>
<li>Warfarin,</li>
<li>Dicoumarol,</li>
<li>Acenocoumarol</li>
</ul>
<p>Mechanism of action
Vitamin K antagonist; these agents inhibit the liver synthesis of vitamin K clotting factor II,VII, IX, X.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="advantages-over-heparin">Advantages over heparin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advantages-over-heparin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Bioavailability is almost 100 percent.
Low volume distribution,
Long half life.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Produces delayed action,
possibility of genetic resistance</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-indication">Clinical indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Treatment deep venous thrombosis.
Pulmonary embolism
Prevent blood clotting in patients with thrombophlebitis, pulmonary embolism and embolism from arterial fibrillation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindication-precaution">Contraindication /precaution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindication-precaution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Not given to pregnant women because it crosses the placenta barrier, it is teratogenic, and can cause an a abortion.</li>
<li>Not given to patients with bleeding disorders e.g. hemophilia, peptic ulcer, sever renal/ liver disease and eclampsia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="monitoring">Monitoring<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#monitoring" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Monitor prothrombin time usually done before administering the dose.</li>
<li>The PT SHOULD BE 1.5-2.5 times the reference value to be therapeutic</li>
<li>If it is below the recommended range warfarin should be increased.</li>
<li>If it above the recommended range warfarin should be decreased.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects-of-warfarin">Adverse effects of warfarin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects-of-warfarin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hematologic effects: increased bleeding, thrombocytopenia</li>
<li>Anorexia, nausea, vomiting, diarrhoea and dermatitis.</li>
<li>Hemorrhage</li>
<li>Interference with bone formation in early pregnancy</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="potentiation-activity">Potentiation activity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#potentiation-activity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Inhibition of metabolism: chloramphenicol, ciprofloxacin, cotrimoxazole, cimetidine.</li>
<li>Displacement from plasma protein; ethacrynic acid.</li>
<li>Platelet function inhibition; NSAIDs (Aspirin)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="retarded-activity">retarded activity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#retarded-activity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>inhibition of absorption; Sucralfate</li>
<li>Enzyme induction; barbiturates, carbamazepine, rifampicin</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acenocoumarol">Acenocoumarol<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acenocoumarol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>take 2-3 DAYS.</li>
</ul>
<p>Indication</p>
<ul>
<li>Arterial fibrillation,</li>
<li>pulmonary embolism,</li>
<li>prophylaxis following insertion of heart valve.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-drug-reaction">Adverse drug reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-drug-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Alopecia, diarrhoea, hepatic dysfunction, pancreatitis vomiting</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-of-warfarin">Precautions during Administration of warfarin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-of-warfarin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Administration is usually oral, once daily.</li>
<li>Obtain the client's baseline vital signs.</li>
<li>Monitor PT levels (therapeutic level 18 to 24 sec ) and INR levels (therapeutic levels 2 to 3 ). INR levels are the most accurate. Hold dose and notify the provider if these levels exceed therapeutic ranges.</li>
<li>Obtain baseline and monitor CBC, platelet count, and Hct levels.</li>
<li>Instruct clients that anticoagulant effects may take 8 to 12 hr and full therapeutic effect is not achieved for 3 to 5 days. For clients in the hospital setting, explain the need for continued heparin infusion when starting oral warfarin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-of-warfarin">Precautions during Administration of warfarin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-of-warfarin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Advise clients that anticoagulation effects can persist for up to 5 days following discontinuation of medication because of long half-life.
Advise clients to avoid alcohol and over-the-counter and nonprescription medications to prevent adverse effects and medication interactions, such as risk of bleeding.
Advise clients to employ nonmedication measures to avoid development of thrombi, including avoiding sitting for prolonged periods of time, not wearing constricting clothing, and elevating and moving legs when sitting.
Advise clients to wear a medical alert bracelet indicating warfarin use.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-of-warfarin">Precautions during administration of warfarin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-of-warfarin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Be prepared to administer vitamin K for warfarin overdose.</li>
<li>Teach clients to self-monitor PT and INR at home as appropriate.</li>
<li>Advise clients to record dosage, route, and time of warfarin administration on a daily basis.</li>
<li>Plan for frequent PT monitoring for clients who are prescribed medications that interact with warfarin. The client is at greatest risk for harm when the interacting medication is being deleted or added. Frequent PT monitoring will allow for dosage adjustments as necessary.</li>
<li>Advise clients to notify the provider regarding warfarin use.</li>
<li>Advise clients to use a soft-bristle toothbrush to prevent gum bleeding</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="thrombolytic-fibrinolytic-medications">Thrombolytic /Fibrinolytic Medications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#thrombolytic-fibrinolytic-medications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Two phenomena which causes hemostasis include,</p>
<ul>
<li>Coagulation of blood .</li>
<li>Formation of a thrombus</li>
</ul>
<p>Formation of a thrombus is restricted through:</p>
<ol>
<li>Fibrin inhibition: anti thrombin III, Ant plasmin, Antitrypsin, Macroglobulin</li>
<li>Fibrinolysis: tissue plasminogen activator and CF XII activate fibrin bound plasminogen to active plasmin, restrict formation of a thrombus.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action-of-fibrinolytic">Mechanism of action of Fibrinolytic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-fibrinolytic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Thrombolytic/fibrinolytic medications dissolve clots that have already formed. Clots are dissolved by conversion of plasminogen to plasmin, which destroys fibrinogen and other clotting factors. The result is clot disintegration.</p>
<p>The commonly used fibrinolytic include:
Streptokinase (Streptase)
Urokinase
Alteplase (Activase, tPA),
Anistreplase
Reteplase (Retavase)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="streptokinase">Streptokinase<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#streptokinase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>streptokinase is a semi synthetic that acts systematically to dissolve the blood clot by activating plasminogen to plasmin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-indication">Clinical indication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-indication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Acute myocardial infarction</li>
<li>Deep vein thrombosis (DVT)</li>
<li>Massive pulmonary emboli</li>
<li>thrombo embolic stroke (alteplase)</li>
<li>Peripheral arterial thrombosis</li>
<li>To open clotted iv catheters</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reaction">Adverse reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic reaction (urticaria, itching, flushing, bronchospasms); possible severe anaphylactic reaction.
*Serious risk of bleeding from different sites (within brain, needle puncture sites, wounds)</li>
<li>Hypotension</li>
<li>Arrhythmias</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Any prior intracranial hemorrhage (hemorrhagic stroke)</li>
<li>Active internal bleeding</li>
<li>History of significant closed head or facial trauma in the past 3 months</li>
<li>Acute pericarditis</li>
<li>Brain tumors</li>
<li>Use cautiously in clients who have severe hypertension, a recent episode of ischemic stroke ( 6 months prior to start of treatment), or a recent major surgery (2 to 4 weeks prior to start of treatment).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="urokinase">Urokinase<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#urokinase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Isolated from human renal cells from tissue cultures.</li>
<li>Helps in direct conversion of plasminogen to plasmin.</li>
</ul>
<p>Therapeutic uses
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Myocardial infarction.
Venous thrombosis.
Pulmonary embolism.
Adverse reaction</p>
<ul>
<li>Fever.
*Hemorrhage.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="alteplase">Alteplase<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#alteplase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Recombinant tissue plasminogen activator (t-PA)
*helps in Critical activation of plasminogen bound in fibrin clot.</li>
</ul>
<p>Reduces the risk of systemic bleeding to an appreciable extent.</p>
<ul>
<li>Half life 4-8 minutes</li>
<li>More efficacious than others</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-use">Therapeutic use<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Lysis of occlusive coronary artery thrombi associated with myocardial infarction.
Deep venous thrombosis.
Ischemic cerebrovascular disease</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reaction">Adverse reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Nausea</li>
<li>Fever</li>
<li>Rash, pruritic</li>
<li>Mild hypertension</li>
<li>Localized bleeding</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-of-thrombolytic-agents">Precautions during Administration of thrombolytic agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-of-thrombolytic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Use of thrombolytic agents must take place within 4 to 6 hr . of onset of symptoms
monitor in a setting that provides for close supervision and continuous monitoring during and after administration of the medication.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Obtain baseline platelet counts, hemoglobin (Hgb), hematocrit (Hct), a PTT, PT, INR, and fibrinogen levels, and monitor periodically.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Obtain baseline vital signs (heart rate, blood pressure) and monitor frequently per protocol.</p>
<ul>
<li>Special care includes continuous monitoring of hemodynamic status to assess for therapeutic and adverse effects of thrombolytic (relief of chest pain, signs of bleeding). Follow facility protocol.</li>
<li>Provide for client safety per facility protocol.</li>
<li>Ensure adequate IV access for administration of emergency medications and availability of emergency equipment.</li>
<li>Do not mix any medications in IV with thrombolytic agents.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precautions-during-administration-cont">Precautions during administration cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Minimize bruising or bleeding by limiting venipunctures and subcutaneous/intramuscular injections.</li>
<li>Discontinue thrombolytic therapy if life-threatening bleeding occurs. Treat blood loss with whole blood, packed red blood cells, and/or fresh frozen plasma. IV aminocaproic acid (Amicar) should be available for administration in the event of excessive fibrinolysis.</li>
<li>Following thrombolytic therapy, administer heparin or aspirin as prescribed to decrease the risk of rethrombosis.</li>
<li>Following thrombolytic therapy, administer beta blockers as prescribed to decrease myocardial oxygen consumption and to reduce the incidence and severity of reperfusion arrhythmias.</li>
<li>Administer H2 antagonists, such as ranitidine (Zantac), or proton pump inhibitors, such as omeprazole (Prilosec), as prescribed to prevent GI bleeding.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-platelets-drugs">Anti Platelets Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-platelets-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These are agents that decrease the formation of platelet plug by decreasing their responsiveness to various stimuli that would cause them to risk and combine together on a vessel wall.
This include;</li>
<li>Acetyl salicylic acid (aspirin)</li>
<li>Thienopyridine analogues</li>
</ul>
<p>Ticlopidine,
Clopidogrel</p>
<ul>
<li>Glycoprotein receptor antagonist:</li>
</ul>
<p>Abciximab
Eptifibatide and Tirofiban</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action-of-platelet-inhibitors">Mechanism of action of platelet inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action-of-platelet-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These agents inhibit the aggregation of platelets in the clotting process by blocking receptor sites on the platelets membrane, preventing platelet to platelet interaction, there by prolonging the bleeding time.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acetyl-salicylic-acid-aspirin">Acetyl salicylic acid (aspirin)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acetyl-salicylic-acid-aspirin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Universally accepted anti platelet drug.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Irreversibly causes inhibition of cyclooxygenase (COX) that leads to formation of thromboxane A2 and prostacyclin.</li>
<li>TXA2 is the key platelet activator inhibition of platelets action.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Primary prevention of acute myocardial infarction</li>
<li>Prevention of reinfarction in clients following an acute myocardial infarction</li>
<li>Prevention of stroke</li>
<li>Acute coronary syndromes (abciximab, tirofiban, eptifibatide)</li>
<li>Intermittent claudication (cilostazol, pentoxifylline, dipyridamole)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="route-of-administration">Route of administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#route-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Aspirin: Oral
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Abciximab: IV
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Clopidogrel: Oral
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Pentoxifylline: Oral</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Aspirin GI effects (nausea, vomiting, dyspepsia) Advise clients to use enteric-coated tablets and to take aspirin with food. Concurrent use of a proton pump inhibitor, such as omeprazole (Prilosec), may be appropriate.
Hemorrhagic stroke
Prolonged bleeding time, gastric bleed, thrombocytopenia
Tinnitus, hearing loss</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Advise clients that prevention of strokes, myocardial infarctions, and reinfarction can be accomplished with low-dose aspirin ( 81 mg ).
Aspirin 325 mg should be taken during initial acute episode of myocardial infarction</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="thienopyridine-analogues">Thienopyridine analogues<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#thienopyridine-analogues" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clopidogre-and-ticlopidine">Clopidogre and ticlopidine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clopidogre-and-ticlopidine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Clopidogre and ticlopidine reduces platelets aggregation by inhibiting the ADP pathway of platelets.</li>
<li>These drugs achieved their antiplatelet effects by irreversibly blocking the ADP receptor on platelets.</li>
<li>unlike aspirin, these drugs have no effects on prostaglandin metabolism.</li>
<li>Important for aspirin intolerant</li>
<li>Use of clopidogre or ticlopidine to prevent thrombosis is now considered standard practice in patients undergoing placement of coronary stent.</li>
<li>Clopidogrel plus aspirin is used for long term treatment of severe cases of coronary syndromes.
*Rashes caused by ticlopidine.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hemostatic-agents-coagulants">Hemostatic Agents/ coagulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hemostatic-agents-coagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Haemostatic agents help to stop bleeding at the local site.thus enhancing and promoting coagulation and formation of network fibrin around the wound.
These drugs are :
Aminocaproic acid and tranexamic</p>
<ul>
<li>These are fibrin stabilizers that maintain or stabilize the clot in the bleeding vessels.</li>
</ul>
<p>Protamine sulfate</p>
<ul>
<li>This agent antagonizes the anticoagulant effects of heparin.</li>
<li>It is derived from fish testis and is high in arginine content.</li>
<li>The positive charge interacts with the negative charge of heparin to form a stable inactive complex.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-for-various-bleeding-conditions">Drugs for Various Bleeding Conditions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-for-various-bleeding-conditions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Epistasis - adrenaline</li>
<li>Overdose of fibrinolytic, bleeding post surgery - aminocaproic acid</li>
<li>Menorrhagia, metrorrhagia - adrenochrome, ethamesylate.</li>
<li>PPH - carboprost</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vitamin-k">Vitamin K<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vitamin-k" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Is a fat soluble vitamin occurs in two forms :
vitamin K1 (phytonadione):leafy vegetables
Vitamin k2 (menadione): GIT through microbes.
Bile salts are required for absorption of vitamin K from the intestines.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vit-k-cont">VIT .K cont.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vit-k-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Deficiency occurs due to two conditions</p>
<ul>
<li>Prolonged gut sterilization. VIT. K2</li>
<li>Obstructive jaundice. VIT. K1, K2.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phytonadione">Phytonadione<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phytonadione" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>may be given orally, IM, IV
if given orally give with bile salts.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="menadione-sodium-bisulphate">Menadione sodium bisulphate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#menadione-sodium-bisulphate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Oral, IM ,IV, or SC
does not require bile salts
Takes longer duration
Vitamin K is given to antagonize oral anticoagulants.
The response to vitamin K is slow, requiring about 24 hours thus, if immediate hemostasis or bleeding control is required, fresh frozen plasma should be ordered.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Vitamin K deficiency.
Treatment of hemorrhagic disease of the newborn.
newborn and premature to cover the reduced intestinal synthesis.
Prolonged anti microbial therapeutic activity.
Obstructive jaundice.
malabsorption</p>
<p>A hematinic is a nutrient required in the formation of blood cells the main hematinic are iron, B12 and Folate. deficiency can lead to anemia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iron-and-iron-salts">Iron and iron salts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iron-and-iron-salts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Iron deficiency is the most common nutritional anaemia in humans</li>
<li>It result from inadequate iron intake, malabsorption, blood loss, or an increased requirement as with pregnancy.</li>
<li>When severe it results in microcytic hypochromic anemia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ferrous-sulphate">Ferrous sulphate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ferrous-sulphate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacokinetics">Pharmacokinetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Iron is given orally as a ferrous salt <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">G</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{MG}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm">MG</span></span></span></span></span></span> is administered daily for the treatment of anemia .
Iron is absorbed readily in presence of gastric acid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ferrous-sulphate-cont">Ferrous Sulphate Cont.....<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ferrous-sulphate-cont" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>It is given before meals though many patients cannot tolerate it due to its irritating effects.</li>
<li>After sometime the patient shows improved appetite, increased erythrocyte cell count and decreased microcytic hypochromic anaemia</li>
<li>At lest six months of therapy is necessary to restore iron levels to storage site.</li>
<li>It can be given parenterally as iron dextran or iron sucrose that is by slow im or iv.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="unwanted-effects">Unwanted Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#unwanted-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Oral can cause GIT discomfort
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Liquid form for infants can stain teeth.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Allergic reactions are possible with chills, urticaria, sweating, fever and even anaphylaxis after parenteral administration.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Patients pass black or dark stool this in harmless results of unabsorbed iron.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="folic-acid">Folic Acid<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#folic-acid" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Folic acid is essential in the production of DNA and erythropoiesis (RBC, WBC, and platelets).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Treatment of megaloblastic (macrocytic) anemia secondary to folic acid deficiency</li>
<li>Prevention of neural tube defects during pregnancy; therefore it is needed in all women of child-bearing age who may become pregnant.</li>
<li>Treatment of malabsorption syndrome such as sprue</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications-precautions">Contraindications/Precautions .<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Indiscriminate use of folic acid is inappropriate because of the risk of masking signs of vitamin B12 deficiency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="medication-food-interactions">Medication/Food Interactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medication-food-interactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Decreased folate levels with concurrent use of sulfonamides, sulfasalazine, or methotrexate.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-during-administration">Precautions during Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-during-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Assess clients for signs and symptoms of megaloblastic anemia (pallor, easy fatigability, palpitations, paresthesia of hands or feet).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Obtain the client's baseline folic acid levels, RBC and reticulocyte counts, Hgb, and Hct levels. Monitor periodically.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Advise clients with folic acid deficiency to concurrently increase intake of food sources of folic acid, such as green leafy vegetables and liver. Monitor clients for risk factors indicating that folic acid therapy may be needed, such as heavy alcohol use and child-bearing age.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="insulin-oral-hypoglycemic-agents">Insulin, oral hypoglycemic agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#insulin-oral-hypoglycemic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="overview">Overview<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Diabetes mellitus is a chronic illness that results from an absolute or relative deficiency of insulin.</li>
<li>Various insulins are available to manage diabetes. These medications differ in their onset, peak, and duration.</li>
<li>Oral hypoglycemic agents work in various ways to increase available insulin or modify carbohydrate metabolism.</li>
<li>Newer injectable medication are used to supplement insulin or oral agents to manage glucose control.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="diabetes-mellitus-and-effects-of-insulin">Diabetes Mellitus and Effects of Insulin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diabetes-mellitus-and-effects-of-insulin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>DM consists of agroup of disorders characterized hyperglycemia, altered metabolism of lipids, carbohydrates and proteins and increased complications from vascular diseases.</li>
<li>Most patients can be classified clinically as having either type1 or type 2 DM.</li>
<li>The criteria for the diagnosis of DM include symptoms (e.g.polyuria, polydipsia, and unexplained weight loss)and a random plasma glucose concentration of greater than 200ml/dl )11.1mmol.</li>
<li>A fasting plasma glucose of greater than (126ml/dl) 7mmol</li>
<li>there two types of DM . DM TYPE 1 and DM TYPE 2</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="insulin-therapy">Insulin Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#insulin-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Insulin polypeptide hormone is the mainstay for treatment</li>
<li>Of all types of diabetes.</li>
<li>Insulin may be administered IM, IV, SC.</li>
<li>long term treatment relies on subcutaneous injections of the hormone.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expected-pharmacological-action">Expected Pharmacological Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expected-pharmacological-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Promotes cellular uptake of glucose (decreases glucose levels)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Converts glucose into glycogen
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Moves potassium into cells (along with glucose)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Insulin is used for glycemic control of diabetes mellitus (type 1, type 2, gestational) to prevent complications.</li>
<li>Clients with type 2 diabetes mellitus may require insulin when:</li>
<li>Oral hypoglycemic, diet, and exercise are unable to control blood glucose levels.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Severe renal or liver disease is present.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Painful neuropathy is present.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Undergoing surgery or diagnostic tests.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Experiencing severe stress such as infection and trauma.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Undergoing emergency treatment of diabetes ketoacidosis (DKA) and hyperosmolar hyperglycemic nonketotic syndrome (HHNS).
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">✓</mi></mrow><annotation encoding="application/x-tex">\checkmark</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6922em;"></span><span class="mord amsrm">✓</span></span></span></span></span> Requiring treatment of hyperkalemia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-insulin-classified-according-to-duration-of-action">Classification of insulin classified according to duration of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-insulin-classified-according-to-duration-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>|  classification | Generic
(trade name) | Onset | Peak | duration  |
| --- | --- | --- | --- | --- |
|  Rapid acting | Lispro insulin
(Humalog), Insulin
aspart (NovoLog),
Insulin glulisine
(Apidra) | Less than 15 min | Less than 15 min 0.5 to
1 hr. | 3 to 4 hr.  |
|  Short acting | - Regular insulin
(Novolin R) | 0.5 to 1 hr. | 2 to 3 hr. | 5 to 7 hr.  |
|  Intermediate acting | neutral protamine
Hagedorn(NPH) insulin
(Humulin N), lente
insulin | 1 to 2 hr. | 4 to 12 hr. | 18 to 24 hr.  |
|  Long acting | Ultra lente, Insulin
glargine (Luntus) | 1 hr. | None | 10.4 to 24 hr.  |</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="premixed-insulins">Premixed insulins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#premixed-insulins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>70% NPH and 30% Regular (Humulin 70/30) - mixture of intermediate acting and short-acting insulin</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> insulin lispro protamine and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> insulin lispro (Humalog 75/25) - mixture of intermediate acting and rapid-acting insulin Complications</li>
</ul>
<p>Side/Adverse Effects</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="risk-for-hypoglycemia-too-much-insulin">Risk for hypoglycemia (too much insulin)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#risk-for-hypoglycemia-too-much-insulin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Monitor clients for signs of hypoglycemia. If abrupt onset, client will experience sympathetic nervous system (SNS) symptoms (tachycardia, palpitations, diaphoresis, shakiness). If gradual onset, client will experience parasympathetic (PNS) symptoms (headache, tremors, weakness).</li>
<li>Administer glucose. For conscious clients, administer a snack of 15 g of carbohydrate ( 4 oz. orange juice, 2 oz. grape juice, 8 oz. milk, glucose tablets per manufacturer's suggestion to equal 15 g<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mclose">)</span></span></span></span></span>.</li>
</ul>
<ul>
<li>If the client is not fully conscious, do not risk aspiration. Administer glucose parenterally such as IV glucose, or SC/IM glucagon.</li>
<li>Encourage clients to wear a medical alert bracelet.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="lipohypertrophy">Lipohypertrophy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lipohypertrophy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>atrophy of the sub cutaneous fat at the site of insulin injection is probably an immune response to insulin.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> It may occur with human insulin if patients inject themselves repeatedly in the same site
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Instruct clients to systematically rotate injection sites and to allow 1 inch between injection sites.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="insulin-allergy-resistant">Insulin Allergy Resistant<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#insulin-allergy-resistant" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Identify the underlying cause.</li>
<li>If allergic reaction to porcine insulin human insulin should be used.</li>
<li>Antihistamines may provide relieve in patients with cutaneous reaction.</li>
<li>Glucocorticoids are used in patients with resistant to insulin or more severe systemic reactions</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drug interaction is often caused by ethanol, adrenergic receptor antagonist, and salicylates.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Adrenergic receptor antagonist pose a risk of hypoglycemia due to inhibition of catecholamine effects on gluconeogenesis and glycogenolysis.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> These agents may also mask he autonomic symptoms associated with hypoglycemia.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Salicylates enhance cell sensitivity to glucose and potentiate insulin secretion and also have a weak insulin - like action in the periphery.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Epinephrine, glucocorticoid, atypical antipsychotic drugs such as clozapine and olanzapine, and ARVS (protease inhibitors) have direct effects on peripheral tissues that counter the effect of insulin.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">□</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">□</span></span></span></span></span> Phenytoin, clonidine, ca2+channel blockers cause hyperglycemia by inhibiting insulin secretion directly or in directly via depletion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">K</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{K}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">K</span><span class="mord">+</span></span></span></span></span> (diuretics).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="oral-hypoglycemic">Oral hypoglycemic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oral-hypoglycemic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<table><thead><tr><th>Medications</th><th>Expected pharmacological action</th></tr></thead><tbody><tr><td>Sulfonylureas</td><td></td></tr></tbody></table>
<ul>
<li>1st generation - tolbutamide (Orinase), chlorpropamide (Diabinese)</li>
<li>2nd generation - glipizide (Glucotrol, Glucotrol XL) ,glyburide (DiaBeta, Micronase, glibenclamide) glimepiride (Amaryl) | Results in insulin release from the pancreas  |
|  Meglitinides repaglinide (Prandin) nateglinide (Starlix) | Results in insulin release from the pancreas  |
|  Biguanides
metformin HCl (Glucophage) | - Reduces the production of glucose within the liver through suppression of gluconeogenesis</li>
<li>Increases muscles' glucose uptake and use  |
|  Thiazolidinedione's (Glitazones), rosiglitazone (Avandia), pioglitazone (Actos) | - Increases cellular response to insulin by decreasing insulin resistance</li>
<li>Results in increased glucose uptake and decreased glucose production  |
|  Alpha glucosidase inhibitors acarbose (Precose), miglitol (Glyset) | - Slows carbohydrate absorption and digestion  |
|  Gliptins - Sitagliptin (Januvia | - Augments naturally occurring incretin hormones, which promote  |</li>
</ul>
<p>All classifications of oral hypoglycemic agents control blood glucose levels in clients with type 2 diabetes mellitus and are used in conjunction with diet and exercise lifestyle changes.
Metformin HCl is used to treat polycystic ovary syndrome (PCOS).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="glipizide-and-repaglinide">Glipizide And Repaglinide<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glipizide-and-repaglinide" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hypoglycemia</li>
</ul>
<p>Metformin</p>
<ul>
<li>Gastrointestinal effects (anorexia, nausea, vomiting, which frequently results in weight loss of 3 to 4 kg [6 to 8 lb<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">]</mo></mrow><annotation encoding="application/x-tex">]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mclose">]</span></span></span></span></span> )</li>
<li>Vitamin B12 and folic acid deficiency caused by altered absorption</li>
<li>Lactic acidosis (hyperventilation, myalgia, sluggishness, somnolence) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> mortality rate</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="rosiglitazone">Rosiglitazone<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rosiglitazone" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Fluid Rosiglitazone retention</li>
<li>Elevations in low density lipoproteins (LDL) cholesterol</li>
<li>Hepatotoxicity .</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="side-adverse-effects">Side/ Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#side-adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="acarbose">Acarbose<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acarbose" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Intestinal effects (abdominal distention and cramping, hyperactive bowel sounds, diarrhea, excessive gas).</li>
<li>Risk for anemia due to the decrease of iron absorption</li>
<li>Hepatoxicity with long-term use</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sitagliptin">Sitagliptin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sitagliptin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>generally well tolerated</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contraindications-precautions">Contraindications/Precautions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications-precautions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Pregnancy Risk Category C: Glipizide, repaglinide, rosiglitazone
Pregnancy Risk Category B: Metformin HCl (Glucophage), acarbose (Precose), sitagliptin (Januvia)
These oral agents are generally avoided in pregnancy and lactation, but the provider may decide to prescribe them.
Use cautiously in clients with renal failure, hepatic dysfunction, or heart failure because of the risk of medication accumulation and resulting hypoglycemia. Severity of disease may indicate contraindication.
Contraindicated in the treatment of diabetic ketoacidosis (DKA) Metformin HCl is contraindicated for clients with severe infection, shock, and any hypoxic condition.
Acarbose is contraindicated for clients with gastrointestinal disorders, such as inflammatory disease, ulceration, or obstruction.</p></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>